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ABSTRACT
Over the last fifteen years, genome-wide association studies (GWAS) have been used to
identify thousands of DNA variants associated with complex traits and diseases, by exploiting
naturally occurring genetic variation in large populations of individuals. More recently,
similar approaches have been applied to RNA sequencing (RNA-seq) data to find variants
associated with expression level, called expression quantitative trait loci (eQTL). Recent
advances in experimental techniques have provided an unprecedented opportunity to measure
gene expression at the single cell level, and the chance to study cellular heterogeneity. This
represents a remarkable advance over traditional bulk sequencing methods, particularly to
study cell fate commitment events in development. The challenge of studying early human
development is partially overcome by advances in stem cell technologies. In particular,
induced pluripotent stem cells (iPSCs) and cells derived therefrom represent a fantastic
system to study development in vitro. In this thesis, I investigate the computational challenges
of using single cell expression profiles to perform expression quantitative trait locus (eQTL)
mapping, and provide suitable approaches for the identification of cell type and context-
specific eQTL using single cell expression profiles. I further explore the application of
such methods across a range of human iPSC-derived cell types, using data from the human
induced pluripotent stem cell initiative (HipSci) project.
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[We might have just found] “The secret of life.”
Francis Crick, 1953
1.1 From peas to GWAS
The observation that human traits are heritable is evident, often visible by eye. Every one
of us has been told that they have their mother’s eyes, their father’s height, their grandfa-
ther’s nose, etc. Similarly, many diseases “run in the family”: for example diabetes and
some types of breast cancer are recurrent from generation to generation. In fact, for some
conditions, family history can be one of the most reliable diagnostic tools. Describing the
mechanisms by which we acquire traits, and the extent to which traits are heritable is at
the core of the science we call genetics, and is a question that has occupied scientists for years.
I use this section to provide a brief historical overview and highlight the key scientific
discoveries and technological advances in the field of genetics - from Mendel’s experiments
on peas in the 19th century to the announcement of the completion of the human genome
sequence in 2000 (sections 1.1.1-1.1.6). Next, I use section 1.1.7 to discuss genome-wide
association studies (GWAS), a statistical method aimed at identifying associations between
common genetic variants and complex traits and diseases. Finally, in section 1.1.8, I describe
expression quantitative trait loci (eQTL) mapping, where GWAS-like approaches are applied
to find variants associated with expression level in order to gain insight into the molecular
and regulatory role of trait- and disease-associated variants.
2 Introduction
1.1.1 Principles of (Mendelian) Inheritance
In ‘On the Origin of Species’ [1], Charles Darwin proposed the theory of evolution, which
is based on the assumption that natural variation between individuals provides differential
reproductive advantages, and that this variation can be inherited from one generation to the
next. This theory explains the adaptation of a species to its environment and the consequent
development of new species, yet the mechanisms by which such variation occurs and the
modes of inheritance were not described. In the words of Darwin himself in ‘On the Origin
of Species’: “our ignorance of the laws of variation is profound” and “the laws governing
inheritance are quite unknown”.
Around the same time, the man who is now universally considered to be the father of genetics
began conducting experiments to tackle exactly this problem. He was actually not a scientist
but a friar, by the name of Gregor Mendel, and in 1853 he performed the now famous
experiments on inheritance in peas. At St. Thomas’ abbey, in Brno, Moravia (then part of the
Austro-Hungarian empire), Mendel meticulously studied seven different traits of the plants
(plant height, pod shape and colour, seed shape and colour, and flower position and colour),
each of which segregated on one of the plant’s seven chromosomes. For example, seeds were
either yellow or green, wrinkled or round. For seven years, Mendel followed generations
and generations of pea plants and noted that some traits occurred far more often than others.
For example, when crossing a plant with round seeds and one with wrinkled seeds, the
offspring (F1) always had round seeds: Mendel called the round seed trait the ‘dominant’ trait.
However, the wrinkled seed trait which had seemingly vanished in the first filial generation
would appear again, in the second generation (F2), in a 1:3 ratio between wrinkle-seed to
round-seed plants. Somehow, this ‘recessive’ trait was being passed on, remaining hidden
when overpowered by the dominant trait, but not forgotten. In 1866, Mendel published his
experiments and results in ‘Versuche über Pflanzenhybriden’ (Experiments in Plant Hybridis-
ation, [2]). In it, he proposes what will be called the Mendelian Laws of Inheritance: i) the
Law of Independent Segregation (every individual contains two factors for each trait, one of
which is passed on to its offspring at random), ii) the Law of Independent Assortment (traits
are inherited independently of each other) and iii) the Law of Dominance (recessive alleles
will be masked by dominant alleles and the trait corresponding to the dominant allele will
be observed) [2]. The publication received almost no attention, but the Laws of Inheritance
described therein built the foundations of modern genetics.
Mendel and Darwin never met, and died remaining unaware of each other’s theories. Mendel’s
research remained completely unknown for decades, until at the turn of the century, in 1900,
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four botanists (the Austrian Erich von Tschermak, the Dutchman Hugo de Vries, the German
Carl Correns and the American William Jasper Spillman) independently rediscovered his
work and validated his findings, officially beginning the modern age of genetics. Around the
same time, the British geneticist William Bateson set out to make Mendel’s work accessible
to scientists that were not proficient in Mendel’s native language, German. It was in a 1901
lecture at the Royal Society’s evolution committee that Bateson described Mendel’s princi-
ples and introduced some fundamental terms of genetics that we still use today, including
‘allelomorph’ (allele), ‘zygote’, ‘homozygous’, ‘heterozygous’ and, even the word ‘genetics’
itself (Box 1). Bateson translated Mendel’s original papers on the Laws of Inheritance
into English and published them, allowing Mendel’s work to become known in the greater
scientific world, more than 40 years after their original publication [3].
An important step towards reconciling Darwin’s theory of evolution with Mendel’s laws of
inheritance was made in 1902, when Theodor Boveri showed, in sea urchin, that different
chromosomes contained different hereditary material and that organisms required a full set
of chromosomes to function. In 1903, Walter Sutton published a paper proposing how these
principles, together with the random segregation of paternal and maternal chromosomes
during gamete formation (which he studied in grasshoppers) could form the molecular basis
for Mendel’s Laws of Inheritance [4]. Importantly, he also noted how the number of traits
was much larger than that of chromosomes, which meant that some traits had to be located
on the same chromosome and be transmitted together.
1.1.2 Genetic Linkage and the birth of modern genetics
In 1908, the American geneticist Thomas Hunt Morgan set out to confirm (or better, disprove)
Mendel’s theories using a model organism that generates new offspring much quicker than pea
plants. It was Drosophila melanogaster, the fruit fly. In his famous ‘fly room’ at Columbia
University, thousands of experiments were performed on flies. Flies with known phenotypes
(for example red or white eyes) were put in jars to mate, and the traits of the progeny were
recorded. Through the key observations that some traits appeared to be sex-linked and that
some other traits were co-occurring more often than expected by chance, Morgan theorised
that ‘markers’ responsible for particular traits were positioned on chromosomes, like beads
on a string. These markers (or genes, Box 1), when close together on a chromosome, were
more likely to be passed on to the next generation. Morgan had described the concept of
genetic linkage and essentially hypothesised the phenomenon of crossing over (exchange of
paternal and maternal chromosomal material during meiosis [5]). In 1913, his student, Alfred
Sturtevant, gathered all the data collected and developed the first genetic map, showing the
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position of the fruit fly’s known markers relative to each other in terms of recombination
frequency [6]. Sturtevant would go on to call the unit of genetic linkage a centimorgan (cM),
in honour of his mentor.
Box 1: Genetic terms & their origin
• Alleles (originally allelomorphs) were defined by Bateson as the units of inheritance de-
scribed by Mendel [3].
• Homozygote and heterozygote were also used by Bateson to describe individuals carrying
the same or different alleles.
• The word gene as a term for the Mendelian factors or units of inheritance was introduced
by Danish botanist Johannsen [7].
• Johannsen also introduced the terms phenotype, as the outward appearance of an individual,
and genotype, as their genetic traits.
• The terms polygenetic (today more often simply polygenic), for traits that are governed
by multiple genes, and pleiotropic, for genes that affect multiple, seemingly unrelated,
phenotypes also made their first appearance at that time.
• A pedigree, from the French pied de grue (crane’s foot), is a diagram that depicts the bio-
logical relationships between related individuals. It is often used to look at the transmission
of genetic disorders.
The Mendelian-chromosome theory, first proposed by Boveri and Sutton [4] and then elabo-
rated and expanded by Morgan and his students [8], described chromosomes as the (paired)
units of heredity that Mendel had described in his laws, and was widely accepted by scientists
by the 1930s. In 1933, Morgan received the Nobel Prize in Physiology or Medicine “for his
discoveries concerning the role played by the chromosome in heredity” [9].
However, the mechanisms of heredity and the physical molecule responsible for it were still
unknown. The concept of the ‘gene’ existed, but it was an abstract entity. Most people in
fact believed that proteins were the carriers of genetic material. In 1944, Erwin Schrödinger,
an Austrian-Irish physicist perhaps better known for his contributions to quantum mechanics,
published ‘What is Life?’ where he introduced the idea that genetic material may be stored as
some sort of a ‘code’, a concept borrowed from Information Theory [10]. He had provided a
theoretical physical description of the mechanism of ‘storage’ of genetic material [11]. Still,
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as did most scientists at the time, Schrödinger bet on proteins as the responsible molecule.
The other candidate, deoxyribonucleic acid (DNA), had been referred to as the ‘stupid
molecule’, a molecule with a chemical structure far too simple to be able to explain the
complexity of life. In fact, DNA consists of only four building blocks, often referred to
by their initials: adenine (A), thymine (T), cytosine (C) and guanine (G) [12]. Proteins
remained the most likely molecule responsible for carrying genetic information until 1944,
when Oswald Avery and colleagues at the Rockefeller Institute in New York demonstrated
experimentally that it had to be DNA. Avery, along with his co-workers Colin MacLeod
and Maclyn McCarthy, performed an experiment in Streptococcus pneumoniae, where he
removed various organic compounds from the bacteria, and observed whether it could still
transform. Only upon treating the bacteria with an enzyme that removed DNA, did the
bacteria stop transforming [13].
1.1.3 The double helix
The question of the physical structure of DNA remained unsolved until 1953, when a team
of scientists at last proposed its structure. Key members of this team were Francis Crick,
James Watson, Rosalind Franklin, Maurice Wilkins and Erwin Chargaff. Jim Watson had
had a fascination for the structure of DNA, and had been studying it for years, starting in his
native Chicago, then during his PhD in Indiana (under the supervision of future Italian Nobel
Prize laureate Salvador Luria). Eventually, he ended up in Cambridge, UK, at the Cavendish
laboratory, which was then directed by Australian-born British X-ray crystallographer Sir
Lawrence Bragg. There, he met Francis Crick, 12 years his senior, a British physicist turned
biologist. Crick had taught himself the mathematical theory of X-ray crystallography and had
worked on determining the most stable helical conformation of amino acid chains in proteins,
the alpha helix, only to be beaten to its solution by American chemist Linus Pauling [14].
Watson and Crick set out to obtain a model for the structure of DNA, building on Crick’s
experience and rigor, and Watson’s intuition. Friend and collaborator of the pair was Maurice
Wilkins, New Zealand-born British physicist at King’s College London, who had extensively
studied X-ray diffraction patterns. His colleague, Rosalind Franklin, had perfected the
technique to produce X-ray crystallography images of the DNA and instructed her assistant,
Raymond Gosling, to take the most precise image to date, the now famous ‘Photo 51’. To
Watson and Crick’s eyes, Photo 51 (which Wilkins had shared without Franklin’s knowledge),
looked without a doubt like the footprint of a helix. The last piece of the puzzle came from a
discovery that Austro-Hungarian Erwin Chargaff made, at Columbia University. He observed
that globally the numbers of As and Ts in DNA were roughly the same, as were the numbers
of Cs and Gs. This provided the idea that bases would be paired up and facing inwards in the
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double helix, As with Ts, Cs with Gs, ensuring that the covalent bonds would be always of
the same length, which would keep the helix stable. In 1953, Watson and Crick published
‘Molecular structure of nucleic acids’ [15]. Their work showed how the four nucleotide bases
(A, T, C, G) formed “two helical chains each coiled round the same axis” [15] spelling out
what Crick called “the secret of life”. For this discovery, Crick, Watson and Wilkins won the
1962 Nobel Prize in Physiology or Medicine “for their discoveries concerning the molecular
structure of nucleic acids and its significance for information transfer in living material” [16].
Rosalind Franklin, who had played a critical role in the discovery, had died four years prior
of ovarian cancer, and her contribution went largely unrecognised at the time.
1.1.4 Biometrics
While Mendel was studying the inheritance of traits in peas, Boveri studied sea urchins,
Morgan fruit flies, Avery bacteria, and long before Crick, Watson and Franklin proposed
a structure for DNA (working on squid), ever since Darwin’s theories others were trying
to quantify inheritance in the context of human traits. One such investigator was Francis
Galton, a half-cousin of Darwin’s, who was interested in mathematically describing and
analysing Darwin’s evolutionary concepts. In particular, Galton was interested in the effects
that evolution had had on humans and how its effects could be used to better the human race.
Galton was one of the founders of the study of biometrics, which attempted to measure and
estimate the heritability of human traits such as height and intelligence. Linked to these
efforts, and on a less honourable note, Galton was also the founder of eugenics, a theory for
which genetics should be used as a tool to force evolution’s hand by encouraging mating of
individuals considered to have especially desirable qualities and by eliminating or preventing
reproduction of individuals considered faulty. Eugenics theories are linked to one of the
most horrifying pages of human history, motivating forced sterilisations of the ‘unfit’ in the
United States in the 1920s and 1930s and of course having been used as justification for the
racial policies of Nazi Germany. Nevertheless, some of the concepts and methods Galton
developed during these studies are still fundamental to genetics today [17]. Among others,
Galton introduced the concepts of correlation, regression toward the mean and the regression
line, which he used to compare the heights of children to those of their parents. Galton and
his student, mathematician Karl Pearson, worked together to make several more important
contributions to statistics. For example, Pearson described the concepts of the p value and
the chi squared (χ2) test [18] and proposed principal component analysis (PCA) [19]1.
1later independently developed and named by the American statistician and economist Harold Hotelling.
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1.1.5 Towards quantitative genetics
By cross-breeding Drosophila lines and performing genetic mapping, Morgan and his stu-
dents had effectively conducted the first genotype-phenotype studies. Similar to Mendel
and Bateson, the phenotypes they observed were predominantly categorical, such as the
colour and shape of seeds in pea plants or the red or white-eyed phenotype in Drosophila.
In contrast, biometricians like Galton and Pearson had mostly looked at continuous traits
in humans, such as height, and believed that those could not be explained by Mendelian
genetics. This controversy has been referred to as the ‘Biometric-Mendelian debate’.
This debate was resolved by British statistician Ronald Fisher, who in a seminal 1918 paper
showed that, if many genes affect a trait, then “the random sampling of alleles at each gene
produces a continuous, normally distributed phenotype in the population” [20]. As the
number of genes grows very large, the contribution of each gene becomes correspondingly
smaller, leading in the limit to Fisher’s famous ‘infinitesimal model’ [21].
In addition to showing that biometrics and Mendelianism are not contradictory but comple-
mentary, Fisher made several other contributions to the field, outlining statistical ideas and
tools still used today. In particular, he published papers outlining an exact test for two-by-two
contingency tables with small expectations (Fisher’s exact test) [22], partial correlation
coefficients [23] and the variance ratio, later named after him as the F statistic [24]. He also
introduced the concepts of variance (as “the square root of the mean squared error”) and
analysis of variance (ANOVA).
Already as an undergraduate student at the University of Cambridge, Fisher published his
first paper ‘On an absolute criterion for fitting frequency curves’ where he outlined the
fundamental ideas of maximum likelihood estimator (MLE). He later extended on this work
and by 1922, he had established the properties of the MLE such as consistency and minimum
variability [25] that are still used today [26]. He demonstrated the utility of maximum
likelihood estimation in genetics by solving a number of equations to elucidate a genetic map
of eight Drosophila melanogaster genes based on their crossing-over frequencies [27].
Three decades later, building on Fisher’s work, the American statistician Charles Henderson
derived the solution of the mixed model equation [28]. Today, linear mixed models are very
popular tools for several genetic analyses and are the models I use throughout this thesis (see
Chapter 2 for more details).
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1.1.6 Molecular biology and technological advances
Whilst established as an official branch of science already in the 1930s, the resolution of
the DNA structure, and all the discoveries that led to it, truly jump-started research in the
new field of molecular biology. In the decades that followed, a critical combination of
scientific discoveries and technological advances eventually led to the completion of the
human genome sequence at the turn of the 21st century [29] (page 13).
Cracking the code
The initial description of the structure of DNA in the early 1950s was a major advance for
the field of molecular biology. At that time, technology did not exist for isolating a gene,
determining its nucleotide sequence, or relating that sequence to the amino acid sequence of
the corresponding protein [30]. Messenger ribonucleic acid (RNA) had not yet been discov-
ered, and very little was known about protein synthesis. In 1941, George Beadle and Edward
Tatum in their pioneering work with the fungus Neurospora had suggested a one-to-one
correspondence between genes and enzymes [31]; yet how the nucleotide sequence of each
gene was related to the amino acid sequence of its encoded protein was not yet understood.
In the years that followed, many fundamental discoveries driven by technological evolution
helped to solve this riddle and greatly contributed to our general understanding of the function
and structure of our genome, and the role of genomic variation. In 1955, Romanian-American
cell biologist George Emil Palade first observed ribosomes [32], and in 1958, Francis Crick
first postulated the central dogma of biology, stating that information is transmitted from
nucleic acids (DNA and RNA) to proteins, but not vice versa [33]. In the following years,
Sydney Brenner, François Jacob and Matthew Meselson discovered the role of messenger
RNA (mRNA) in transporting genetic information from DNA in the nucleus to the protein-
making ribosomes in the cytoplasm [34]. Finally, in 1961 Nirenberg deciphered the genetic
code, discovering that combinations of three base pairs (called codons) code for one of 20
amino acids [35–37, 30]. Today, we know that DNA gets transcribed into RNA aided by the
DNA polymerase molecule, and RNA gets translated to amino-acids making up proteins in
the ribosome with the help of transfer RNA (tRNA) [12].
In addition to cracking the genetic code, many other advances were made around this time
and in the following years, contributing to the knowledge of the molecular machinery we
have today (Fig. 1.1).
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Fig. 1.1: 150 years of genetics.
A number of scientific discoveries, in combination with key advances in technology and statistical
modelling, have led to the identification of thousands of genetic variants which are associated to
complex and molecular traits [29]. Several fundamental contributions have been made, from Mendel’s
peas to the structure of DNA, to large databases cataloguing genetic variation of hundreds of thousands
of individuals. Here, I have attempted to highlight the key events that led to today’s field of quantitative
genetics in the GWAS and post-GWAS era.
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Sequencing DNA
In terms of technology, one major leap in our understanding of the biological basis of genetic
variation was the development of DNA sequencing, which allowed the nucleotide sequence
of a DNA segment to be determined. In the mid 1970s, two different DNA sequencing tech-
niques were independently developed: the well known and still used Sanger chain-termination
method [38, 39] and a chemical sequencing method that has been almost forgotten, known as
Maxam–Gilbert sequencing [40]. The former, named after its developer Frederick Sanger,
relies on in vitro DNA replication by DNA polymerase, which had been isolated some
twenty years prior by Arthur Kornberg and colleagues [41]. The selective incorporation
of ‘chain-terminating’ dideoxynucleotides (ddNTPs)2 alongside regular nucleotides during
DNA synthesis, and the use of polyacrylamide gel electrophoresis to separate the resulting
fragments, allows the sequence of an input DNA fragment to be determined.
Sanger sequencing eventually became the standard for DNA sequencing, and subsequent
innovations led to the development of automatic sequencing machines able to sequence DNA
fragments of about one kilobase (kb) in length. For sequencing longer stretches of DNA, a
novel strategy named ‘shotgun sequencing’ was developed [42, 43]. In shotgun sequencing,
the long DNA of interest is randomly broken up into shorter DNA fragments which are
cloned and sequenced separately. The occurrence of overlapping DNA fragments allows for
the in silico reconstruction of longer DNA fragments.
In 1995, the first genome of a living organism (the bacteria Haemophilus influenzae) was
sequenced and assembled by shotgun sequencing [44], shortly followed by that of another
bacterium, Mycoplasma genitalium [45]. The genomes of other model organisms were to
follow in subsequent years - the budding yeast S. cerevisiae [46], the bacterium E. coli [47],
the worm C. elegans [48], the bacterium M. Tuberculosis [49], the fruit fly D. melanogaster
[50] and the flowering plant Arabidopsis taliana [51]. The first two human chromosomes
(chromosome 22 and chromosome 21) were sequenced in 1999 and 2000, respectively
[52, 53], and the first draft of the entire human genome was published in 2001 [54, 55] (see
page 13). The mouse genome was published in 2002 [56].
2either ddATP, ddCTP, ddGTP or ddTTP. These nucleotides are missing a 3’ -OH group, which is required
for the formation of a bond between two nucleotides, causing DNA polymerase to stop the extension of DNA
when a modified ddNTP is incorporated - thus the name chain-terminating sequencing.
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Understanding the genetic basis of disease
In parallel, along with the increasing understanding of the molecular structure of genes and
the genome, scientists began to investigate the molecular basis of disease. One of the first
conditions to be linked to a genetic cause was alkaptonuria3, which in 1902 Garrod had
identified to follow the Mendelian rules of inheritance [57]. In 1956, Vernon Ingram traced
the cause of a disease to a genomic alteration for the first time: he discovered that sickle cell
disease is caused by a chemical change in a hemoglobin protein [58].
Until the 21st century, success in identifying genetic factors responsible for human traits
and diseases was predominantly through the use of genetic linkage studies, first proposed
in 1980 by David Botstein [59]. These rely on the concept of linkage, first introduced by
Morgan and his students: during meiosis, physically close genes remain ‘in linkage’, whereas
genes that are further apart are less likely to co-segregate due to recombination events. When
analysing a disease segregating4 in a family, linkage analysis involves i) identifying a genetic
marker (with a known location) that is linked to the (unknown) disease gene and then ii)
testing each of the nearby genes to determine the one that causes disease [60]. Using this
method, the first disease gene was mapped in 1983, when Gusella and colleagues linked a
gene on chromosome 4 to Huntington’s disease [61]. Shortly after, in 1989, there followed a
study from Francis Collins and others, identifying the genetic basis of cystic fibrosis as a
single base deletion on chromosome 7 [62]. As of 2003, about 1,200 genes were linked to
Mendelian traits [63].
Mendelian disorders, as the name suggests, are those that follow the Mendelian laws of in-
heritance. They are often called monogenic, as they are typically driven by mutations within
a single gene with high penetrance (defined here as the probability of having a trait/disease
given the predisposition score). Examples of such traits include X-linked muscular dystro-
phies, cystic fibrosis, Fanconi anaemia and phenylketonuria. Mendelian traits are typically
rare in the general population but often cluster in families. Genetic linkage analyses are best
powered to discover these highly penetrant monogenic disease genes [64].
In comparison, complex traits are typically common in the general population5. They are
driven by a combination of multiple genetic risk factors across the genome (hence the name
3a rare recessive condition that affects mainly the joints and causes unusual pigmentation.
4recurring within a family but without affecting all of its members.
5The genetic architecture of human disease is captured on a spectrum [65], but can be broadly categorised
as i) Mendelian (monogenic), ii) complex (polygenic) or iii) chromosomal (e.g. Down’s syndrome).
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polygenic), environmental risk factors, as well as interaction effects between genetic variants
and environmental exposures (GxE). These common, multifactorial diseases have a genetic
architecture that is highly distinct from that of monogenic disease. They are known to be
heritable (heritability estimates for most common diseases are estimated at 40-60% [65–69]),
but their full etiology contains both a genetic and an environmental component. Consequently,
it is the cumulative effect of many subtle genetic variants and environmental risk factors
working in concert, that trigger disease onset. Complex diseases include, for example, heart
disease, type 2 diabetes, asthma, cancer, schizophrenia and Parkinson’s disease.
Whilst there was some success in using linkage studies to identify genetic regions involved
in common diseases6, genetic linkage studies in general proved underpowered to detect
regions with significant linkage for complex traits and diseases [72, 73]. This was in line with
the ‘common disease/common variant’ (CD/CV) hypothesis [72, 74], which postulated that
common traits are driven by genetic variation that is common in the population, i.e. multiple
variants, each with low penetrance. This hypothesis was described as early as 1996, and
had already suggested that family-based linkage studies would be underpowered to detect
variants with modest effects [75].
Instead, it was proposed that the combined use of linkage disequilibrium (LD)7 and population-
(rather than family-) based studies would be more suitable [75, 77] - thus practically proposing
the design for genome-wide association studies (GWAS) [75]. However, at the time, imple-
mentation of GWAS was not possible, for two primary reasons. First of all, the technology
required to genotype thousands to millions of markers in a single experiment for the larger
required sample sizes was not available [75, 78]. Secondly, the distribution and density
of genetic polymorphisms across the genome, and the LD between genetic variants across
different populations, were unknown.
In some sense, population-based association studies can be viewed as an extension of family-
based linkage studies, in which the population studied (derived from common ancestors) acts
as an extended pedigree and a much greater number of meiotic recombinations will have
occurred between the analysed samples. As a consequence, LD regions are much smaller
than within pedigrees of close relatives, thus requiring a more dense panel of genetic markers
to be examined [79].
6For example BRCA1 for breast and ovarian cancer [70, 71].
7LD: the nonrandom allocation of alleles at nearby variants to individual chromosomes as a result of recent
mutation, genetic drift or selection, manifest as correlations between genotypes at closely linked markers [76].
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The Human Genome Project
In order to study genomic variation, and therefore its role in disease, it was necessary to
generate a reference genome. This was the goal of the Human Genome Project (HGP),
which aimed at sequencing the entire human genome. The HGP was a major breakthrough
that dramatically changed the landscape of genetics, and was described by United States
President Clinton as “an epic-making triumph of science and reason” [80] at the announce-
ment of its completion. Driven by and a driver of technological breakthroughs in DNA
sequencing and genotyping, the HGP was a massive international undertaking and a truly
collaborative effort; sequencing and analysis took place across twenty centers in six different
countries (USA, UK, France, Germany, Japan, China) and took 13 years to complete, costing
approximately $2.7 billion [81]. Led in the US by then NIH director Francis Collins and by
founder of Celera Genomics8 Craig Venter, and with large contributions from the UK, in
particular from the Sanger Institute directed by John Sulston (who had first sequenced the
genome of C. Elegans), the HGP was announced as a joint US-UK statement on June 26th,
2000. After a first publication in 2001, the project was truly completed on April 25th, 2003,
on the 50th anniversary of the Watson and Crick paper describing the helical structure of DNA.
The HGP provided the first map (obtained from the genomes of a small number of individ-
uals) of the ∼3 billion bases in the human genome [54, 83, 84], and revealed that human
DNA consists of surprisingly few exons (1.1% of the genome), whereas introns cover 24%
of the genome [55, 54]. Additionally, the number of genes was found to be smaller than
expected, with around 30,000 being identified in 2001, and circa 21,000 genes being the latest
(still debated) estimate at the time that this thesis is written [85]. Additional breakthroughs
in sequencing technologies have expanded and refined the reference genome, which now
captures more than 92% of the genome and provides a landscape of its genes [81].
With a complete map of the human genome in place, genetic variants could now be identified
as those bases discovered in an individual that did not match the (reference) base annotated
in the human genome map. Common variants, i.e. variants with minor allele frequency
(MAF)9 larger than 5%, were called single nucleotide polymorphisms (SNPs). Previous
studies had estimated that approximately 0.1% (1 base per 1,000) of an individual’s genome
was a polymorphism [87–89].
8The company Celera Genomics was formed in May 1998, with the objective of sequencing much of the
human genome in three years [82].
9The frequency of an allele at a genetic locus is the proportion of chromosomes in the study sample that
carry that allele [86]. For a biallelic variant (a variant for which only two possible alleles are observed in the
population), the frequency of the less common (minor) allele is called the minor allele frequency (MAF).
14 Introduction
These SNPs were scattered across the genome and it was now time to describe what type of
variants they were, where in the genome they were located, and what (if any) effect they had
on human phenotypes.
The International HapMap Project
The International HapMap Project was the first effort of its kind to systematically catalogue
genomic variation. Additionally, it aimed to characterise the LD structure of the human
genome, which would make GWA studies feasible. The HapMap was officially started in
October 2002 as a collaboration between research groups and private companies in Canada,
China, Japan, Nigeria, the United Kingdom and the United States with the goal of developing
a haplotype map (HapMap) of the human genome [90]. By genotyping individuals of African
(YRI), European (CEU) and East Asian (JPT, CHB) descent, in Phase I HapMap assembled
a publicly available database of common variants (MAF>5%) in global samples [91]. The
HapMap expanded rapidly. By Phase II (2007), the database contained 2.1 million SNPs
from the four original populations [92]. Phase III (2010) added genotyping from seven
additional populations, for a total of over 3 million SNPs in 11 global ancestry groups10 [93].
The growing popularity of genetic association studies in parallel with the expansion of the
HapMap effort paved the way for the last needed technological breakthrough: microarrays.
By knowing the genetic location of thousands of variants, commercial companies were able
to develop so-called ‘SNP chips’ [94, 95], which allowed for genotyping at specific locations
across the genome. In parallel, the data generated by the HapMap project enabled calculation
of the LD11 between SNPs within the genome, effectively describing the chance that two
SNPs will be inherited together [72]. This enabled the identification of haplotypes and thus a
minimal set of SNPs that capture the majority of the haplotype diversity within a population,
called ‘tag SNPs’ [90]. The collective LD information gathered by academics in those years
[96–98] allowed companies such as Affymetrix and Illumina to develop SNP arrays that
contained these tag SNPs, effectively capturing information about common variation across
a large percentage of the genome while only directly genotyping a few thousand SNPs.
10ASW (African ancestry in Southwest USA); CEU (Utah residents with Northern and Western European
ancestry from the CEPH collection); CHB (Han Chinese in Beijing, China); CHD (Chinese in Metropolitan
Denver, Colorado); GIH (Gujarati Indians in Houston, Texas); JPT (Japanese in Tokyo, Japan); LWK (Luhya in
Webuye, Kenya); MEX (Mexican ancestry in Los Angeles, California); MKK (Maasai in Kinyawa, Kenya);
TSI (Tuscans in Italy); YRI (Yoruba in Ibadan, Nigeria).
11Pearson’s correlation coefficient squared, r2, is commonly used
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1.1.7 Genome-wide association studies
The data generated by the International HapMap Project combined with development of
appropriate chip-based microarray technology, which enabled simultaneous genotyping of
more than one million SNPs, led to the first wave of GWAS [78]. GWAS are a hypothesis-
free12 approach to test for statistical association between the genotype frequency of common
genetic variants (considered one by one across the genome) and a phenotype of interest [76].
The development of GWAS was accompanied by great enthusiasm, and the hope that these
studies could better our understanding of the genetic underpinning of human disease, leading
to improvement of prognosis and acceleration of drug and diagnostics development.
Initially, GWAS focused on complex phenotypes with binary outcomes, using a case-control
design (i.e. diseased vs healthy). Then, for each SNP and binary trait, the association was
evaluated using a Cochran–Armitage (trend) test, a χ2 test or a Fisher’s exact test comparing
the numbers of cases and controls when stratified by their alleles at the locus of interest.
The first successful GWAS was published in 2002 on myocardial infarction [99]. The same
design was then applied in a landmark GWA study conducted in 2005 for age-related macular
degeneration (AMD), using 96 cases and 50 healthy controls and testing for associations at
∼100,000 SNPs [100]. In 2007, the Wellcome Trust Case-Control Consortium (WTCCC)
published a study where they performed GWAS on seven different common diseases, using
2,000 cases for each of bipolar disorder (BD), coronary artery disease (CAD), Crohn’s
disease (CD), hypertension (HT), rheumatoid arthritis (RA), type I and II diabetes (T1D,
T2D) and a common set of 3,000 healthy controls, demonstrating the feasibility of the use of
a shared set of controls across several traits [101].
A year later, in 2008, the GWAS Catalog was founded to keep a record of all published GWAS
and identified associations [102]. As of September 2020, when I am writing this thesis, the
GWAS Catalog includes 4,694 publications, describing 197,708 SNP-trait associations [103].
Over time, quantitative traits have become increasingly popular to use as phenotypes, in
addition to binary traits. These include continuous traits such as height, weight and blood
pressure. Furthermore, linear regressions and their derivations have become more popular
methods to assess association, due to their flexibility to include covariates [76]. I describe
these models in detail in the next chapter (Chapter 2).
12bar the selection of SNPs on the chip. More recently, shallow DNA-seq has been increasingly used as an
alternative, making the approach truly hypothesis-free.
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GWAS results are often visualised using a Manhattan plot [76], where the negative log
p value (as a measure of significance) is plotted on the y axis, against the corresponding
genomic position (ordered by chromosome and position) on the x axis (Fig. 1.2). Peaks on
these plots represent loci (multiple variants in LD) that display evidence of association with
the analysed phenotype. Variants are deemed to be significantly associated with a trait if they
exceed an appropriately chosen p value threshold.
Fig. 1.2: Manhattan plot.
Manhattan plot for Crohn’s disease (CD) from the WTCCC study [101]. On the x axis are plotted
the genomic positions of the SNPs tested, one chromosome after the next. On the y axis are the
association significance values. Alternating colours are used to distinguish chromosomes (odd
numbered chromosomes -and chromosome X- are dark, even numbered chromosomes are light).
Highlighted in green are statistically significant SNPs (p value < 5×10−8).
From global traits to molecular traits
Despite the success, the path from GWAS to biology is not straightforward, because an
association between a genetic variant at a genomic locus and a trait is not directly informative
of the causal mechanisms whereby the variant is associated with phenotypic differences [104].
GWAS have robustly associated thousands of genomic loci with complex traits. However,
the interpretation of the identified variants is often far from trivial: the true causal variants
are often oscured by LD, and the genes mediating a variant’s effect on the trait are rarely
ascertainable from GWAS results alone, especially for non-coding variants, which account
for the majority of GWAS-identified risk alleles [65, 105, 106]. Maps of regulatory annota-
tions and connections in disease-relevant tissues, generated by projects such as ENCODE
(ENCyclopdia Of DNA Elements, [107]) and Epigenome RoadMap [108] can help the inter-
pretation of these (putative) regulatory variants. Additionally, molecular quantitative trait loci
(QTL) mapping, where genomic variants are associated with changes in expression (eQTL
[109]), chromatin accessibility (caQTL [110]), DNA methylation (mQTL [111]), histone
modifications (hQTL [112]), or protein level (pQTL [113]), have added an interpretative
layer to the molecular mechanisms associated with disease-associated variants.
In this thesis, I focus on gene expression, i.e., the transcriptome, as a molecular phenotype. I
use the next section (section 1.1.8) to describe key aspects of eQTL mapping.
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1.1.8 Expression quantitative trait loci
Mechanisms of the genetic regulation of gene expression
During gene expression (or transcription), the genetic information stored in restricted portions
of the DNA (genes) is used to produce RNA molecules. Next, during translation, the majority
of RNA molecules are translated into proteins. As we have seen, only approximately 1% of
the human genome is made up of protein-coding genes [54] whereas a large portion of the
remaining sequence is thought to play a role in the regulation of gene expression [107].
The impact of genetic variation on traits and disease is the consequence of perturbations
to this complex molecular machinery. An easily interpretable mechanism through which
genetic variants may affect a phenotype is the direct alteration of the sequence and therefore
functionality of the coded protein [114]. For example, sickle cell anaemia is caused by a
SNP in the HBB gene, which causes one amino acid substitution in the sequence of the
corresponding protein [86]. In alternative, genetic variation may affect the regulation of gene
expression. One possible such mechanism would be the disruption of a specific sequence that
affects the binding of proteins regulating the expression of a gene, for example a transcription
factor (TF). In this scenario, the regulatory variant is said to be acting in cis. An alternative
mechanism is the alteration of the DNA structure, which in turn can affect the functionality
of regulatory elements, and ultimately gene expression [107, 108]. In this case the regulatory
genetic variant is trans-acting.
Mapping eQTL
In the early 2000s, the new field of ‘genetic analysis of global gene expression’ or ‘genetical
genomics’ [115] emerged, which applied traditional techniques of linkage and association
analysis to thousands of transcript levels measured by microarrays [116]. This was partly
driven by the decrease in cost of high-throughput profiling of gene expression, which made
it possible to measure gene expression levels in large numbers of individuals. Genomic
variants that were in this way associated with gene expression were termed eQTL. The
first genome-wide maps of eQTL were performed in the early 2000s, using genetic linkage
analysis, first in yeast [117], then in mammals, including humans [109]. A few years later,
in 2007, the first modern eQTL studies using a GWAS-like approach were conducted in
humans [118, 119]. It soon became clear that gene expression levels are strongly heritable:
for all human genes the average heritability (portion of phenotypic variation due to genetic
variation) was estimated to be around 0.25 [120–122, 114], making eQTL studies extremely
popular.
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RNA-sequencing13, or RNA-seq, was a major breakthrough in the late 2000s and has been
widely used since, substituting microarrays as the go-to technique to measure gene expression
[123]. RNA-seq allows the measurement of the average expression abundance for each gene
across a large population of input cells (section 3.1.1). The quantitative genetics field adapted
quickly, and the first studies to perform eQTL mapping using RNA-seq data to measure
expression level were published back-to-back in 2010, by groups in Chicago and Geneva
[124, 125]. Today, (bulk) RNA-seq is the standard method to measure gene expression for
eQTL mapping [126–128]. One of the advantages of RNA-seq compared to microarrays is
that, in addition to the quantification of protein-coding genes, it also gives insights about
other RNA traits, including splicing, exon level and increasingly also transcript level (see also
section 3.1.1). As a consequence, splicing QTL (sQTL), can be mapped alongside standard
(protein-coding) gene-level eQTL [125, 124], as well as exon eQTL (eeQTL), transcript ratio
QTL (trQTL) and miRNA eQTL, among others [126, 129].
Cis and trans eQTL
An eQTL is a genomic locus that explains a fraction of the genetic variance of a gene
expression phenotype (Fig. 1.3). As we have seen, regulatory effects on gene expression can
usually be divided into those that act in cis (on the same molecule of DNA) and those that
act in trans (on a different molecule of DNA, often through an intermediate). To identify true
cis and trans effects, differences in gene expression abundance between a pair of individuals
can be compared to the level of allele-specific expression (ASE) observed in their F1 hybrid,
similar to a classical cis-trans complementation test [130, 131]. In this test, a real cis effect
would result in differential expression between the parents and corresponding ASE in the
offspring. In contrast, a real trans effect would result in no ASE in the offspring.
On the other hand, standard eQTL analysis involves a direct association test between markers
of genetic variation with gene expression levels, without requiring any previous knowledge
about specific cis or trans regulatory regions. This association analysis can be performed
proximally or distally with respect to the gene. Conventionally, variants within 1 Mb
(megabase) on either side of a gene’s transcription start site (TSS) are called cis eQTL, while
those at least 5 Mb downstream or upstream of the TSS or on a different chromosome were
considered trans acting [132, 114]. Although this terminology is technically not accurate, it
has been widely embraced by the eQTL mapping community, and I adopt this convention in
this thesis.
13Today we would call this technique ‘bulk’ RNA-sequencing as opposed to the more recent single cell
RNA-sequencing; yet back then it was simply called RNA-sequencing, or ‘RNA-seq’.
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Fig. 1.3: Cis and trans eQTL.
Cis eQTL affect the expression of genes directly. Trans eQTL, in contrast, affect the expression
of typically more distant genes, often by first having a cis effect on the expression of intermediate
regulatory genes. Figure adapted from [114].
Typically, cis-eQTL have a large effect size [133], thus relatively modest sample sizes (from
80-100 samples) permit the detection of cis-eQTL for thousands of genes [118, 134]. cis-
eQTL effects appear to be mostly additive [135], and cis-eQTL SNPs are often located close
to the TSS of genes or within gene bodies [136]. An eQTL effect sizes generally increases as
the distance between the eQTL SNP and the gene’s TSS decreases. In contrast, the effect
sizes of trans-eQTL are generally small [137, 138]. In addition, many more SNP variants
need to be assessed, across all chromosomes, resulting in a much more severe multiple testing
burden (see section 2.2.2). Combined, these two aspects mean that much larger sample sizes
are required to detect trans eQTL. As a result, the number of reported trans-eQTL has
remained small [138] in comparison to the number of reported cis-eQTL [114]. In this thesis,
I worked on datasets with relatively small sample sizes, and so only performed proximal (cis)
eQTL mapping.
From tissue-specific to cell type-specific eQTL
Early studies mainly performed eQTL mapping in whole blood or blood-derived cells, due
to sample accessibility [118, 125]. However, more recently, several studies have published
eQTL derived from a number of normal human tissues [134, 139–147], motivated by the
observation that gene expression levels vary considerably between different tissues and cell
types [148]. Perhaps most notable are those from the genotype-tissue expression (GTEx)
project, which set out to collect and analyse gene expression profiles across several primary
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tissues collected from post-mortem donors [149]. Since the publication of their pilot study
in 2015 [127], several versions have been published [150, 151]. The most recent version
(v8) was released in 2019 and it includes data from 53 tissue types14 from 948 donors.
These studies have collectively identified cis eQTL for the vast majority of human genes,
emphasising their complex and cell type–specific nature, finding that 29%–80% of eQTL are
cell type-specific [127, 141–143].
While eQTL from normal tissues provide valuable insights, tissues are constituted of multiple
distinct cell types, each with specific gene regulatory profiles, as exemplified by the seminal
work by Fairfax et al., mapping eQTL in different blood-isolated cell types (monocytes and
B cells [143]). Yet, apart from a few studies using purified cell types [143, 152, 153] or
deconvolution methods [154, 155], eQTL datasets representing single primary cell types
have been lacking [156]. Additionally, these methods are of limited use for less abundant
cell types, and are dependent on accurately defined marker genes [157].
With the advent of single cell RNA-sequencing (scRNA-seq), eQTL mapping studies are
now possible at the level of individual cells. scRNA-seq can be used to investigate rare cell
types [158], and thus enables identification of cell type-specific eQTL in an unbiased manner.
A first proof-of-concept study was published in 2013 on 15 individuals, where 92 genes were
studied in 1,440 cells [159]. In 2018, the first genome-wide single cell eQTL mapping was
performed in blood, on 45 individuals [160]. For further discussion on performing eQTL
mapping using single cell RNA-seq as opposed to bulk RNA-seq, see Chapter 3.
Context-specific eQTL
In addition to cell type-specific eQTL, some effects of genetic variants on gene expression
levels have been shown to manifest themselves only within cells that have been activated by
a certain external stimulus (often called response eQTL [161–163]) or only in cells under
certain conditions [164] - both are sometimes referred to as ‘context-specific eQTL’ [114].
14Adipose - Subcutaneous, Adipose - Visceral (Omentum), Adrenal Gland, Artery - Aorta, Artery - Coronary,
Artery - Tibial, Brain - Amygdala, Brain - Anterior cingulate cortex (BA24), Brain - Caudate (basal ganglia),
Brain - Cerebellar Hemisphere, Brain - Cerebellum, Brain - Cortex, Brain - Frontal Cortex (BA9), Brain -
Hippocampus, Brain - Hypothalamus, Brain - Nucleus accumbens (basal ganglia), Brain - Putamen (basal
ganglia), Brain - Spinal cord (cervical c-1), Brain - Substantia Nigra, Breast - Mammary Tissue, Cells - Cultured
fibroblasts, Cells - EBV-transfortmed lymphocytes, Cervix - Ectocervix, Cervix - Endocervix, Colon - Sigmoid,
Colon - Transverse, Esophagus - Gastroesophageal Junction, Esophagus - Mucosa, Esophagus - Muscularis,
Fallopian Tube, Heart - Atrial Appendage, Heart - Left Ventricle, Kidney - Cortex, Kidney - Medulla, Liver,
Lung, Minor Salivary Gland, Muscle - Skeletal, Nerve - Tibial, Ovary, Pancreas, Pituitary, Prostate, Skin -
Not Sun Exposed (Suprapubic), Skin - Sun Exposed (Lower leg), Small Intestine - Terminal Ileum, Spleen,
Stomach, Testis, Thyroid, Uterus, Vagina and Whole Blood.
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Using eQTL to link genes to disease
Whilst useful in their own right to understand genetic regulation of gene expression across
cell types and states, eQTL mapping can also be used for annotating variants associated
with complex traits, as such variants are likely enriched for eQTL [165]. A recent study
suggested that two thirds of candidate complex trait mediating genes identified as eQTL are
not the nearest genes to the GWAS lead variants, highlighting the utility of this approach
in annotating GWAS loci [166]. Importantly, GWAS variants are enriched in eQTL in a
tissue-specific manner. For instance, whole blood eQTL are enriched with autoimmune
disorder-associated SNPs but not with GWAS SNPs for bipolar disorder, or type 2 diabetes
[127]. Thus, it is critical to use eQTL data from relevant tissues and cell types when following
up GWAS loci for different diseases.
GWAS-eQTL colocalisation
Integrating eQTL maps with GWAS can identify potential molecular mechanisms underlying
disease associations. One such integration method consists in testing for ‘colocalisation’ of a
GWAS trait and a gene’s expression trait - i.e. test for whether the same variant is causal to
both traits [167]. Intuitively, if it can be established that a causal variant for a GWAS trait
and one for a gene’s expression are the same, this may suggest a regulatory role of the eQTL
SNP in the pathway to the GWAS trait [168, 169].
However, simple overlap of GWAS and eQTL signals does not guarantee mechanism. First,
the two variants may be two independent causal SNPs in LD with each other. Second, eQTL
are abundant [126], with 48% of common genetic variants estimated to act as eQTL for at
least one gene [170], making the overlap between GWAS and eQTL signals possible by
chance. This motivated the development of formal statistical tests that estimate the probability
of the overlaps between the two signals being due to chance - these are called colocalisation
tests.
Early models [171–173] required full individual-level genotype data, which are seldom avail-
able [174]. More recently, Giambartolomei et al. proposed a colocalisation test (COLOC)
which computes the odds of colocalisation compared to the null hypothesis using GWAS
summary statistics [175]. Briefly, COLOC is a Bayesian statistical approach that tests for
pairwise colocalisation of GWAS variants with eQTL, and generates posterior probabilities
for each locus weighting the evidence for competing hypotheses of either no colocalisation
or sharing of a distinct SNP at each locus [176]. Since its release, COLOC has become a
reference method for colocalisation testing. Alternative models for colocalisation include
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MOLOC (an expansion of COLOC to include multiple traits [177]). JLIM [178], HEIDI
[166], Sherlock [168], eCAVIAR [179] and, most recently, ‘jointsum’ [180].
Transcriptome-wide association studies
Colocalisation analyses effectively use genome-wide significant SNPs to nominate causal
genes for complex traits. However, the majority of variants contributing to complex traits
and diseases have not yet been identified, arguably because their effect sizes are too small to
be detected at current GWAS sample sizes [104]. Theoretically, one may want to use tissue-
specific gene expression, rather than genotypes, for association testing. However, carrying
out such studies is currently unfeasible, as it would require profiling gene expression across
hundreds of thousands of individuals in both cases and controls, and across dozens of tissues
[174]. Instead, transcriptome-wide association studies (TWAS) leverage eQTL information
to predict (impute) the gene expression of the cases and controls from a GWAS, and then per-
form direct association of traits and genes - without directly profiling gene expression in every
individual included in the GWAS [106]. Several methods have been proposed, such as TWAS
[181], PrediXcan [182] and summary statistics-based Mendelian randomisation (SMR) [166].
In summary, both colocalisation and TWAS combine eQTL and GWAS catalogues with the
aim to prioritise genes causally involved in complex diseases. In particular, colocalisation
analysis integrates association signals from GWAS and eQTL on a locus-by-locus basis to
identify instances in which both traits share a causal variant. In contrast, TWAS leverages
information from eQTL data to impute gene expression values for all individuals in a GWAS,
and then associates genes directly to traits. The availability of eQTL catalogues from a wider
variety of cell types, as well as of larger sample sizes, will improve gene prioritisation and
translate GWAS results to refined sets of disease-causal genes [174].
eQTL mapping in iPSC and iPSC-derived cells
In addition to human primary tissues, eQTL have been described in human induced pluripo-
tent stem cells (iPSCs) and iPSC-derived cells (see section 1.2.6). In the second part of
this introduction (section 1.2), I describe the use of human iPSCs as an in vitro model for
early human development and as a resource to generate donor-matched cell types and tissues
that are impossible to access in vivo. Population-scale iPSC derivation and differentiation
provides an outstanding resource to investigate the role of genetic variants on expression in
disease-relevant tissues and during development.
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“It is not birth, marriage, or death, but gastrulation which is truly the most important time in
your life.”
Lewis Wolpert, 1986
1.2 Human iPSCs to study cell differentiation
Human iPSCs and cells derived therefrom are the biological system I use throughout this
thesis to study the effect of common genetic variants on expression during cell differentiation.
I use this section to provide some rudiments of human embryology and to describe the role
of human stem cells in scientific research. I focus especially on the iPSC technology, which
allows reprogramming of cells from easily accessible somatic tissues such as skin and blood
to regain stem-cell like (pluripotent) properties and to be subsequently differentiated into
virtually any desired cell type, when provided with the right stimuli.
In particular, in section 1.2.1, I provide a brief historical overview of the study of early
development in humans and in section 1.2.2 I describe the key stages of human embryology,
which we attempt to mimic using iPSC-derived differentiation protocols. Then, in sections
1.2.3 and 1.2.4, I introduce the two key concepts of embryonic stem cells (ESCs) and somatic-
cell nuclear transfer (SCNT), or somatic cloning. ESCs are cells collected at a very early
stage of the embryo’s development that can be grown in vitro to model development. Somatic
cloning, on the other hand, involves introducing the nucleus of a donor’s somatic cell into an
enucleated ovum which can either be implanted into a host and let develop, creating a ‘clone’
for the donor; or, alternatively, grown in vitro for research purposes. Next, in section 1.2.5, I
describe induced pluripotent stem cells (iPSCs), a technology that allows somatic cells to
be reprogrammed to a pluripotent state, which can, in turn, be differentiated into virtually
any differentiated cell types. This allows the generation of ESC-like cells directly from a(ny)
donor, bypassing the need for cloning. In this section, I will describe the technology and
highlight advantages and challenges in the use of iPSCs in biological research. Finally, in
the last section (section 1.2.6), I describe applications of human iPSCs generated from many
individuals to perform population-scale genetic analyses across a variety of iPSC-derived
cell types.
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1.2.1 From homunculi to developmental biology
In the previous section, we learnt that DNA encodes all instructions of life, and that each one
of us contains a mixture of genetic information from both parents, which is identically copied
in every one of our cells. But how do we go from one single cell containing our genetic
fingerprint to a whole organism made of some 37 trillion highly specialised cells which differ
in function and morphology and work together in harmony as a single organism?
Interest in the study of human development and the embryo has ancient origin. We define
an embryo as the first stages of development of a fertilised ovum in the uterus. The word
derives from the Greek εµβρυον (embryon, literally ‘young one’). Early embryology (from
embryon and -λογια, -logia, ‘study of’) was first proposed by an Italian, Marcello Malpighi,
who was a promoter of preformationism. The theory of preformation believes that an embryo
is contained in the semen (thus only derives from the father) and that it is essentially a pre-
formed miniature infant (‘homunculus’) which just gets larger during development (Fig. 1.4).
Fig. 1.4: Early theories of development.
Illustration of the two leading theories on human embryology
before the 19th century. Left, Illustration of Preformation: A
tiny person (homunculus) growing inside a sperm, as drawn
by Nicolaas Hartsoeker in 1695. Right, Epigenesis: study of
foetus deveopment by Leonardo Da Vinci, c. 1510.
The alternative explanation for em-
bryonic development was epigene-
sis, originally proposed by Aristo-
tle approximately 2,000 years ear-
lier. Much early embryology and
support for epigenesis came from
the work of Italian anatomists such
as Aldrovandi and Leonardo da
Vinci (Fig. 1.4) in the Renaissance.
According to the theory of epigene-
sis, the shape of an animal emerges
gradually from a relatively form-
less egg. Yet for centuries, most
people believed in preformation-
ism over epigenesis. Only as imag-
ing techniques improved during the
19th century, could biologists see
that embryos take shape in a series
of progressive steps, leading to epigenesis replacing preformation as the preferred explanation
among embryologists.
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Modern embryology developed from the work of Estonian-born Karl Ernst von Baer. Von
Baer is credited with discovering the mammalian ovum in 1827 and with becoming the
first person to observe human ova. Only in 1876 did Oscar Hertwig prove that fertilisa-
tion is due to the fusion of an egg and a sperm cell [183]. Additionally, von Baer laid
the foundation for the field of comparative embryogenesis in his ‘On the developmental
history of animals’, published in 1828 [184]. In it, he formulated what became known as
Baer’s law of embryology. In particular, he observed that large changes in embryo devel-
opment precede more specific changes and that at a time in development embryos from
different species look very similar, despite looking very different as adults. Some of his ideas
were later used by Darwin in his theory of evolution. In his study of embryology, Von Baer
discovered the blastula and formulated the germ layer theory (see next section, section 1.2.2).
Human embryology as a scientific discipline is closely linked to the creation of human
embryo collections [185–187]. The seminal work of Franklin Mall led to the creation of the
Carnegie collection in 1887, which includes more than 10,000 human embryo specimens, and
established the basic staging criteria for the developmental classification of human embryos
[188]. Other collections were later created, such as the Kyoto collection, which today holds
around 44,000 specimens [189]. Indeed, much of our current textbook knowledge of human
development is derived from the early studies describing these samples.
The development of in vitro fertilisation (IVF) of human eggs [190–192], followed by the
development of conditions to culture these fertilised eggs for up to 5-6 days [193, 194],
allowed scientists to describe the dynamics of key morphological and genetic changes during
early human development (see section 1.2.2).
In parallel, ever since the 1950s, with the helical structure of DNA being unraveled (see sec-
tion 1.1.3), and with increasing knowledge in the field of molecular biology, developmental
biology had emerged and was growing rapidly as a field of study that attempts to determine
the interplay between morphological and gene expression changes during embryogenesis.
Indeed, development requires both mechanical changes in cell and tissue shape, which drive
morphogenesis, as well as gene expression changes, which regulate cell fate decisions and
tissue patterning [195, 196]. Mechano-chemical feedback at the molecular, cellular and
tissue level coordinates this crosstalk and instructs tissue self-organisation [197].
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1.2.2 Human Embryogenesis
I use this section to briefly outline the key steps of human embryogenesis as this is the system
we aim to mimic in vitro using differentiating human iPSCs. Embryogenesis describes the
first eight weeks of development15 after fertilisation, after which we generally refer to fetal
development [201].
Thanks to technological advances in microscopy and in vivo experiments in model organisms
such as fruit flies and mice, we have learnt a lot about this process since the pioneering
experiments of von Baer. In particular, embryogenesis starts with a zygote, which is the
single cell resulting from the fusion of gametes, an egg and a sperm cell; the fusion is known
as fertilisation. Then, the first 12-to-24 hours post-fertilisation are spent in cleavage, which
consists of very rapid cell (mitotic) division and no growth [202].
At around day 3, cells start to get clumped together in a process called compaction [203]. At
this point (day 3/4), the 16-32 cell embryo is called the morula (which is the Greek word for
mulberry), which will undergo blastulation [204] (Fig. 1.5). At around day 4, cells are still
dividing, but they also begin to differentiate and develop specific forms and functions. Two
layers develop: the cells on the outer layer are called trophoblasts, and the cells inside are
embryoblasts [196, 195]. Next, at around day 5, the embryoblasts clump even further into an
inner collection of cells called the inner cell mass, which is pushed to a side of the sphere
formed by the trophoblast. The rest of the fluid-filled cavity is called the blastocoel and this
conformation is called blastocyst. This is also the time when the zona pellucida (a protective
membrane that surrounded the egg cell and that was limiting the embryo’s growth) begins to
disappear, allowing the blastocyst to grow, change shape and start moving [205].
The ability of the embryo to move allows the beginning of implantation: at around day 7, the
embryo has now left the Fallopian tube and reached the uterus and attaches to its wall, the
endometrium. The trophoblasts divide and then fuse with the endometrium - initiating the
process that will eventually build the placenta.
During the second week, these cells form another cavity called the amniotic cavity. At
the same time, they start differentiating further into two layers: the epiblast (closer to the
amnitioc cavity) and the hypoblast (closer to the blastocoel) [202].
15covering the 23 Carnegie stages. The Carnegie system was based on work by Streeter [198] and O’Rahilly
and Müller [199, 200] at the Carnegie Institution of Washington (based on the Carnegie collection, page 25).
The system is standardised and provides a unified developmental chronology of the vertebrate embryo.
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Fig. 1.5: Human Embryogenesis.
Early stages of human embryogenesis. (a) From zygote to morula: stages of clevage. (b) The
blastocyst. Cells divide and form an outer layer, the trophoblasts. Inner cells also called embryoblasts
get compacted and move to a side forming the inner cell mass (ICM), leaving a fluid filled cavity
called the blastocoel. (c) The formation of the bilaminar disk. The ICM splits into the epiblast and
hypoblast which distribute along the surface and result into two more cavities, the amniotic cavity and
the primitive yolk sac, respectively. (d) Gastrulation: from bilaminar to trilaminar disk. The primitive
streak forms and cells start to migrate moving down in between the epiblast and the hypoblast. The
endoderm, mesoderm and ectoderm form and are called the trilaminar disk.
Together, the epiblast and the hypoblast form the bilaminar disc [206]. Only the epiblast
contributes to the embryo, thus I do not discuss the hypoblast further (Fig. 1.5).
The next stage of early embryogenesis is gastrulation [207]. Famously called “the most
important moment in your life” by Lewis Wolpert [208], gastrulation is the process during
which the three germ layers (endoderm, mesoderm and ectoderm) form. At this stage, we call
the cell mass a ‘gastrula’. The first step of gastrulation is the formation of the primitive streak
(∼day 16). The primitive streak determines the midline of the body, separating the embryo’s
left and right sides. At this point, cells are moving down from the epiblast, ending up
between the original epiblast layer and the hypoblast. The first layer to invaginate descends
the deepest and ends up closest to the hypoblast - this is the endoderm. The next layer forms
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the mesoderm, and the remaining epiblast cells that continue to border the amniotic cavity
are the ectoderm (Fig. 1.5).
The next stage is called neurulation (week 3-5). Directly underneath the primitive streak,
mesoderm cells form a thin rod, known as the notochord. The notochord induces a change
within the ectoderm above it, leading to the formation of the neural plate which then dives into
the mesoderm to form the neural tube. This is the end of what is called ‘early embryogenesis’.
Next, the germ layers start forming the various organs in a process called organogenesis.
Briefly, the endoderm forms the gastro-intestial tract, from which upper tract the lungs, the
liver and the pancreas form. The tube itself forms the esophagus, the stomach, and the small
and large intestines. Second, the mesoderm forms some inner layers of the skin (endothelial
cells), the muscles (including the heart), the bones, the kidneys, the bladder, ovaries and/or
testis and blood cells. Finally, the ectoderm forms the outer layer of the skin (epithelial
cells), sweat glands and hair, and importantly our nervous system. After eight weeks since
fertilisation, we call the embryo a foetus, and fetal development begins.
1.2.3 Human Stem Cells
In mammals, roughly 50–150 cells make up the inner cell mass during the blastocyst stage of
embryonic development, at around days 5–14 (Fig. 1.5). These have stem cell16 capability,
meaning that they can eventually differentiate into all of the body’s cell types (making them
‘pluripotent’). Only the zygote is considered to be truly ‘totipotent’ as it is able to form
not only cells of the body (derived from the epiblast) but extra-embryonic tissues as well
(from the hypoblast), which are necessary for the formation of a living organism. Cells with
stem-cell properties are still present in the adult body, and are called somatic or adult stem
cells. These are less potent than inner mass cells. In particular, some adult stem cells have
the ability to differentiate into a whole suite of cell types, and are called ‘multipotent’. For
example, this is the case for hematopoietic stem cells, which give rise to all the cell types
of the blood and the immune system. Other stem cells are more specialised, like epidermal
stem cells, which are only able to differentiate into epidermal cells, or fibroblasts. These are
called ‘unipotent’ (Fig. 1.6).
16stem cells are characterised by their self-renewing abilities and the ‘potency’ to differentiate into more
specialised cells.
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Fig. 1.6: The potency tree of stem cells.
The spectrum of potency along human development: from the totipotent zygote to terminally differen-
tiated cells.
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The existence of stem cells was first demonstrated by Canadian biologists Ernest McCulloch
and James Till in the early 1960s. Together with graduate student Andy Becker and senior
scientist Lou Siminovitch their work was published in Nature in 1963 [209].
Embryonic stem cells
In 1981, embryonic stem (ES) cells were first isolated and successfully cultured using mouse
blastocysts by British biologists Martin Evans and Matthew Kaufman [210, 211]. In the
1990s, ES cell lines from two non-human primates, the rhesus monkey [212] and the common
marmoset [213], were derived, and these offered closer models for the derivation of human
ES cells. The first human embryonic stem cells (hESCs) were finally isolated in 1998 by
the American developmental biologist James Thomson [214]. Thomson and colleagues
derived hESC lines by culturing human blastocysts in a cocktail of growth factors and
supporting mouse feeder cells. Indeed as they first demonstrated, human inner mass cells,
when isolated and cultured in vitro, can be kept in the stem-cell stage and are known as hESCs.
Because they can proliferate without limit and can contribute to any cell type, human ES
cells offer unprecedented access to tissues from the human body [215]. As a consequence,
hESC lines held great promise for research purposes, as an in vitro model for both human
development and disease [216]. First, embryonic stem cells have been used widely to improve
our understanding of embryogenesis and development in general. Both in human and mouse,
ESCs have been differentiated into a plethora of cell types. Additionally, ESCs can be grown
not only in a 2D culture but also in 3D structures, to better mimic the formation of organs
(i.e. organoids [217, 218]) or even entire (early) embryos (the so called ‘gastruloids’ [219]).
Additionally, they can be used as disease models and for in vivo drug testing.
Second, ESCs could be used for cell replacement therapy, and, down the line, regenerative
medicine [220]. Indeed, not only do ESCs have the ability to self-renew indefinitely, but in
theory they can also be differentiated into any cell type in the body, thus providing functional
replacement or support to worn-out or dysfunctional cells and tissues and, in a future, replac-
ing organ transplants entirely.
However, in order to isolate ESCs the embryo needs to be destroyed which, naturally, caused
a big ethical debate. Such ethical concerns caused the generation of ESCs to be reduced
substantially or even made illegal in some countries. Today, a number of lines have been
isolated and frozen and are available for research. Stem cell banks from a few countries
provide (managed) access to several hundred hESC lines including the UK Stem Cell Bank
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(139 lines) and the US NIH Human Stem Cell Registry (484 lines). In total, it is estimated
that there are between 800 and 1,000 hESC lines available in the world which are, in the vast
majority, derived from discarded IVF embryos [221].
In addition to the ethical controversies that the use of human embryos faces, which hinder
the applications of human ES cells, it is difficult to generate patient- or disease-specific ES
cells, which may be required for their effective clinical application [222].
1.2.4 Nuclear cloning of somatic cells
One early solution for the latter problem involved transplanting the nucleus of an adult donor
cell in an enucleated oocyte in a process called nuclear cloning.
Nuclear cloning17, also referred to as nuclear transfer or nuclear transplantation, denotes the
introduction of a nucleus from an adult donor cell into an enucleated oocyte to generate a
cloned embryo [223]. This embryo has the potential, when implanted into the uterus of a
female host, to grow into an infant that is a clone of the adult that provided the donor cell,
in a process termed ‘reproductive cloning’. In alternative, the embryo can be explanted in
culture, and give rise to embryonic stem cells that can differentiate into any adult cell type.
The first to perform nuclear cloning in animals was the British developmental biologist Sir
John Gurdon. During his PhD in the Zoology department at Oxford, Gurdon worked on
nuclear transplantation in a frog species of the genus Xenopus. In 1958, he successfully
cloned a frog using intact nuclei from the somatic cells of a Xenopus tadpole [224]. This
critical study proved that eggs receiving transplanted nuclei from a more mature cell type
could be differentiated, directly contradicting what was believed at the time [225].
The first cloned mammal was Dolly the sheep, born on July 5, 1996. She was cloned by Keith
Campbell, Ian Wilmut and colleagues at the Roslin Institute at the University of Edinburgh,
using the process of somatic-cell nuclear transfer (SCNT) [226]. Dolly had three mothers:
one provided an unfertilised oocyte (cytoplasmic donor), another provided the nucleus (from
a mammary gland cell18, nuclear donor) and finally a surrogate ewe hosted the embryo until
its birth.
17The word ‘clone’ comes from the Greek word for twig, as it was first applied in plants.
18It is the use of a mammary gland as somatic cell source that motivated the name’s choice: Dolly was named
after country singer Dolly Parton, who is apparently famous (also) for her breasts.
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Following the successful cloning of Dolly the sheep and the pioneering work of Tada et al.,
who demonstrated somatic cloning by fusion of the somatic differentiated cells with ES cells
[227], many other species have been cloned, including pigs, cats, dogs, horses, camels and
even macaques. Combined, this work proved that somatic (differentiated) cells could be
reprogrammed to a pluripotent state [228].
Until the early 2000s, the prospect of human cloned embryos explanted in culture was
essentially the only envisoned way to generate patient- or disease-specific stem cells [222].
However, application of SCNT in human cells proved extremely challenging [229]19. In
parallel, funding restrictions and ethical concerns around hESCs provided the impetus to find
alternative approaches for generating stem cells with the same degree of pluripotency.
1.2.5 Induced pluripotent stem cells
The need to find both more ethical solutions and more effective ways of generating donor-
specific stem cells led to the generation of the first induced pluripotent stem cells (iPSCs).
Discovered in 2006 by Japanese stem cell researcher Shinya Yamanaka, iPSCs are somatic
cells (originally mouse fibroblasts) which are reprogrammed into acquiring a stem-cell iden-
tity [231]. Yamanaka has stated that it was the success of the cloning of Dolly the sheep
that proved to him that reprogramming of somatic cells (in mammals) was possible. The
next year, the labs of Yamanaka and Thomson20 successfully generated iPSCs from human
somatic cells [231–233], surpassing nuclear transplantation as the first step toward effective
regenerative medicine and becoming the leading alternative to hESCs for developmental
research.
In 2012 Sir John Gurdon and Shinya Yamanaka were jointly awarded the Nobel Prize in
Physiology or Medicine for their combined efforts in discovering that “mature cells can be
reprogrammed to become pluripotent” [234] (Fig. 1.7).
19Only more recently has somatic cell nuclear transfer been successfully performed to generate human ESCs
(NT-ESC), providing an alternative method to convert human somatic cells to a pluripotent state [230].
20The Thomson group had also isolated human ESCs for the first time in 1998, see page 30.
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Fig. 1.7: Historical timeline of key events leading to the development of iPS cells.
Key events including somatic cloning and isolation of ES cells that eventually led Shinya Yamanaka
and colleagues to generate iPSCs in 2006 and Yamanaka to win the 2012 Nobel Prize for Physiology
and Medicine alongside Sir John Gurdon.
Inducing pluripotency
The generation of iPSCs involves the reprogramming of differentiated somatic cells from
readily accessible tissues (such as skin or blood) into a pluripotent state by the introduction
of a cocktail of factors that are able to ‘reset’ the transcriptional programme of the cells to an
embryonic state [216].
The induction of iPSCs (in mice) was first described in a seminal paper published in Cell. In
it, Takahashi and Yamanaka first demonstrated induction of pluripotent stem cells from mouse
fibroblasts (both embryonic and adult) by induction of four transcription factors, Oct3/421,
Sox2, c-Myc and Klf4, under ES cell culture conditions [231]. In the paper, the authors
demonstrate that iPSCs exhibited similar morphology, proliferation properties and doubling
times compared to ESCs. Additionally, iPSCs expressed major ES cell marker genes like
SSEA-1 and Nanog and formed teratomas upon injection into immunocompromised mice22.
21also called Pou5f1.
22A teratoma is a non-malignant tumor comprised of a disorganised mixture of cells from all three germ
layers. In a teratoma assay, putative pluripotent stem cells are implanted into an immune-compromised mouse
where they may proliferate and differentiate to form a teratoma.
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However, these ‘first generation’ iPSCs failed to generate adult chimerae23 or contribute
to the germline [231], suggesting that the iPSCs were only partially reprogrammed [236].
In 2007, Yamanaka and other laboratories modified the induction protocols to generate
fully reprogrammed ‘second generation’ iPSCs that were competent for adult chimera and
germline transmission [237, 238, 235].
A year later, the Yamanaka and the Thomson labs demonstrated, at around the same time,
successful induction of pluripotent stem cells in human. In the Yamanaka paper [232] human
iPSCs were derived from adult human dermal fibroblasts using a retroviral system and using
the same 4 factors used in mice, which later became known as the Yamanaka factors: Oct3/4,
Sox2, Klf4 and c-Myc (or OSKM). In their paper, published on the same day, the Thomson
group also showed successful generation of human iPSCs, using a slightly different technique:
they used a lentiviral system to express the factors, and changed two of the inducing factors
used: Oct4 and Sox2 remained, but the other two were replaced by Nanog and Lin28: this
set of factors is sometimes called OSNL [233].
In the next two years (2007-2009), the same technology was successfully applied by several
groups and across a range of human cell types, including fibroblasts [239] and other somatic
cell types, such as pancreatic β cells [240], neural stem cells [241, 242], stomach and liver
cells [243], mature B lymphocytes [244], melanocytes [245], adipose stem cells [246] and
keratinocytes [247], demonstrating the universality of cellular reprogramming [236].
Challenges in the use of iPSCs
Yet for iPSCs to fulfil their promise (that they are viable and possibly superior substitutes for
ESCs in disease modeling, drug discovery, and regenerative medicine), several challenges on
the road to their clinical application needed (and some still need) to be overcome. First, very
low efficiency was recorded: in the original Yamanaka paper, only 0.01–0.1% [231] of the
starting cells effectively exhibited pluripotency, and other initial reports did not exceed 1%
[232, 235, 248].
23A chimera is a single organism composed of cells with more than one distinct genotype. The name derives
from Greek mythology, where a chimera was a fire-breathing monster that was part lion, part goat, and part
dragon. To generate a chimera, induced pluripotent stem (iPS) cells (e.g. with a gene-specific mutation) are
injected into blastocysts, which are then transplanted into the uteri of pseudo-pregnant mice. By breeding a
chimeric mouse with a wildtype mouse and observing the corresponding phenotype, e.g. coat colour, one can
assess the contributions of the iPSCs to the germline [235].
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Second, the over-expression of oncogenes (genes that have the potential to cause cancer)
such as c-Myc and Klf4 during the generation of iPSCs raised safety concerns. Indeed, in the
original report of germline-competent iPSCs, ∼20% of the offspring developed tumors that
could be traced back to the reactivation of the c-Myc transgene [235]. Furthermore, there is
the risk of insertional mutagenesis due to virus-based delivery methods [231–233]. Finally,
several studies have reported incomplete reprogramming, with cells maintaining some degree
of ‘epigenetic24 memory’ from their somatic cell of origin, which can lead to their biased
differentiation potential into certain cell types depending on the donor cell source [249, 250].
Much progress has been made in the past decade to address these limitations and to improve
the reprogramming technique, including the development of new methods to induce repro-
gramming. In the following sections I present an overview of the advances made to improve
the reprogramming technique, and discuss methods for characterising iPSCs in general.
Reprogramming factors
Generating iPSCs requires the introduction of pluripotency related factors into the somatic
cell. The generation of iPSCs by the Yamanaka and Thomson groups using different cocktails
of transcription factors may suggest that different factors activate the same reprogramming
pathway by reinforcing each other’s synthesis. As a consequence, apart from the ‘fantastic
four’ OSKM transcription factors, Oct4, Sox2, Klf4, c-Myc and the alternative OSNL
combination described by the Thomson group containing Oct4, Sox2, Nanog and Lin28
[233], other factors, sometimes referred to as ‘reprogramming enhancers’, have been found to
increase reprogramming efficiency and iPSC quality [251]. Those include other transcription
factors, small molecules, microRNA’s (miR) and different culturing conditions.
Mechanisms of iPSC induction
Several studies have described how the ectopic expression of OSKM in somatic cells induces
the transition to a pluripotent state [222, 252–256]. Based on these studies, we can now
describe the order of events during the reprogramming process, which can be divided broadly
into two waves or phases: an initial, stochastic early phase (phase 1) and a more deterministic
and hierarchical late phase (phase 2) [236, 251, 257].
24Epigenetics, from the Greek prefix epi- (meaning on top, around, in addition), refers to heritable changes of
gene expression that do not involve variation in the genetic sequence of DNA. For example, DNA methylation
and histone modifications are common epigenetic changes.
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During induction using the OSKM factors, the first transcriptional wave (phase 1) is mostly
mediated by c-Myc and occurs in all cells, whereas the second wave (phase 2) is mostly
targeted to ‘reprogrammable’ cells, and involves a gradual increase in the expression of the
Oct4 and Sox2 targets, leading to the activation of other pluripotency genes that aid in the
activation of the pluripotency network. Klf4 seems to support both phases by repressing
somatic genes during the first phase and facilitating the expression of pluripotency genes in
the second phase [258].
The two phases describe the mechanisms of reprogramming in the cells that successfully
become pluripotent iPSCs. However, as we have seen, these are a rather small percentage of
all transduced cells. Three models, the elite, stochastic and deterministic models have been
proposed to explain the reasons behind such low reprogramming efficiency [236]. For more
detail into these three models, I refer the reader to Takahashi & Yamanaka [251].
Delivery methods
A number of different methods have been used to deliver the reprogramming factors into
somatic cells. These delivery methods can be categorised into two groups: integrative sys-
tems (involving the integration of exogenous genetic material into the host genome) and
non-integrative systems (involving no integration of genetic material into the host genome).
Early methods to deliver the reprogramming factors were integrative. These were mainly
viral vectors, including retrovirus [231, 232, 238, 235, 222, 237], lentivirus [233, 259], and
inducible and excisable retrovirus [260] or lentivirus [247] systems. Overall, integrative
delivery methods have higher reprogramming efficiency as compared to non-integrative
methods, but they are less safe, due to the risk of insertional mutagenesis.
Indeed, the introduction of efficient, integration-free methods for cell reprogramming was
crucial to reduce safety risks. These alternative non-integrative induction methods have
been developed in recent years, and involve the transient expression of reprogramming
factors, including the use of viral vectors (adenovirus [240] and Sendai virus [261, 262])
and non-viral vectors, such as plasmids [263–266], transposons [267, 268, 263] synthetic
mRNAs [269] and recombinant proteins [270].
Because they are safer, the use of non-integrative methods is overall more appealing for
iPSC generation and use in clinical settings. Currently, episomal vectors, Sendai viruses and
synthetic mRNAs are the most popular methods used for generating integration-free iPSCs.
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Fig. 1.8: iPS cells - derivation and applications.
The generation of iPSCs starts with a biopsy from, for example, the skin of an adult donor. Adult cells,
in the example fibroblasts, are then isolated and pluripotency is induced through four reprogramming
factors, for example the Yamanaka factors: Oct4, Sox2, Klf4 and c-Myc (OSKM). The factors can
be delivered using a number of systems, see page 36. The resulting induced pluripotent stem cells
(iPSCs) are self-renewing and are virtually indistinguishable from ESCs. They can be subsequently
differentiated towards other cell types, including disease relevant cell types, for example dopaminergic
neurons for Parkinson’s disease, or pancreatic beta cells for diabetes. In the future, iPSC-derived
cells might be used for cell therapy, i.e. they could be transplanted into the patient, with no risk
of allogenic rejection. In the meantime, iPSCs and iPSC-derived differentiations can be used to
model development and disease, and to do compound screening and drug testing. Figure created with
BioRender.com.
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Somatic cell of origin
As for the cell source for reprogramming, somatic cells should preferentially be easily ac-
cessible, susceptible for reprogramming and the reprogramming process should ideally be
highly efficient [257]. Several different human somatic cell types have been successfully
reprogrammed; however, reprogramming efficiencies and kinetics vary between somatic
cell types. Keratinocytes for example showed a 100 times higher reprogramming efficiency
(∼0.8%) and were reprogrammed two times faster than skin fibroblasts under the same
conditions [271].
Today, human iPSCs have been derived from a multitude of cell types [272], including dermal
skin fibroblasts [232, 233], adipocytes [273], nucleated blood cells from peripheral blood
[274, 275], dental pulp [276], keratinocytes from hair follicles [271] and renal tubular cells
from urine samples [277]. However, approximately 80% of human iPSCs used in published
studies are generated from fibroblasts [251].
As mentioned above, the choice of cell source may also have consequences in terms of the
epigenetic makeup of the iPSCs generated. Indeed, during the reprogramming process the
somatic cells’ epigenetic signature must be erased in order to adopt a stem cell-like epigenome.
These changes include chromatin reorganisation, DNA demethylation of promoter regions of
pluripotency genes like NANOG, SOX2 and OCT4, reactivation of the somatically silenced X
chromosome, and genome-wide resetting of histone post-translational modifications [232,
237, 238, 258]. If the reset is incomplete, cells may maintain some degree of ‘epigenetic
memory’ from their somatic cell of origin, which can lead to biased differential potential
[249, 250]. However, it has been shown that their residual epigenetic memory diminishes as
the cells are passaged in culture over a period of time [278].
Characterising iPSCs
As we have seen, reprogramming iPSC is a complex and not particularly efficient method. As
a consequence, it is important to carefully characterise the iPSCs obtained after reprogram-
ming [257] and establish criteria to evaluate the ‘quality’ of iPSCs. Different methods have
been and should be used in combination to deeply characterise iPSCs. First, the characteristic
ESC-like morphology of iPSCs is often used as an indication of their correct formation.
iPSCs can be observed as small cells with large nucleus/cytoplasm ratios that form tightly
packed colonies with clear, sharp edges.
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Second, iPSCs are characterised by the expression of pluripotency markers including Oct4,
Nanog, SSEA-3, SSEA-4, TRA-1-60 and TRA-1-81 [279]. Additionally, bioinformatics
tools, such as the PluriTest [280], have been developed which use gene expression to assess
the level of pluripotency.
In addition to morphological and gene expression considerations, iPSCs can also be evaluated
functionally by their differentiation potential. Indeed, iPSCs should be able to terminally
differentiate into cells of all three germ layers (endoderm, mesoderm, ectoderm) - which can
be evaluated through in vivo teratoma formation assays or in vitro differentiation through
embryoid body (EB) formation. Finally, since reprogramming influences the genetic and
epigenetic make-up of the cells, iPSCs should be carefully characterised for their genetic
and epigenetic profiles. Specifically, karyotyping is commonly used to evaluate genetic
abnormalities in iPSCs, i.e. to verify that cells are diploid. Additionally, if transgenes are
used for reprogramming, it is important to verify that the expression levels of the transgenes
are properly down regulated once the iPSCs are formed. As for the evaluation of the
epigenetic profile of the iPSCs, DNA methylation patterns can be assessed. Since DNA
methylation contributes to silencing of genes, it is important that the generated iPSCs show
DNA demethylation at key pluripotency genes (e.g., Oct4, Nanog, Sox2), while genes specific
to the donor somatic cell type become methylated and silenced [257, 236].
Heterogeneity of iPSCs and between cell line variation
An important aspect of iPSC biology is the large variability observed between different iPSC
lines and clones (even when derived from the same donor). This includes differences in terms
of their differentiation capacity, epigenetic status, immunogenic and tumorigenic potential,
maturation level, batch variability and co-occurrence of heterogenous populations of lineage
subtypes and/or non-relevant cells as contaminating cell populations [258]. This observed
diversity, which is greater than what has been described in ESCs, can be explained by the
residual epigenetic memory, genetic background and other characteristics acquired during
reprogramming and differentiation [249, 250, 281]. Naturally, understanding these sources
of variable differentiation, particularly in terms of efficacy and safety, will be critical for the
successful use of cell replacement therapies in the clinical setting [258].
Thus, it is important to investigate sources of variable differentiation potential across lines,
including lines derived from genetically distinct individuals.
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1.2.6 Applications of human iPSCs in genetics
In contrast to ES cells, the use of which, as we have seen, raises important ethical concerns25,
iPSCs can be derived from easily accessible tissues such as blood or skin, bypassing all such
issues. Because they are fairly easy to derive, they can be generated for individuals from
all genetic backgrounds, including individuals carrying a genetic disorder of interest. In the
future, the iPSC technology opens the way to regenerative medicine where tissues can be
re-generated with one’s own cells thus avoiding the risk of immune rejection (when the body
rejects a donor’s allogenic organ as a foreign object).
In addition to the study of genetic disorders and the use for tissue regeneration, the iPSC
technology can be applicable to basic biological research of human development and disease
modeling. Indeed, human iPSCs have already been differentiated into a plethora of differenti-
ated cell types, including neural stem cells [282], cortical, dopaminergic and motor neurons
[283–285], astrocytes [286] and oligodendrocytes [287] as well as cardiomyocytes [288],
skeletal muscle cells [289], vascular endothelial/smooth muscle cells [290], hepatocytes
(liver cells) [291], pancreatic beta cells [292] and lung epithelial cells [293].
In recent years, as the iPSC technology became more established, iPSC lines have been
derived from large cohorts, allowing deeper characterisation of these cells across multiple
individuals. This paved the way to the study of how common genetic variants affect gene
expression in iPSCs. These large cohorts represent a resource which allows differentiation of
a number of these lines and the interrogation of eQTL in derived differentiated cell types.
HipSci and other human iPSC consortia
The Human Induced Pluripotent Stem Cell Initiative (HipSci) [294] is the largest human
iPSC cohort to date, and the results described in this thesis are all obtained using HipSci
lines. The original goal of HipSci was to generate a large, high quality reference panel
of human iPSC lines for the research community to help deeply characterise these cells.
All HipSci donors are volunteers from the Cambridge area in the UK. Donors are for the
vast majority of European descent, both male and female and across a range of ages (for
healthy donors, [50-54]-[65-69]). The majority of lines are derived from healthy donors,
with small groups of diseased26 samples. For sample collection, primary fibroblasts from
skin biopsies (from the inner upper arm to minimise somatic mutations due to sun exposure)
25as it involves the destruction of the embryo
26Diseases included in HipSci are monogenic diabetes, Bardet-Biedl syndrome, Usher syndrome, Hyper-
trophic cardiomyopathy and a few others, see http://www.hipsci.org.
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were collected from consented research volunteers recruited from the NIHR Cambridge
BioResource and iPS cell derivation was performed either using the Sendai reprogramming
kit or episomal plasmids expressing the (human) Yamanaka factors: human (h)OCT3/4,
hSOX2, hKLF4 and hMYC [263]. Following transfer to feeder free culture and expan-
sion, each line was submitted to quality control and the criteria for line selection were:
(i) level of pluripotency, as determined by the PluriTest assay [280]; (ii) number of copy
number abnormalities; and (iii) ability to differentiate into each of the three germ layers [294].
Additional iPSC consortia and large studies include iPSCORE (a panel of fibroblast-derived
iPSC lines from 222 ethnically diverse and sometimes related individuals [295]), GENESiPS
(a collection of 317 peripheral blood mononuclear cell (PBMC)-derived iPSC lines from
101 individuals [296]), PHLiPS (containing PBMC-derived iPSC lines from 91 individuals
of European and African-American ethnicity [297]), and Banovich et al (a cohort of 58
lymphoblastoid cell line (LCL)-derived Yoruban lines, [298]).
eQTL mapping using iPSCs and iPSC-derived cells
In 2017, the HipSci consortium published a first paper, where they assessed iPSC lines
through various assays, and mapped eQTL in 711 cell lines from 301 unique donors [294].
At around the same time, another map of iPSC eQTL was published in Cell Stem Cell
[299]. Most recently, a meta-study was published as the result of an effort to combine
iPSC resources into the i2QTL consortium [129]. Collectively, these studies have identified
iPSC-specific eQTL, i.e. eQTL that function primarily in pluripotent cells. A subset of
these tagged disease-associated loci, suggesting that they are capturing molecular changes
early in development which are not well captured by studies of differentiated primary tissues
from adult individuals. Alternatively, iPSC eQTL may be capturing stem-cell like molecular
mechanisms, which are similar to mechanisms active in cancer [294].
In the last few years, eQTL have also been mapped in several iPSC-derived cell types.
These include iPSC derived- macrophages [300], hepatocytes [297], neurons [301] and
cardiomyocytes [302, 298]. These eQTL promise to greatly improve our understanding of
genetic regulation in cell types that we do not typically have access to, including cells at
early developmental stages and cells that are difficult to isolate, such as neuronal cell types.
Combined with GWAS results (i.e. page 21), they can contribute to our understanding of the
genetic architecture of complex diseases by facilitating analysis in the relevant cell types, for
example dopaminergic neurons for Parkinson’s disease (Chapter 5) or endoderm-derived
(Chapter 4) pancreatic beta cells for diabetes.
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1.3 Thesis outline
The overall aim of this thesis is to provide suitable computational methods for the identifica-
tion of cell type and context-specific eQTL using single cell expression profiles, and explore
their application across a range of human iPSC-derived cell types, using data from the HipSci
project.
Specifically, in Chapter 2, I provide an overview of the use of linear and linear mixed models
(LMMs) for genetic association analyses, focusing on their application in eQTL mapping.
In Chapter 3, I describe best-practice approaches to perform eQTL mapping using single-
cell RNA sequencing (scRNA-seq) profiles and demonstrate these methods on matched bulk
and single cell expression of around 100 human iPSC lines.
In Chapter 4, I present a dataset of almost 40,000 cells from 125 human iPSC lines differen-
tiating to definitive endoderm, and demonstrate different approaches to eQTL mapping using
scRNA-seq data, identifying genetic variants that affect gene expression dynamically along
differentiation and across other cellular states.
In Chapter 5, I present a dataset of over one million cells from 215 human iPSC lines
differentiating to midbrain dopaminergic neurons. We identify thousands of eQTL across
a number of cell types and upon external stimulation. In addition, we identify hundreds of
colocalisation events with variants that are known to be associated with neurological traits
and diseases. Moreover, we investigate sources of variation in the capacity of individual cell
lines to differentiate toward neurons.
Finally, in Chapter 6, I conclude and discuss future directions.
2
Linear mixed models for eQTL mapping
In Chapters 3-5 I describe various models for eQTL mapping using single cell expression
profiles. All of these models build on a linear mixed model (LMM) framework. I use this
chapter to provide an overview of linear and linear mixed models and their application in
quantitative genetics, with a focus on their use for eQTL mapping. I will also briefly intro-
duce LMM-based models to test for genotype-environment (GxE) interactions, to provide
the necessary theoretical foundations for some of the analyses in Chapter 4.
LMMs are a very popular framework for many genetic analyses. They are especially ap-
pealing because they provide robust control for confounding factors. One drawback of
these methods is that inference using LMMs is typically computationally costly, yet efficient
implementations of specific LMMs exist, enabling application to large cohorts. I use this
chapter to provide an overview of the use of LMMs in genetic association studies: in sections
2.1-2.2, I discuss the linear model (also called linear regression) and basic applications for
genome-wide association studies (GWAS) and quantitative trait locus (QTL) mapping. In
section 2.3, I introduce the LMM and discuss applications in genetics, with a focus on the
use of LMMs for eQTL mapping. Finally, in section 2.4, I briefly discuss extensions of the
LMM framework to test for GxE interactions.
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For mathematical model descriptions throughout this thesis, I use the following notation: bold,
lower-case letters symbolise one-dimensional column vectors (e.g. v) and bold capitalised
letters matrices (e.g. M). A normal distribution is specified by N (µ,σ2), where µ , σ are
two scalars representing the mean and standard deviation parameters. For simplicity, I use the
same notation for multivariate normal (e.g. N (µ ,Σ)), noting that the specified parameters
(µ and Σ) are an N ×1 mean vector, and an N ×N covariance matrix, respectively.
2.1 The linear regression model
A linear model, or regression, is a statistical approach to modelling a continuous output
variable (dependent variable, or outcome) as a linear function of one or more input variables
(features, or independent variables). For F features, the outcome variable for a single sample





xi, f β f +ψi, (2.1)
where the noise term ψi (ψi ∼N (0,σ2n )) accounts for measurement noise of yi, reflecting
the non-deterministic relationship between yi and xi, f , and is assumed to follow a normal
distribution with 0 mean and constant variance σ2n . Furthermore, the noise term is assumed
to be independent across samples, i.e. cov(ψi,ψ j) = 0 for every i ̸= j. For N samples, the
model in eq. (2.1) can be expressed in matrix form as:
y = Xβ +ψ , (2.2)
where y is the N × 1 outcome vector, X is the N ×F feature matrix, and β is the F × 1
corresponding weight vector. Finally, ψ is the N×1 noise vector such that: ψ ∼N (0,σ2n IN),
where IN denotes the N ×N identity matrix.
2.1.1 The maximum likelihood solution
Equation (2.2) is a realisation of the probability distribution of the data p(y|X,β ,σ2n ) given
the input variables X and the model parameters β and σ2n . This is known as the likelihood of
the model and is considered as a function of the model parameters, denoted as L(β ,σ2n ). We
can then express the model in eq. (2.2) as:
L(β ,σ2n ) = p(y|X,β ,σ2n ) =N (y|Xβ ,σ2n IN), (2.3)
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or, equivalently, as:
y ∼N (Xβ ,σ2n IN). (2.4)
In parameter inference, the maximum likelihood estimator (MLE) of the model parameters
is defined as the set of parameter values that maximise the likelihood. In practice, it is
often convenient to work with the natural logarithm of the likelihood function, called the log
likelihood (ℓ= logL), noting that both functions will be maximised by the same parameter
values. The log likelihood of the model can be explicitly specified as:




N log(2πσ2n )+ log |IN|+
1
σ2n









(y−Xβ )T (y−Xβ ).
(2.5)
Denoting with β̂ and σ̂2n the MLEs of β and σ
2
n , we can write:
β̂ , σ̂2n = argmaxβ ,σ2n ℓ(β ,σ
2
n ). (2.6)
By setting the gradient of the log likelihood in eq. (2.5) with respect to both parameters to














(y−Xβ̂ )T (y−Xβ̂ ) = 1
N
(y−X(XT X)−1XT y)T (y−X(XT X)−1XT y). (2.9)
Note that the solution for β̂ in eq. (2.8) is equivalent to the ordinary least squares (OLS)
solution [303].
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2.1.2 The restricted maximum likelihood solution
In Gaussian models as in eq. (2.4) the MLE of the variance parameter σ̂2n suffers from down-
ward bias1 because the weights β̂ are estimated from the data, which involves a reduction of
the effective number of degrees of freedom.
Patterson and Thompson [304] presented a β -free estimation of σ2n via the restricted (or
residual) maximum likelihood (ReML). Given the model in eq. (2.2) the ReML can be
obtained by projecting the output vector in a space that is orthogonal to X such that:
AX = 0. (2.10)
Using eq. (2.10) and rewriting eq. (2.2) in terms of the projection w we obtain:
w = Ay = A(Xβ +ψ ) = Aψ , (2.11)
which provides an expression of y that is independent of β .








log |XT X|− 1
2σ2n
(y−Xβ̂ )T (y−Xβ̂ ), (2.12)




(y−X(XT X)−1XT y)T (y−X(XT X)−1XT y), (2.13)
which is now an unbiased2 estimator for σ2n .
Note that eq. (2.13) is identical to eq. (2.9) except for the fact that N is replaced by (N −F),
denoting the loss of F degrees of freedom.
1The bias of an estimator refers to the difference between this estimator’s expectation (here, E[σ̂2n ]) and the
true parameter value (σ2n ). Downward bias indicates that E[σ̂2n ]< σ
2
n .
2i.e. E[σ̂2n ReML] = σ
2
n .
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2.2 Regression models for association studies
As we have seen (section 1.1.7), originally GWA studies used contingency table tests (such
as the χ2 test) to assess the significant effect of a variant on a dichotomous trait [76]. How-
ever, these tests are sub-optimal in the case of quantitative traits, such as height and weight,
which would need to be arbitrarily discretised. Additionally, these tests are not equipped
to account for confounding factors (these are described in more detail in section 2.3). As a
consequence, regression-based models became the preferred approach, because they allow
covariate adjustment, and can directly provide a measure of the effect size for each tested
variant [72].
When applying regression models in genetic association studies, the phenotype of interest
is modeled as the outcome variable (y). In GWAS, we typically look at ‘organismal phe-
notypes’, including traits such as height and eye colour or disease status/risk for complex
disorders [76]. In (molecular) QTL mapping, we consider ‘molecular phenotypes’, such as
gene expression (i.e. eQTL), or protein level (pQTL).
The genotype at the SNP of interest is modelled as the independent variable. We assume
all SNPs to be biallelic, that is that they can only assume two possible values - A (major
allele) and a (minor allele)3. Three models can be considered for the minor allele a. First,
a dominant model (i.e. AA = 0, Aa = 1, aa = 1; where one copy of the minor allele is
sufficient to have a phenotypic effect); second, a recessive model, (AA = 0, Aa = 0, aa = 1;
where two copies of the minor allele are necessary for observing a phenotypic effect); finally,
an additive model (AA = 0, Aa = 1, aa = 2; where the phenotypic effect is proportional
to the number of minor allele copies). Throughout this thesis, we will consider an addi-
tive genetic model, which is commonly used in both GWAS and eQTL mapping analyses [86].
The test, then, consists of assessing the effect of each individual SNP (g) on the phenotype (y),
one at a time. For quantitative traits, including molecular traits such as gene expression and
some complex traits such as height, blood pressure or BMI4, a linear regression is typically
used5:
y = gβ +ψ . (2.14)
3The notation of major and minor alleles refers to the allele frequency in the population studied. Alternatively,
it is possible to denote A as the reference allele and a as the alternative allele, based on the reference genome.
4BMI: body mass index, a measure of weight normalised by height.
5In contrast, case-control designs are better modeled by a logistic regression, i.e. logit(E[y]) = gβ +ψ
[305, 306].
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2.2.1 Statistical hypothesis testing
To test for whether an association between a genetic variant and a trait is present, we can
compare the hypothesis where the genetic variant has no effect on the trait (called null
hypothesis, H0) and the alternative hypothesis when the variant does have an effect (effect
different from 0, H1). Formally, the association hypothesis test for eq. (2.14) is:
H0 : β = 0 (2.15)
vs
H1 : β ̸= 0. (2.16)
We are then comparing the following models:
H0 : y ∼N (0,σ2n IN) (2.17)
and
H1 : y ∼N (gβ ,σ2n IN). (2.18)
Statistical hypothesis testing comprises three fundamental steps: i) define a test statistic; ii)
obtain a p value and iii) upon a threshold on the p value, reject or accept the null hypothesis.
A test statistic is a random variable that measures the level of concordance between the
observed sample and the null hypothesis H0. Using this test statistic, we calculate a p value
as the probability, under the assumption that the null hypothesis H0 is correct, of sampling a
test statistic at least as extreme as the one we observed. An extreme value of the test statistic
generally indicates evidence against H0. The p value is a function of the test statistic and, by
definition, it is uniformly distributed under H0. Finally, if this probability is low (under a
defined threshold, e.g. p value < 0.05), H0 is rejected.
Two types of errors can be made in statistical hypothesis testing. A false positive (type I
error) occurs when we reject H0 when H0 is true; in contrast, a false negative (type II error)
is generated when we reject H1 when H1 is true. Other key concepts in statistical hypothesis
testing are summarised in Box 2).
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Box 2: Key concepts of statistical testing
Confusion matrix for statistical classification:
Test Result
reject H0 accept H0
Actual value
H1 True Positive (T P) False Negative (FN)
H0 False Positive (FP) True Negative (T N)
Below, I list some key concepts in statistical testing and their relationship to the confusion
matrix above:
• Type I error = FP
• Type II error = FN
• Sensitivity = Recall = True positive rate (TPR) = Power = T PT P+FN
• Specificity = True negative rate (TNR) = T NT N+FP
• False positive rate (FPR) = 1−Specificity = Size = FPT N+FP
• Precision = Positive predictive value (PPV) = T PT P+FP
• Accuracy = T P+T NT P+T N+FP+FN
• F1 scorea = 2 PPV∗T PRPPV+T PR =
2T P
2T P+FP+FN
• Family-wise error rate (FWER) = P(FP ≥ 1) = 1−P(FP = 0)
• False discovery rate (FDR) = FPT P+FP = 1−Precision
aHarmonic mean of precision (PPV) and sensitivity (TPR).
Three approaches are commonly used for statistical testing in genetic association analyses:
the Wald test, the likelihood ratio test (LRT), and the score test (Fig. 2.1). In the next
paragraphs, I will describe briefly all three but note that only the LRT is used in this thesis.
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Fig. 2.1: The Wald test, the likelihood-ratio test and the score test.
The three most commonly used statistical testing approaches are illustrated here in the univariate case
(single parameter θ ). On the x axis is the parameter θ , and on the y axis the log likelihood ℓ(θ). The
Wald test essentially evaluates the difference between the MLE θ̂ and the parameter under H0, θ0.
The likelihood-ratio test evaluates the difference between the log likelihoods evaluated at those values,
i.e. ℓ(θ̂) and ℓ(θ0). Finally, the score test evaluates the slope of ℓ(θ) at θ0. Note that the slope at θ̂ is
= 0 by definition, as the MLE maximises ℓ(θ).
Wald test
First, let us consider the Wald test and the generic null hypothesis H0 : θ = θ 0 and the
alternative H1 : θ ̸= θ 0, where θ are the parameters in our model and θ 0 are their values
under H0. The Wald test statistic is defined as:
W = (θ̂ −θ 0)T [var(θ̂ )]−1(θ̂ −θ 0), (2.19)
where θ̂ are the MLEs for the θ parameters (values of θ that maximise the likelihood).
It can be shown that, under some assumptions [307], W follows a chi-squared (χ2) distribu-
tion with number of degrees of freedom (dof) d equal to the number of the parameters tested
(W ∼ χ2d ).




∼ χ21 . (2.20)
Intuitively, our chance of rejecting the null hypothesis increases as the distance between θ̂
and θ0 increases, and as our confidence in the estimation of the MLE increases (i.e. var(θ̂)
decreases).
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Likelihood ratio test




= ℓ(H1)− ℓ(H0), (2.21)
where we compare the value of the log-likelihood of the model under the null and alternative
hypotheses, by evaluating eq. (2.5) (or eq. (2.12)) using MLE parameters estimated under
H0 (0, σ20 ) or H1 (β̂ , σ̂21 ).
The Wilks theorem [308], under some assumptions, guarantees that 2LLR, too, follows a χ2
distribution with d dof (2LLR ∼ χ2d ). The p value can then be calculated as:
P(LLR) = 1−Fχ2(2LLR;d). (2.22)
Score test
Finally the score test, also known as Lagrange multiplier test, is the last hypothesis test we
consider. It was first developed by Rao in 1948 [309]. First, we define the score vector of





The score test statistic is the Lagrange Multiplier (LM) and is defined as follows:
LM = S(θ 0)T [var(θ 0)]−1S(θ 0). (2.24)
It can be shown that the LM, too, follows a χ2 distribution with d dof (LM ∼ χ2d ). To




∼ χ21 . (2.25)
At the MLE θ̂ , the log likelihood is maximised and therefore its gradient S(θ̂) is equal to 0.
On the contrary, in principle, S(θ0) ̸= 0 (Fig. 2.1). Intuitively, the further S(θ0) is away from
0, the more likely we are to reject the null hypothesis.
52 Linear mixed models for eQTL mapping
Intuition on differences between the three tests
In this thesis, I only apply the LRT. However, for different applications one might want to
use alternative approaches. I use this paragraph to highlight the key differences between the
three tests and provide an intuition as to when we should use one or the other. First of all, it
can be shown that [310]:
W ≥ LLR ≥ LM, (2.26)
which guarantees that the Wald tests statistic is always equal to or greater than the log-
likelihood ratio, which in turn is always equal to or greater than the Lagrange multiplier.
The Neyman-Pearson lemma [311] proves that, as a consequence, the power of the Wald
test, defined as the probability of rejecting the null hypothesis when it is false: P = P(reject
H0|H1) (Box 2) is the same or higher than the power of the LRT, which is the same or higher
than the power of the score test:
PW ≥ PLLR ≥ PLM. (2.27)
On the other hand, the false positive rate (FPR, Box 2) of the LRT, defined as the probability
of rejecting the null hypothesis when it is true: FPR = P(reject H0|H0) is also the same or
higher than the FPR of the score test (but the same or lower than the Wald test). The LRT
can be therefore considered as a good compromise between statistical power and accuracy.
Moreover, one advantage of the LRT is that it is robust to re-parametrisation of the parameters,
whereas the score and Wald tests are not. On the other hand, one main advantage of the
score test is that it does not require the evaluation of the MLE of the parameters under the
alternative hypothesis, but only under the null hypothesis. Additionally, while eq. (2.27) is
generally true, close to the null the score test is considered “locally most powerful”. Finally,
the LLR follows a χ2 distribution (asymptotically) only under the assumptions of the Wilks’
theorem, which can be violated in certain applications. Namely, the value of parameters
tested should be far away from the boundaries of the possible values the parameter can
assume. For example, −∞ < β < ∞, so testing H1 : β ̸= 0 satisfies the assumption. On the
other hand, 0 < σ2 < ∞ so testing H1 : σ2 ̸= 0 violates the assumption, because the value
0 is at the boundary. Similarly, the score test statistic does not follow a χ21 distribution in
the presence of variance parameters, however an alternative test statistic can be defined
which follows a linear combination of χ21 distributions, and efficient methods to evaluate its
significance have been proposed by Davies [312], Kuonen [313] and Liu [314, 315].
In the analyses in the following chapters (Chapters 3-5), I will use use tests that only evaluate
the value of β , thus the LRT is well suited for these applications.
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2.2.2 Correcting the multiple testing burden
In a typical GWAS one might test hundreds of thousands or millions of genetic variants. In
eQTL mapping, tens of thousands of genes are tested, each essentially equivalent to a GWAS
trait. Even when we only test for local eQTL (in cis, only SNPs within a window around the
gene position, see section 1.1.8), we will still test hundreds of variants per gene, taking the
average number of tests performed well into the millions. When performing so many tests,
considering single test p values results in a high number of false positives (for example, for p
value < 0.05 and 106 tests we expect 50,000 false positives under the null hypothesis). This
is known as the ‘multiple hypothesis testing problem’. I use the next section to provide a
brief overview of commonly used approaches to correct for multiple hypothesis testing in the
context of genetic analysis, with a focus on methods used in eQTL mapping.
Family-wise error rate correction
One strategy to perform multiple testing correction is to control the probability of having at
least one false positive for a trait, which corresponds to a trait-wise p value known as the
family-wise error rate (FWER, Box 2). The widely-used Bonferroni method follows this
strategy assuming independence between tests [86]. Given a desired family-wise significance
level α , the method consists of calculating ‘adjusted p values’ for each of the un-corrected p
values (P) as Pad j = P∗n, where n is the number of tests carried out. Next, setting Pad j < α
ensures FWER < α . The Bonferroni correction strategy is conservative, because of the
assumption of independence between tests, which ignores correlations between genotypes
due to LD (page 12).
An alternative strategy, which accounts for the dependency of the statistical tests, is to use a
permutation-based approach. The idea here is to build a background model by drawing from
the empirical distribution maintaining the dependency structure of the underlying data but
permuting the genotype data across individuals. This way, we disrupt a possible association
between phenotype and genotype whilst maintaining the overall data dependencies. For each
association test (resulting in an observed p value pi), we can perform the same test M times,
each time considering a different permutation of the genotype data across individuals. The
resulting p values qi,m represent the null distribution, i.e. the p values we might expect in the
absence of any associations. One first approach is to use the p values from these M additional
experiments to calculate a per-SNP adjusted p value, as the fraction of the M permutation-p
values that are lower than the observed p value. For test i, the experimental adjusted p value
after M permutations is calculated as:
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Ppermad j,i =
1+∑Mm=1 qi,m ≥ pi
1+M
, (2.28)
where qi,m is the p value obtained at the mth permutation run equivalent to test i, and ones are
added to avoid zero divisions. This strategy accounts for local LD, thereby increasing the
statistical power, and has been widely used in cis molecular QTL mapping to estimate gene-
level p values [127, 316]. However, as evident from eq. (2.28), the lower bound of Ppermad j,i
depends on the number of selected permutations6 for which the test statistic is calculated,
and thus a higher number of permutations may be required to estimate a p value with high
enough accuracy [317]. This can be improved by increasing the number of permutations, e.g.
using M as large as 100,000, but that entails a great computational burden and can become
unpractical in molecular analyses of large cohorts.
A second approach is to adjust for multiple testing when considering a more complex
hypothesis, for example by pooling across variants, thus requiring fewer permutations. As an
example, in the method described in [318], the minimal p values for each permutation across
all SNPs are selected, and used to build a beta distribution of background p values, against
which to compare the real p values. This method has been shown to robustly work for as little
as (M=) 50-100 permutations, making use of the benefits of the assumption-free permutation
approach without too much of the computational burden [318]. This is the method I will use
in the following chapters (Chapters 3, 4 and 5) of this thesis to control for FWER at gene
level when performing large scale eQTL mapping.
False discovery rate correction
An alternative solution for multiple testing correction is to control the false discovery rate
(FDR), i.e. the expected percentage of false discoveries (Box 2). The most widely used
FDR-based correction method is the Benjamini-Hochberg (BH) procedure [319], which again
assumes independence between tests7. Let us consider T tests with p values p1, p2, ..., pT and
let r1,r2, ...,rT be their ranks (the smallest p value has rank 1, the largest has rank T), defining
adjusted p values as Pad j,i =
T∗pi
ri
and setting Pad j,i <α ensures FDR < α [321]. Alternatively,
the Storey procedure (proposed in 2002 [322, 323]) optimises the BH procedure by taking
into account the distribution of the p values in the experiment. FDR-corrected p values are
sometimes called ‘q values’. For eQTL mapping, the assumption of independent tests holds
6For example, for M=1,000 the smallest adjusted p value we can obtain is only Ppermad j,i =0.001 (when no
permuted p value is smaller than the p value observed).
7Although, more recently, the BH procedure has actually been shown to hold under positive dependency
[320].
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when we consider a single SNP per gene. In this case, the number of tests T coincides with
the numbers of genes tested. In practice, in most applications one is interested in the lead
SNP for each gene, i.e. the SNP corresponding to the minimum p value. Conditional analyses
(where we include the top SNP as a covariate in the model) can be used subsequently to
detect secondary and tertiary effects for a gene.
Multiple testing correction for cis eQTL mapping
A typical strategy to correct for multiple hypothesis testing in cis-eQTL mapping is to use
a two-step procedure [127]. First, for each gene an experiment-wise p value is obtained by
correcting for multiple testing across variants using a FWER-based method. These gene-level
p values are probability values for the hypothesis of a gene having at least one eQTL in the
analysed region (i.e. of being an eGene). Second, the gene-level p values are corrected to
control the FDR, for example using the Benjamini-Hochberg procedure.
In the analyses in Chapters 3-5 of this thesis, I adopt this two-step approach. I use M=1,000
permutations and the method described in [318] to correct p values at the gene level (I will
call the p values obtained this way ‘empirical feature p values’). Then, I select the top SNP
per gene and correct the corresponding empirical feature p values a second time, using the
Storey procedure [322]. I will call the resulting p values: ‘globally corrected p values’.
2.2.3 Calibration studies and distributions of p values
Under the assumption of no association between genetic variants and the analysed trait,
an association model is expected to produce p values that approximately follow a uniform
distribution. If that is the case, the model is said to be ‘calibrated’. To verify that a model is
calibrated we can disrupt the association between genotypes and phenotypes, by randomly
permuting the genotypes. A representation that is often used to compare the observed
(permuted) and the expected distributions of p values is the quantile-quantile (QQ) plot.
In a QQ plot the observed negative log10(p value) is plotted against the expected negative
log10(p value), where the expected value is obtained by drawing from a uniform distribution.
I define as ‘confounding’, variables that are correlated with the genotype g (and sometimes
also the phenotype y) and thus may create spurious associations when left unaccounted for
(see also section 2.3). Inflated QQ plots are typically associated with the presence of such
confounding factors, and can be used as a diagnostic tool (Fig. 2.2).
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Fig. 2.2: Example QQ plots.
Examples of quantile-quantile (QQ) plots, displaying the expected negative log p values (x axis)
versus the observed negative log p values (y axis) under the null hypothesis (diagonal blue line) and
observed (red circles) in (a) when no associations are present, such that there is no departure from
the null distribution, (b) in the presence of confounding factors, such that there is constant departure
from the null distribution and (c) in the presence of a genuine genetic association, such that there is
departure from the null in the tail of the distribution. Adapted from [76].
2.2.4 Including covariates in a linear model
The model in eq. (2.14) models the SNP tested as the only factor affecting the measured
phenotype. However, if available, additional relevant information for the samples tested
(such as the sex or the age of the individuals) can be added to the model as covariates (W),
and often improve discovery power by controlling for additional phenotypic variation. The
model becomes:
y = Wα +gβ +ψ , (2.29)
where W is an N ×P matrix whose columns are known covariates, and α is a P×1 vector
of the corresponding weights. Here, covariates are implemented as fixed effects (FEs), and
they only contribute to the mean value of y, such that E[y] = Wα + gβ , while Var(y) =
Var(ψ ) = σ2n IN, as before. In some cases, we can add FE covariates to adjust for technical
batches or other factors that might affect y, increasing the accuracy of our model. In eQTL
mapping, we can often take advantage of the full transcriptome to identify factors affecting
gene expression in a global manner, thus efficiently capturing known and potentially hidden
covariates affecting expression across all genes. For example, we can perform principal
component analysis (PCA) on the full expression matrix (genes x samples) and include
such expression PCs as covariates in the model. Alternative more sophisticated methods to
compute factors capturing global trends include, among others, SVA [324], PEER [325, 326],
f-scLVM [327], pCMF [328], scVI [329, 330] and MOFA [331].
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Different approaches can be used to determine the optimal number of PCs (or other factors) to
include in the model. A popular approach is to choose the number of factors that maximises
the number of eQTL discoveries [114, 150, 151]. The assumption is that global effects
captured by PCs are orthogonal to the effects of a single variant on the expression of one
gene, and thus there is no risk of generating false positives. There remains however a risk
of over-correction, which can introduce synthetic associations as a result of collider bias
[332]. Alternatively, to verify that specific covariates of interest (not modelled explicitly)
are accounted for in the PCs, one may verify that PCs explain enough variance for those
covariates (see for example the analysis I describe in Chapter 5, section 5.5.1).
2.3 Population structure and linear mixed models
One major source of confounding effects in genetic analysis - that I have purposefully not
discussed thus far - is latent population substructure, which includes population stratification
(i.e. the presence in the study sample of individuals with different ancestral and demographic
histories) and relatedness between individuals, both known relatedness (e.g. known familial
relations within a sample) and cryptic relatedness (i.e. evidence that individuals in the
study sample have residual, non-trivial degrees of relatedness) [76]. It was acknowledged,
even before the first GWAS was conducted, that there was a possibility of identifying false
positives (or that true positives may be masked) when using population based association
studies (instead of family based linkage studies), due to those confounding effects [333]. This
is because both phenotypic prevalence (proportion of individuals exhibiting the phenotype)
and allele frequencies (frequencies of a specific allele within a population) vary across
different populations, which may result in the identification of spurious association between
variants and the phenotype of interest due to ethnicity or population sub-structure (including
relatedness) [333] (Fig. 2.3).
2.3.1 Early approaches to account for population structure
Various approaches have been proposed to account for population structure. An early so-
lution was genomic control [334]. Genomic control correction adjusts for inflation due to
confounding effects by dividing the test statistic of each marker by the genomic control
parameter (λGC8).
8λGC compares the test-statistic value with the median value, such that λGC ≈ 1 means there is no evidence
for confounding, λGC ≫ 1 indicates that the presence of confounding is likely.
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Fig. 2.3: Confounders and covariates.
Traditionally ‘confounders’ are variables that are correlated with both the genotype vector and the
phenotype, i.e. hidden common causes of both g and y. For example, population structure (K) is a
confounder in population genetics studies. On the other hand, other covariates such as sex (unless we
are testing genes on the X or Y chromosomes) and batch (W), only have an effect on y. By including
them as covariates in the model, we control for additional phenotypic variation and thereby increase
association power. We note that in the illustration, a linear mixed model is used to illustrate how
to account for both effects, with a random effect term used to correct for population structure, and
covariates included as fixed effects. However, mathematically, both can be treated in the same way
(i.e. they both can be included as fixed or random effects). In contrast the motivation for including
them, and the effect their inclusion has, are different.
2.3 Population structure and linear mixed models 59
However, as different markers have different abilities to distinguish between populations, this
uniform adjustment is far from optimal. Indeed, as a result, markers that strongly segregate
across different population groups are only partially corrected, whereas markers that do
not segregate tend to be over-corrected [335, 336]. Alternatively, a method that attempts
to correct the underlying problem is STRUCTURE, which assigns individuals to discrete
population subgroups and then combines the evidence for association across the different
subgroups [337]. A limitation of this method is that only discrete subgroups can be con-
sidered. Additionally, it does not scale with sample size and is also highly sensitive to the
number of defined population clusters [336].
The analysis of genotype data from large population studies, showed that genome-wide
genetic variation could be used to accurately infer population structure [338–340]. In
particular, it could be shown that the first principal components (PCs) calculated from the
genotypic data were correlated with geographic axes [341]. As a result, one approach to
account for population structure is to add the first genotypic PCs as covariates in the model
(or to regress them out [336]):




PCibi +gβ +ψ . (2.30)
The number of leading PCs p can be determined as the number of principal component (PC)s
that cumulatively describe a certain proportion of the total genotypic variance. This approach
(eq. (2.30)) was shown to perform relatively well in removing global population structure,
but often failed to detect the more subtle relatedness effects. Therefore, when PCs are used
to correct for population structure, closely related individuals have to be removed from the
association analyses, prior to PCA calculations. Even then, cryptic relatedness might still be
present and would not be properly accounted for by this method.
2.3.2 Linear mixed models for genetic analyses
Alternatively, linear mixed models (LMMs) can be used to successfully account for con-
founding effects linked to both population stratification and cryptic relatedness [342–347].
In an LMM, istead of being used to calculate principal components, the genotype data is used
directly to estimate an N ×N kinship matrix, K, that describes the genetic similarity between
pairs of individuals (see section below for a description of commonly used approaches to
generate K).
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This genetic similarity is modelled through the use of an additional random effect term in the
linear model described by eq. (2.29), as follows:
y = Wα +gβ +u+ψ , (2.31)
where u ∼N (0,σ2g K). The use of the notation K signifies the fact that this matrix reflects
a degree of ‘kinship’ between individuals. It can be shown that the LMM approach is
theoretically equivalent to the PC approach when all PCs are regressed or included as
covariates (see Hoffman et al. [348] for details), explaining why LMMs are able to account
for more subtle population structure than the PC approach. However, regressing all PCs or
including all PCs as covariates is not feasible in practice (as the number of variables would
exceed that of observations).
Kinship matrices
The covariance matrix K captures the latent population sub-structure of the samples consid-
ered, including population stratification and genetic relatedness. Several approaches have
been proposed to compute this matrix, which is sometimes called the genetic relatedness
matrix (GRM). Fisher’s infinitesimal model (see section 1.1.5) [20] demonstrated that under
an additive model with an infinite number of infinitesimal genetic effects, the phenotype
follows a normal distribution, and the correlation of phenotypes between individuals is
proportional to the fraction of genetic material that is ‘identical-by-descent’ (IBD)9. A
consequence of this observation is that we can define the genetic relatedness between two
individuals by using the predicted proportion of the genome that is IBD between them. Tradi-
tionally, an IBD (relatedness) matrix was estimated using known pedigrees (see Box 1) [349].
An alternative, increasingly popular solution is to estimate the relatedness matrix using
genome-wide SNPs. The use of SNP-based relatedness matrices improves heritability
estimates [350–352] and allows the user to better account for population structure [343, 353]
compared to pedigree-based matrices. Different ways of estimating relatedness matrices from
genotype data have been proposed [354–356]. Finally, a commonly-used approximation of





9A genetic locus is IBD between two individuals if it has been inherited by a common ancestor.
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where G is the N ×M genotype matrix with standardised genotypes across individuals and
M denotes the number of genome-wide variants. The RRM can be directly obtained from
the polygenic model (where many genetic variants contribute to the trait):
y ∼ N(Wα +Gb,σ2e I), (2.33)
where b is an M × 1 vector containing the weights corresponding to G defined as above
(standardised genotype matrix). If we assume that b is drawn from a normal distribution such




10, and marginalising out the random effect we obtain the RRM in one
of the terms of the covariance:
y ∼ N(Wα ,σ2g
1
M
GGT +σ2e I), (2.34)
The RRM can also be interpreted as an IBD relatedness matrix where the base population is
the current population [357]. Throughout this thesis, we use the RRM described in [358] as
implemented in PLINK [355].
2.3.3 Fast implementation of LMMs
The biggest limitation of the use of LMMs for association studies is that they are in general
very computationally intensive. Computations associated with the parameter inference
in LMMs scale cubically with the number of individuals in the dataset. Indeed, for the
generic LMM the evaluation of the (restricted) marginal likelihood entails the computation
of operations with O(N3) complexity, specifically the inversion and the determinant of the
total covariance. However, for the model in eq. (2.31), i.e. when the covariance matrix is
known (does not depend on any parameters), and which can be alternatively expressed as:
y ∼N (Wα +gβ ,σ2g K+σ2n I), (2.35)
it is possible to speed up computations [343, 344, 359, 346], thus enabling application
to large population studies. These stratagems reduce the computational complexity from
O(N3) per-SNP to a single O(N3) cost upfront, and a per-SNP complexity of O(N2). The
complexity can be further reduced to O(N2) for the upfront computation and a per-test
complexity of O(N), provided the genetic relatedness matrix is low-rank.
10Note that each genetic marker explains on average variance
σ2g
M , so that genome-wide variants jointly
explain variance σ2g .
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I use this section to briefly describe the efficient FaST-LMM algorithm proposed by Lippert
et al [359]. This is the algorithm implemented within the LIMIX toolset [360, 361] which I
use throughout this thesis.
The intuition is to project all data into a space where phenotypic variables (y) and covariates
(W,g) are uncorrelated so that in the rotated space the joint system to estimate the optimal
model parameters can be solved in closed-form. To do so, we perform eigen decomposition
of K from eq. (2.35), such that: K = QSQT , where S is a diagonal matrix containing the
eigenvalues of K on the diagonal and zeroes elsewhere, and Q is orthonormal (QQT = I),
with columns corresponding to the eigenvectors of K. Then, if we define δ = σ2n/σ2g and
consider it fixed, the full covariance matrix can be expressed as:
Var(y) = σ2g K+σ
2
n I = σ
2
g (QSQ
T +δ I) = σ2g Q(S+δ I)Q
T . (2.36)
To simplify notation, we use Σ = K+ δ I; X = [W,g] and β = [α ,β ], such that we can
express the full log-likelihood as:




N log(2πσ2g )+ log |Σ|+
1
σ2g
(y−Xβ )T Σ−1(y−Xβ )
}
. (2.37)
Computationally, the two expensive operations are the calculation of the inverse of the
covariance matrix Σ (i.e. Σ−1) and its determinant (|Σ|). Both can be solved efficiently as
follows:
Σ
−1 = [Q(S+δ I)QT ]−1 = Q(S+δ I)−1QT = QDδ QT , (2.38)
where we define Dδ = (S+δ I)−1 which is a diagonal matrix whose ith element is: 1Sii+δ and
use the property of orthonormality of Q (i.e. Q−1 = QT ). As a result, this operation can be
computed in linear time O(N). Next,
|Σ|= |Q(S+δ I)QT |= |Q||(S+δ I)||QT |= |S+δ I|= |Dδ−1|=−|Dδ |, (2.39)
where we used the property of orthonormality of Q (|Q| = 1), and the determinant of a
diagonal matrix (|diag(λ )|= ∏Ni=1 λi) as well as properties of the logarithm11.
11log |Dδ −1| = log |S + δ I| = log(∏Ni=1(Sii + δ )) = ∑Ni=1(log(Sii + δ )) = −∑Ni=1 1log(Sii+δ ) =
− log∏Ni=1 1(Sii+δ ) =− log |
1
S+δ I |=− log |Dδ |
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We can now re-write the log-likelihood as:

































(ỹ− X̃β )T Dδ (ỹ− X̃β ),
(2.40)
where ỹ = QT y and X̃ = QT X are the rotated phenotype vector and covariate matrix (includ-
ing the genotype vector g).
If we consider δ fixed, the first and third terms are constant, so we can rewrite:













2 X̃β ]. (2.41)









QT Xβ ,σ2g I). (2.42)
To further speed up computations, α and δ are only optimised once, under H0, which is the
same for all SNPs for a given trait. Since there is no closed-form for δ , we use the Brent
search numerical procedure [362] to find the optimal δ̂ . For every SNP, we find the MLEs
for β and σ2g using the closed-form from equations (2.8),(2.9).
When the rank of K is much smaller than the number of individuals rank(K)<< N, we can
further speed up the algorithm by computing the ‘economical’ eigen decomposition [359],











For details on this implementation I refer the reader to the Supplementary note from Lippert
et al. [359].
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Whilst extremely efficient, I note that the described implementation is limited to one random
effect term only (besides the identity, see eq. (2.36)). Indeed, the stratagem used to reduce
the computational complexity and calculate the inverse (eq. (2.38)) and the determinant
(eq. (2.39)) of the covariance matrix in quadratic (or linear, in case of low-rank kinship
matrix) time only works for a single kinship matrix12. While I am aware of alternative
implementations that allow the use of several kinship matrices (e.g. [363]), these are currently
optimised for SNP-heritability estimates, and the application to association testing is not
trivial. Thus, in this thesis, I only present LMMs with one single random effect term.
2.3.4 Modelling non-Gaussian data
Linear regressions and linear mixed models are established approaches for mapping associa-
tions between genotype and phenotype. One limitation of these models, however, is that they
assume the residual noise to be normally distributed, a premise that rarely holds in practice.
Deviation from normality can result in model mis-specification, which in turn can lead to
false conclusions and reduced statistical power [364].
To alleviate this issue, it is common to preprocess the phenotype vector (y) to ‘gaussianise’ it.
For example, common approaches involve applying different kinds of non-linear transforma-
tions to y. Log-transformations are universally used on gene expression values (measured
using RNA-seq) to reduce the range of possible assumed values. In addition, several other
‘variance-stabilising’ transformations can be applied later, including Box-Cox transforma-
tions [365] or rank transformations [366]. More recently, warped LMM [367] was proposed,
which learns from the data the optimal phenotype transformation to be applied prior to testing
for associations using an LMM.
Note that these models assume that the noise level in the transformed phenotype space is
constant, which may not be an appropriate assumption in some cases. In such instances, it
will remain appropriate to use generalised LMMs (GLMMs13) with non-Gaussian likelihoods
that enable to incorporate stronger assumptions about the nature of the data [367, 368].




n I = σ21 QSQ
T +σ22 UDU
T +σ2n I, which
cannot be further simplified.
13Generalised linear mixed models (or GLMMs) are an extension of linear mixed models to allow response
variables from different distributions, as long as those belong to the exponential family. Common example of
exponential family distributions are the Bernoulli, Exponential, Gamma, Normal and Poisson distributions.
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2.3.5 Linear mixed models for eQTL mapping
In this thesis, we perform different sets of eQTL mapping, adopting the FaST-LMM algorithm
(section 2.3.3) as implemented in LIMIX. The expression of each gene is normalised and
log transformed (more details are specified in the various applications from the next chapters).
Next, when running the FaST-LMM algorithm in the context of eQTL mapping, we run the
model for each gene separately. For a given gene, the model under H0 is fixed. In order to
perform cis eQTL mapping, we define a cis window around the gene (typically ranging from
100 kb to 1 Mb) and a minimum MAF (e.g. 0.05) and test all SNPs within the window with
MAF > 0.05 in our population. We test each SNP independently, with only the alternative
model changing. This means that all weights α excluding the SNP effect, as well as δ are
only computed once per gene.
Typically, for each gene-SNP pair tested the reported values are i) the p value (e.g. obtained
using eq. (2.22)), ii) the estimated effect size β , and iii) the effect size standard error (se(β )).
Subsequently, multiple testing correction is applied, first at the gene level (using FWER) and
then globally (using FDR, as described in section 2.2.2). The resulting adjusted p values
are also reported. To summarise a typical eQTL map, a number frequently reported is the
number of genes with at least one eQTL (from now on ‘eGenes’), often reported together (or
as a fraction of) the number of genes tested.
In the analyses in Chapters 3-5 of this thesis, I report significant results (i.e. number of
discoveries) at FDR<5% or 10%, which are commonly used in the field [294, 150, 151]. This
allows me to put these numbers in context, particularly to assess differences in number of
discoveries between results obtained using single cell data (from this thesis) with existing
eQTL results (typically obtained using bulk RNA-seq data).
2.4 Linear Mixed Models for interaction tests
The statistical test described in section 2.2.1 refers to an ‘association test’ where the aim
is to test for an effect that the SNP of interest has on a trait directly14. However, the same
LMMs and fast implementation approaches described so far can be applied, with care, to
testing for genotype-environment (GxE) interactions instead (‘interaction test’ for simplicity).
14Note that this was described for a linear regression but can be equivalently applied to the linear mixed
model, i.e. H0 : y ∼ N(0,σ2g K+σ2n I) vs H1 : y ∼ N(gβ ,σ2g K+σ2n I), where the test assesses β = 0 vs β ̸= 0.
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In particular, a significant statistical GxE interaction is defined when there is a significant
difference in the genetic effect between groups of individuals with different environmental
exposures (Fig. 2.4).
Fig. 2.4: Illustration of GxE effect for two environmental groups.
Illustrated are the mean phenotype values across three genotypic groups for a given locus (AA:
homozygous major allele, aA: heterozygous individuals, aa: homozygous minor allele). The first
plot (left) describes the case of a genetic effect of the variant on all individuals. β represents the (in
this case positive) effect size of the locus tested. The second plot (middle) shows that two groups
of individuals characterised by different environmental exposure (represented by the colours). The
environments have an effect on phenotype (as represented by a shift upwards for the orange group)
but the genetic effect remains constant. Finally, the third plot (right) shows a GxE effect. There is an
interaction effect between the individuals’ genotypes and their environmental exposure, such that for
one group (orange) the genetic effect was exacerbated whilst for the other group (seagreen) the effect
was dampened.
In the following, I describe various approaches to test for GxE interactions, which all build
on the LMM framework. One possible way to detect interaction effects is to stratify samples
into discrete subgroups based on their environmental exposure. In eQTL mapping, one might
for example cluster cells into cell types, or separate samples into different condition groups.
Then, an LM (eq. (2.29)) or LMM (eq. (2.31)) can be applied to each stratum and the
marginal variant effects can be compared to assess whether there is a significant difference in
these effects across the sub-populations. This method can be defined as a ‘stratified inter-
action test’. However, as more detailed environmental data is collected, allowing for finer
stratification of the population, these methods are no longer optimal as the sub-populations
become too small to obtain stable estimates of the variant effects. For example, as more and
more rare cell types are identified and as the definition of cell types becomes more blurred,
joint analyses may be preferable.
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Another commonly-used method to test for interaction effects is an extension of the LM or
LMM to include two additional FE terms, an interaction term (GxE) and an environment
term (E):
y = Wα + eγ +gβG + e⊙gβGxE +u+ψ , (2.44)
where e represent the environment term, γ is its corresponding weight and where two genetic
effect terms are present, βG which is the ‘persistent’ genetic effect size whilst βGxE is
the effect of the interaction term (GxE). Finally, ⊙ denotes element-wise multiplication
(Hadamard product). The test is:
H0 : βGxE = 0 (2.45)
vs
H1 : βGxE ̸= 0. (2.46)
This model allows to directly test for a GxE interaction effect with a certain environ-
ment/factor15, beyond the additive effects of the SNPs and the environment themselves.
Of course, the same model can also be extended to the case of multi-environment interaction
by simply adding more environments as FE terms:
y = Wα + e1γ1 + e2γ2 + ...+gβG + e1 ⊙gβGxE,1 + e2 ⊙gβGxE,2 + ..+u+ψ . (2.47)
However, this becomes quickly infeasible for large numbers of environments, especially for
relatively small sample sizes, because of the degrees of freedom loss when increasing the
number of parameters to estimate (two additonal parameters to estimate for every environ-
ment included).
Finally, in the specific context of measuring genetic effects on gene expression, and testing
for interactions between environmental exposures and such genetic effects, an alternative
approach is to model the effect that these environments have on allele-specific expression
(ASE, see Box 3 in the next chapter). I describe this approach in more detail upon its
application in Chapter 4 (section 4.5).
15Or with another genetic variant, to test for epistasis [369].
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2.5 Discussion
Linear mixed models are widely applied in genetic association analysis because they offer
great control for confounding effects. Throughout this thesis, I will use different models for
eQTL mapping using single cell expression profiles, which all build on this framework. I
have used this chapter to lay the foundation and notation for which we build extensions in
the coming chapters.
Specifically, in Chapter 3, I provide a best-practice pipeline for performing bulk-like eQTL
mapping using single cell data, where I test various aggregation methods as well as design
matrices and then use the standard linear mixed model from eq. (2.31) to map eQTL. I
compare our results to an eQTL map obtained using bulk RNA-seq from the same samples
and also compare results across scRNA-seq technologies for a subset of donors. Next, in
Chapters 4 and 5 I use different adaptations of linear and linear mixed models to test both
for associations (eq. (2.31)) and interactions (eq. (2.44)) in two separate population-scale
human scRNA-seq datasets.
3
Comparison of eQTL mapping using bulk
and single cell RNA-seq readouts
As discussed in section 1.1.8, in traditional eQTL mapping individual-level gene expression
is measured using bulk RNA-sequencing, where the quantified expression profiles represent
several thousands of cells from each individual. As we have seen, recent technological
advances have allowed molecular phenotypes, including gene expression, to be assayed at
the level of single cells. In particular, scRNA-seq is now an established technique, and can
be deployed at population-scale, across several individuals. Owing to their ability to identify
cell types and cell states in a data-driven manner, scRNA-seq data from a single experiment
can be used to define homogeneous cell populations, quantify expression levels within them,
and then map eQTL in each of them separately. As a consequence, studies where single
cell expression profiles (rather than bulk) are used to perform eQTL mapping have emerged
recently, and promise to greatly improve our understanding of the genetic architecture of
gene regulation across tissues, in both human disease and development. However, the use of
single-cell RNA-seq to map eQTL maps as opposed to using bulk RNA-seq profiling has not
been systematically benchmarked. To address this, here I select a very homogeneous cell type
(iPSCs), where direct comparison is possible. In particular, I use matched bulk and single
cell RNA-seq from over 100 human iPSC lines to assess our ability to detect eQTL using
single cell RNA-seq data, and the extent to which we can replicate eQTL identified using
bulk RNA-seq, when mapping eQTL using a common analytical framework based on LMMs
(see Chapter 2). Additionally, for a subset of lines, I compare results using two different
scRNA-seq technologies. As more and more single cell-eQTL (sc-eQTL) studies emerge, I
believe that the insights presented here will help establishing a ‘best practice’ workflow, to
optimise yield of sc-eQTL maps and to establish uniform methods across the field.
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Contributions In this chapter, I present results from two main bodies of work.
First, I describe a set of results from analyses I have conducted in the context of a
larger collaborative project between the Stegle, Marioni and Vallier labs. In particu-
lar, the data was generated by Ludovic Vallier’s lab at the Sanger Institute, and the
experiments were led by Mariya Chhatriwala, using cell lines from the HipSci project.
Davis McCarthy and I processed the scRNA-seq data and performed quality control.
Marc Jan Bonder processed the bulk RNA-seq data. I performed all analyses presented
in the first part of this chapter, under the supervision of Oliver Stegle and John Mar-
ioni. The code for processing, analysing and plotting the data is open source and
freely accessible here: https://github.com/single-cell-genetics/singlecell_endodiff_paper.
The analyses presented here are part of the following paper, which is available at
https://www.nature.com/articles/s41467-020-14457-z and has been published as:
Anna S.E. Cuomo*, Daniel D. Seaton*, Davis J. McCarthy*, Iker Martinez, Marc Jan
Bonder, Jose Garcia-Bernardo, Shradha Amatya, Pedro Madrigal, Abigail Isaacson, Flo-
rian Buettner, Andrew Knights, Kedar Nath Natarajan, the Hipsci Consortium, Ludovic
Vallier, John C. Marioni, Mariya Chhatriwala, Oliver Stegle. Single-cell RNA-sequencing
of differentiating iPS cells reveals dynamic genetic effects on gene expression. Nature
Communications, 2020, (* equal contribution).
In the second part of this chapter, I present more recent preliminary results from work
in collaboration with Giordano Alvari and Marc Jan Bonder, from the Stegle laba. This
project was designed by Marc Jan Bonder and myself, to extend the results presented in
the first part of this chapter. Giordano performed most of the analyses, under mine and
Marc Jan Bonder’s supervision. Marc Jan Bonder and I performed the remaining analyses
and summarised the results.
I generated all figures included in this chapter.




As outlined in section 1.1.8, since the publication of the first human eQTL map in 2003
[109], the field has adapted to adopt technological advances as they emerged, both in terms of
statistical approaches (from linkage analysis to genome-wide scans), and of new technologies
for the estimation of gene expression (from microarrays to RNA-seq). I use this section to
give a brief overview of methods to estimate gene expression (section 3.1.1), the advent
of single cell RNA-seq (section 3.1.2) and the consequent birth of the (very new) single
cell-eQTL mapping field of research (section 3.1.3).
3.1.1 Measuring gene expression
Early methods for estimating the number of expressed mRNA molecules associated with
a particular gene (hereafter defined as a gene’s expression) were Northern blots [370] and
quantitative reverse transcription polymerase chain reaction, qRT-PCR [371]. In Northern
blots, electrophoresis is used to separate RNA, which is then visualised by hybridisation with
labelled probes. A key limitation of Northern blots is that they require large amounts of input
material and the results are mostly only qualitative. In qRT-PCR, RNA is reverse-transcribed
into complementary DNA (cDNA) and then amplified using PCR, after each cycle of which
the concentration of DNA is measured using a fluorescent dye. This required normalisation
relative to a standard gene (e.g. a housekeeping gene, or a ribosomal gene) which was
assumed to be ‘stable’, making this method also not very quantitative. Additionally, both of
these methods were very low-throughput, typically used only to quantify one, or at most few
genes - hence being referred to as ‘single gene approaches’.
In 1995, DNA microarrays were introduced [372], which for the first time allowed the
estimation of expression levels for many genes simultaneously. Like qRT-PCR, microarrays
rely on the reverse transcription of RNA into cDNA. This cDNA is then labelled with a
fluorescent dye and hybridised to a DNA microarray containing complementary DNA for
thousands of known transcripts at specific locations. The RNA levels can then be estimated by
measuring the intensity of fluorescence at each location and either normalising it using RNA
transcripts of known concentration (called RNA spike-ins; ‘one colour array’) or directly
comparing it to a second sample on the same microarray using two different fluorescent
dyes (‘two colour array’). Microarrays quickly became the most commonly used method for
measuring gene expression levels. However, since microarrays only allow the measurement
of RNA with a known sequence, they are not suitable for the detection of novel transcripts or
alternative splice isoforms.
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In the late 2000s, RNA sequencing (RNA-seq), based on next-generation sequencing (NGS),
was introduced. RNA-seq allows for the direct sequencing and quantification of cDNA
libraries [373] and has since been shown to be superior to microarrays in almost all regards
[374], as it provides information about a gene’s sequence, in addition to its expression level.
In particular, in addition to the quantification of known transcripts, RNA-seq also enables the
identification of completely new genes, previously unknown genetic variants in the genes,
variation in alternative splicing, or post-transcriptional modifications (see also section 1.1.8).
In recent years, next generation sequencing approaches have been extended to quantify
variation in RNA expression at single cell resolution, starting the ‘single cell RNA-seq era’.
3.1.2 The ‘resolution revolution’
The first single-cell RNA sequencing (scRNA-seq) experiment was published in 2009, and
it involved profiling of only eight cells [375]. Seven years later, 10X Genomics released
a dataset of 1.3 million cells [376]. All in all, in the last decade, over 1,000 scRNA-seq
datasets have been published [377–379], using a number of different technologies [380–390]
(Fig. 3.1).
Fig. 3.1: Scale of scRNA-seq experiments.
Number of single cells reported in all scRNA-seq publications to date (as collected in [379], y axis),
ordered by publication date (x axis). Key scRNA-seq methods are indicated. Similar to [377].
Single cell RNA-seq protocols differ extensively in terms of scalability, costs and sensitivity
[391, 377]. However, they can be broadly categorised into methods that are ‘plate-based’ or
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‘droplet-based’, based on the capture technology used (Fig. 3.2).
Initially, most studies used plate-based assays, where cells are isolated using micropipettes
or flow cytometry into individual wells of a plate, where the library preparation is performed
(Fig. 3.2). This class of methods include single-cell tagged reverse transcription sequencing
(STRT-seq [380]), Cell Expression by Linear amplification and Sequencing (CEL-seq [381]),
massively parallel single cell RNA-seq (MARS-seq [385]) and Smart-seq [382, 383, 390].
On the other hand, droplet-based methods employ microfluidics to capture individual cells in
nanolitre-sized droplets, each loaded with all the necessary reagents for library preparation.
The droplet suspension is later broken down for pooling of cell libraries prior to sequencing
(Fig. 3.2). These methods have been developed by academic groups (InDrop [387] and
Drop-seq [386]) and commercially, by 10X Genomics (Chromium [389]). These protocols
share similar technologies, particularly the use of unique molecular identifiers (UMIs) to
correct for biases in PCR amplifications [392].
Each approach has its own advantages and disadvantages. The main advantage of plate-based
methods is the higher quality of libraries and, in the case of Smart-seq, the full length tran-
script information which enables the quantification of splice variants [393], allele-specific
expression [394] and RNA velocity information [395]. However, this comes at the ex-
pense of lower cellular throughput, processing hundreds or thousands of cells compared to
the hundreds of thousands that droplet-based methods can achieve. Indeed, by capturing
cells in individual droplets, each containing all necessary reagents for library preparation,
droplet-based protocols allow the profiling of thousands or even millions of cells in a single
experiment. This, however, comes at the cost of reduced sensitivity. Additionally, current
droplet methods capture gene information exclusively from the 3’ or 5’ end of each transcript,
and are more likely to produce ‘doublets’, where two different cells become labelled with the
same barcode (Fig. 3.2).
In the last 10 years, technological improvement (Fig. 3.1) has gone hand-in-hand with com-
putational advances to analyse the resulting data, which require a new set of considerations
that were not relevant for bulk RNA-seq data. Indeed, to complement the explosion of
scRNA-seq studies published, an entire ecosystem of computational methods for analysing
them has emerged. In some cases, those methods have been directly borrowed from bulk
RNA-sequencing methods; other times, methods tailored specifically for single cell data
were proposed [397–399].
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Fig. 3.2: Plate-based vs droplet-based methods for scRNA-seq.
An illustration of the key differences between plate-based methods (exemplified by SmartSeq2 [383])
and droplet-based methods (represented by 10X Genomics Chromium [389]). The key trade-off is
between the cell-throughput (much higher for droplet-based methods) and the read-depth per cell
(higher for plate-based methods). Additionally, the full-length transcripts obtained using SmartSeq2
allow quantification of allele-specific expression and splice variants, which are not possible with
3’ tag 10X data. Finally, all droplet-based methods include unique molecular identifiers (UMIs),
which allow the robust quantification of PCR duplicates. Note that these last two differences (in
terms of UMIs and full length) specifically hold true for the two methods shown here (and used in
this thesis: SmartSeq2 and 10X Genomics). Indeed, not all plate-based methods provide full-length
transcript information (e.g. MARS-seq [385] and CEL-seq [381] do not). In contrast, the most recent
SmartSeq3 [390] can include UMIs, despite being a plate-based method. Figure similar to [396].
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Single cell-specific bioinformatics workflows such as Cell Ranger [389], indrops [387],
SEQC [400], or zUMIs [401] have been developed to perform raw data processing tasks, i.e.
read-level QC, assignment of reads to their cell barcodes and mRNA molecules of origin
(i.e. ‘demultiplexing’), alignment to the reference genome, and quantification. Additional
methods allow the assignment of cells to their donor of origin, in case of multi-individual
pooled designs [402, 403]. The data resulting from a scRNA-seq experiment are typically
represented as an integer matrix of gene expression levels, with entries representing the
number of sequenced reads (or molecules, if UMIs were used) assigned to a particular gene
in a specific cell [396]. Starting from these count matrices, a common scRNA-seq analysis
workflow may be divided into pre-processing steps and downstream analysis [399] - and
scRNA-seq-specific tools have been implemented for several of the steps along the pipeline.
In particular, methods have been proposed to perform cell calling, i.e. to detect, and exclude,
empty droplets [404], doublets [405–407], and ambient RNA [408]. Moreover, methods
for normalisation have been described in [409–411]. After normalisation, data matrices are
typically log(x+1)-transformed. Additionally, several novel methods allow to correct for
confounding factors including batch effects [412–417] and cell cycle effects [418, 419]. To
ease the computational burden on downstream analysis tools, reduce the noise in the data,
and to visualise the data, one can use several approaches to reduce the dimensionality of
the dataset. First, feature selection, for example by detecting highly variable genes (HVGs)
[420, 421]. Next, dimensionality reduction is performed either using linear methods, such as
PCA, or non-linear methods, with the latter being preferred for visualisation purposes. In
particular, t-distributed stochastic neighbour embedding (tSNE) [422] and uniform manifold
approximation and projection (UMAP) [423] are extremely popular (for a review of other
methods, see [424]). Downstream analysis methods can be classified into cell-level and
gene-level. The former include clustering [425, 426], often followed by cell type annotation
[427], as well as pseudotime inference [428–431]. Finally, single cell-specific methods have
been developed for gene-level analyses, including differential expression analysis [432], and
gene regulatory networks identification [433–435].
A typical workflow for single cell RNA-seq data implemented in R can be found on Biocon-
ductor1 using scRNA-seq specific R packages scran [436, 437], scater [438], and SingleCell-
Experiment [439]. Other pipelines for scRNAseq data analysis include Seurat [413], Scanpy
[440], and SINCERA [441].
1at https://bioconductor.org/packages/devel/bioc/vignettes/scran/inst/doc/scran.html and
https://osca.bioconductor.org.
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3.1.3 Single cell eQTL mapping
With the ability to identify cell types and states in an unbiased manner [442, 443], the use
of scRNA-seq data, combined with genotype information, is uniquely positioned to provide
an extra layer of information on the regulatory role of common genetic variants on gene
expression, across a plethora of cell types and states. As a consequence, single cell eQTL
mapping is increasingly feasible, and promises to improve our understanding of genetic
regulation both in health and disease across tissues [159, 160, 444–447].
When performing eQTL mapping using scRNA-seq profiles, a first important step is to verify
the feasibility of traditional ‘mean level’ eQTL mapping, i.e. to reproduce eQTL previously
identified using bulk RNA-seq. Only then can we explore new avenues and alternative types
of eQTL analyses, which are especially enabled by the single cell resolution (Fig. 3.3).
Fig. 3.3: Overview of single cell eQTL mapping methods.
Matched genotypes and scRNA-seq data from several individuals allow the detection of cell type-
specific eQTL, variance eQTL (genetic effects on cell-to-cell transcriptional variability), and dynamic
eQTL (dynamic genetic effects along cellular differentiation or other cellular states).
In this chapter, we address the first point (i.e. mapping mean-level sc-eQTL). To do so, we
leverage bulk and single cell gene expression of matched human iPSC lines from around 100
donors to identify general guidelines for eQTL mapping using scRNA-seq data.
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3.2 What is different in single cell data?
When we perform eQTL mapping, we are interested in finding differences in expression level
between individuals, when stratified by their genotypes at a genomic locus of interest (page
19). Under the assumption that we are looking at an otherwise homogeneous population of
cells (e.g. all cells are from the same cell type), it is reasonable to consider the total (or the
average) expression for each individual and gene, across all cells. When we use bulk RNA
sequencing expression profiles, that is essentially what happens: all cells from an individual
are pooled, the mRNA is extracted, reverse-transcribed to cDNA, and then sequenced. The
resulting reads are then mapped onto a reference genome, and the expression level of each
gene is quantified as the number of reads (raw counts) obtained from one donor that uniquely
map to that gene, after normalisation, e.g. transcripts per million (TPM)2. A bulk RNA-seq
experiment, therefore, results in one individual measure of ‘abundance’ of each gene for
each donor. Such a measure results in aggregating over hundreds of thousands of cells and,
at least for expressed genes (e.g. average TPM > 1), the vector of gene expression across
individuals follows a distribution that can be approximated as Gaussian [448]. On the other
hand, whilst scRNA-seq data provides increased resolution and promises great insights into
cellular function, the data are also much sparser, and the number of cells that can be assayed
for an individual is limited compared to bulk (often as little as 10-100 cells). In addition, the
number of cells that can be assessed often varies substantially from individual to individual.
As a result, the distribution of total counts from a single cell experiment as opposed to its
corresponding bulk experiment has lower mean (fewer cells, fewer reads, Fig. 3.4) and
higher variance (due to the variable number of cells across donors, Fig. 3.4 vs Fig. B.1).
Fig. 3.4: Distribution of reads.
Distribution of total reads (across all genes, log10-transformed) per individual for matched iPSC data
(108 individuals) using single cell (left, from [447]) and bulk (right, from [449]) RNA-seq data.
2i.e. for every 1,000,000 RNA molecules in the RNA-seq sample, x came from this gene/transcript.
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3.3 Single cell and bulk RNA-seq profiling of iPSCs
The data I use in this chapter to benchmark methods for single cell eQTL mapping were
generated as part of a larger study, where iPSC lines from over 100 donors (from HipSci)
are differentiated towards definitive endoderm. A pooled design was adopted, where cells
from 4-6 lines were differentiated together, to avoid for individual genetic differences to be
confounded with batch variation, and to increase throughput. Cells were later assigned to
their donor of origin using Cardelino [403]. Next, cells were collected at four time points
(day0, day1, day2, day3) and sequenced using SmartSeq2 [383], a plate-based single cell
technology (Fig. 3.2). This study was published earlier this year [447], and I discuss the key
results from it in the next chapter (Chapter 4).
Here, I focus on the earliest time point (i.e. day0), where cells are still pluripotent, prior to
cell differentiation. We expect iPS cells to be fairly homogeneous, so it is the ideal cell type
to use to perform this kind of study. After QC3, data was available from 9,661 iPS cells and
11,231 genes, from 112 unique unrelated donors, across 24 differentiation pools (Fig. 3.5).
Fig. 3.5: Overview of iPSC data used in this chapter.
We use SmartSeq2 [355] data from 111 iPSC lines (from 111 individuals) from [447], across 24
experimental pools, each containing cells from 4-6 cell lines (middle). For 108 of those lines, we
have bulk RNA-seq profiles from [449] (top). Finally, for five of the pools (corresponding to 29
individuals/lines), we also have scRNA-seq data sequenced using the 10X Genomics pipeline [389]
(bottom).
3Some QC steps were performed for all time points jointly, therefore I refer the reader to the detailed QC
pipeline described in the next chapter, at page 105.
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To map eQTL, I considered only donors with at least 10 cells, which excluded one donor,
bringing the sample size down to 111. The number of cells per individual varied widely,
ranging from 10 to 383 iPS cells from individual to individual. Additionally, we have
matched bulk RNA-sequencing profiles generated as part of the HipSci project [294] for the
vast majority of cell lines used (108/111, 97%). Finally, we have scRNA-seq data measured
using a droplet-based technology (10X Genomics [389]) for a subset of common lines (29
iPSC lines, from five of the experimental pools, Fig. 3.5).
3.4 eQTL mapping pipeline
To map eQTL, I use a pipeline which was originally written by Marc Jan Bonder, and which
I have expanded to the use for single cell eQTL. It is a wrapper around LIMIX [360, 361],
and it is publicly available at https://github.com/single-cell-genetics/limix_qtl. For all three
eQTL maps (single cell SmartSeq2, bulk, single cell 10X), I used the same pipeline and
tested the same set of genes (n=10,840). In particular, I performed cis eQTL mapping,
considering common (minor allele frequency > 5%), in HWE (p value > 0.001)4, variants
within a cis-region spanning 250 kb upstream and downstream of the gene body. For each





αiPCi +gβ +u+ψ , (3.1)
where y is the N ×1 standardised5 expression-level phenotype vector (i.e. bulk expression
or mean single cell expression; details in next section); the first P=10 PCs calculated on the
expression values (matrix with y as columns, before standardisation) are included as fixed
effect covariates6, and αi are the corresponding weights; g is the N ×1 vector of alleles for
each sample at the locus tested (modelled as the number of minor alleles present - 0, 1 or
2), and β is the corresponding effect size; u is a random effect term used to account for
the samples’ population structure, i.e. u ∼N (0,σ2g K), where K is an N ×N kinship matrix
estimated using PLINK [355], and ψ ∼N (0,σ2n I), where I is the N ×N identity matrix, is
the noise vector.
4HWE: Hardy-Weinberg equilibrium.
5Centered at 0 and scaled to have variance = 1.
6This is a common approach to correct for both known and unknown unwanted variation, including batch
effects, which usually affect the expression of many genes, and therefore are detectable in the principal
components of expression. Moreover, these global effects are orthogonal to the effects of a single variant on the
expression of one gene (see section 2.2.4).
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All models were fitted using LIMIX [360, 361]. Note that, in order to map eQTL efficiently
using the fast implementation described in section 2.3.3, we are limited to a single random
effect term (u; rather than being able to incorporate for example pool as a random effect).
The significance was tested using a likelihood ratio test (i.e. β ̸= 0, section 2.2.1). In order
to adjust for multiple testing (section 2.2.2), we used a permutation scheme, analogous to
the approach proposed in Ongen et al. [318]. Briefly, for each gene, we generated 1,000
permutations of the genotypes while keeping covariates, kinship, and expression values
fixed. We then adjusted for multiple testing using this empirical null distribution. To control
for multiple testing across genes, we then applied the Storey procedure [323]. Genes with
significant eQTL were reported at FDR < 10%.
3.5 Single cell eQTL map of iPS cells
Using the method just described, we first tested for associations between common genetic
variants and gene expression in iPSCs using our SmartSeq2 single cell data. To reproduce
bulk-like abundance measurements, we considered a gene’s average expression level for each
sample, across cells. In particular, expression level is measured as log2(CPM+1)7 using
scater [438].
Since we did not use any batch correction method on the single cell expression data a priori,
we cannot exclude differences across batches. As internal control we have, for a subset
of donors (23/111), data from two (or three, in one case) distinct experimental batches.
We therefore compute average expression levels not for each individual line, but for each
line-experiment combination (i.e. cell_lineA-experiment1, cell_lineA-experiment2), which
enables effective correction for batch-to-batch differences using PCs as covariates (see above
and section 2.2.4). The linear mixed model described in eq. (3.1) can be readily adapted to
include the resulting replicate measures from the same line: N will now be not the number of
unique lines but that of line-experiment combinations. Additionally, both the genotype vector
g and the kinship matrix K need to be adjusted8, such that the latter is now in fact accounting
at once for the population structure and the repeatedness of the samples tested (Fig. 3.6).
Using this approach, I identified 1,833 genes with at least one eQTL (from hereon ‘eGenes’),
at FDR <10%, out of 10,840 genes tested (17%).
7CPM: counts per million, mapped reads are count-scaled by the total number of fragments sequenced per
cell, times one million.
8i.e. expanded, by duplicating genotype values across pool replicates.
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Fig. 3.6: Kinship matrix highlighting repeated structure of samples used.
Heatmap of the kinship matrix used to map eQTL using single cell data. Replicate observations for a
line across experimental batches are genetically identical, which is captured by the kinship (maximum
relatedness, red). Line-to-line relatedness is effectively 0 (grey), indicating unrelated individuals. On
the right, zoom-in to only consider the first 20 iPSC lines, highlighting the repeated samples.
3.6 Replication of iPSC eQTL using bulk RNA-seq
For comparison, I performed cis-eQTL mapping using the matched bulk RNA-seq data. I
used the same pipeline (eq. (3.1))9 and tested the same set of genes. This yielded 2,908
significant genes at an FDR of 10% (27% of genes tested). Such difference in number of
discoveries can be explained, at least in part, by the reduced noise in the gene expression
estimates when using bulk RNA-seq, partly due to the more consistent number of cells, and
as a consequence reads, across individuals (Fig. 3.4).
In terms of agreement between the sets of results, I found that over 70% of eQTL identified
using scRNA-seq data were replicated in the bulk study, where a single-cell eQTL lead
variant (top variant per gene) was replicated if it achieved nominal significance (p value
< 0.05) and had consistent direction of effect in the full set of results from the bulk eQTL
analysis (Fig. 3.7). On the other hand, only around 50% of the eQTL identified (at FDR <
10%) using bulk RNA-seq could be replicated in our single cell eQTL map. However, when
we subsetted to eQTL identified using bulk data at a more stringent FDR threshold (1%), the
replication proportion was much larger (76%), and the more stringent the FDR threshold, the
more bulk eQTL we could replicate using single cell data (Fig. 3.7).
9The only difference of course is that there were not multiple replicates from the same line in the bulk
RNA-seq data, but the model in eq. (3.1) still holds.
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Fig. 3.7: Replication of iPSC bulk eQTL using single cell data and vice versa.
Replication of iPSC eQTL discovered with (matched-sample) bulk RNA-seq data using scRNA-seq
data, and vice versa. The total number of genes with at least one eQTL (i.e. eGenes) discovered is
shown, along with the number of discoveries replicated in the other dataset, at various FDR thresholds.
FDR: false discovery rate; sc: single cell.
This result suggests that we are able to detect the stronger eQTL signals, but lack the statistical
power (compared the corresponding test using bulk RNA-seq profiles) to identify smaller
effects.
3.7 Replication of iPSC eQTL using 10X data
Next, to further confirm our iPSC eQTL map, we performed eQTL analysis (eq. (3.1)) using
scRNA-seq data generated from a subset of 5 experiments (29 lines) using a droplet-based
approach (10X Genomics [389], Fig. 3.5).
Similar to before, we assessed how many bulk-identified iPSC eQTL could be replicated
using 10X samples. Since this study is fairly underpowered with only 29 samples, we did
not consider the opposite analysis, i.e. 10X discoveries replicated in bulk. We did, however,
compare results to an iPSC eQTL map using the SmartSeq2 data, when sub-setted to the
same 5 experiments (and 29 lines, Fig. 3.8).
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Fig. 3.8: Replication of iPSC bulk eQTL using single cell across technologies.
Replication of iPSC eQTL discovered with bulk RNA-seq (108 samples), using single cell RNA-seq
data from a common set of 29 samples (SmartSeq2 in sand, 10X Genomics in red). The total number
of bulk eGenes discovered is shown, along with the number of discoveries replicated using single cell
profiles, at different FDR thresholds. As before, replication was defined as nominal significance, at p
value < 0.05, and same direction of effect. FDR: false discovery rate; eGene: gene with at least one
eQTL detected (at a given FDR threshold).
Overall, we observe that replication of bulk eQTL using scRNA-seq is reduced when we
reduce sample size (for example, at FDR < 10% replication was 41% using 29 lines compared
to 54% using all 111 lines in Fig. 3.7), but comparable across technologies (SmartSeq2, 10X
Genomics), with SmartSeq2 slightly outperforming 10X (Fig. 3.8).
Once again, we can explain these differences in the number of discoveries at least partly as
the result of differences in sequencing depth. If the variability between donors was the main
difference between bulk and plate-based scRNA-seq (Fig. 3.4), here the key difference is
the reduced number of reads obtained using the 10X technology, compared to SmartSeq2.
Indeed, despite the higher number of cells (15,168 vs 2,275 for the same set of 29 lines), the
total read count is significantly lower (median of 9 compared to 36 million reads per donor
on average10, Fig. B.2).
10For reference, the equivalent median reads per donor using bulk is 44.
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Additionally, we found good agreement in terms of effect sizes between the eQTL maps
obtained using the two different single cell technologies, highlighting the robustness of the
approach (Fig. 3.9).
Fig. 3.9: Effect size agreement of bulk eQTL between single cell technologies.
Scatter plots of eQTL effect sizes obtained when testing association of iPSC eQTL discovered using
bulk RNA-sequencing (108 cell lines), using SmartSeq2 ([383] x axis) and 10X Genomics ([389] y
axis) on cells from 5 experimental batches (experiments 31, 40, 41, 43, 44; 29 cell lines in total). The
number of eQTL examined and the correlation between effect sizes is indicated when we consider
bulk iPSC eQTL discoveries at four different FDR thresholds (0.1, 0.01, 0.001 and 0.0001).
Since the vast majority of scRNA-seq datasets presented recently use droplet-based (rather
than plate-based) technology, as it allows, as we have seen (page 74), the assessment of
a much larger number of cells in a single experiment, it is important to show that this
approach would work for such datasets as well. Whilst in this case we had data from too
few individuals to make a very strong argument, the good concordance of results between
10X and SmartSeq2 suggests that this approach would work well for all single cell RNA-seq
datasets, across technologies.
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3.8 Preliminary steps towards a best-practice pipeline
The results presented so far are included in Cuomo et al. [447], the other results of which I
discuss in detail in the next chapter (Chapter 4).
More recently, in collaboration with Marc Jan Bonder and Giordano Alvari from the Stegle
group, I have worked on a best-practice pipeline which extends on the work presented so
far, by testing the effect of different parameters of the model, to optimise yield of single cell
eQTL mapping. In particular, using the same iPSC data described in this chapter so far (Fig.
3.5), we systematically compared results when mapping eQTL i) using various aggregation
strategies to obtain ‘pseudo-bulk’ expression levels to use as phenotypes in the model, and ii)
varying the type and number of ‘global expression effect’ covariates (see section 2.2.4) that
are included in the model.
3.8.1 Overview of the iPSC data used
As I have mentioned, we broadly use the same iPSC data as before, i.e. scRNA-seq from
[447] and (matched) bulk RNA-seq from the HipSci resource. However, we implemented
some changes, to increase our confidence in this comparison. First, to make the data most
comparable between the scRNA-seq data and the bulk RNA-seq data, we re-quantified single
cell expression at the gene level using the ‘featureCounts’ tool [450], as was done for the
bulk RNA-seq data (rather than relying on the quantification using the pseudo-aligner salmon
[451], which was used to obtain the results described above and all results in Chapter 4).
Additionally, to remove further possible confounding effects, a small group of lines from
monogenic diabetes donors were excluded, as well as four lines which were slight outliers in
the genotype space (Fig. B.3). In total, we map single cell eQTL for 88 cell lines (from 88
donors).
In addition to cells from 4-6 donors being multiplexed in 24 distinct pools (Fig. 3.5), cells
from one pool were often sequenced in several runs (‘sequencing run’, or ‘run’), which adds
one layer of batch. As a cell-QC step, we calculated the average correlation of each cell with
all other cells. Then, for each sequencing run, we calculated the median of the resulting
cell-correlation values. If a run had median cell-correlation < 0.7, all cells from the run were
discarded (Fig. 3.10, panel a). In a second step, cell-cell correlations were calculated again,
between cells from the remaining runs only. This time, we considered line-run combinations,
and discarded all combinations that had median cell-correlation < 0.5 (Fig. 3.10, panel b).
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Fig. 3.10: Correlation-based cell QC
(a) Median cell-correlation calculated per run. Runs with median cell-correlation < 0.7 were discarded.
(b) For the remaining runs, donor-run (i.e. sample) level median cell-correlations were calculated, and
samples with median cell-correlation < 0.5 were discarded.
Moreover, in order to compare eQTL results across genes at different expression levels, we
chose to be more lenient on the criteria for gene inclusion. Indeed, we considered all variable
genes as obtained by ranking all genes (n=50,42511) by their squared coefficient of variation
(CV 2)12 across all cells, and selecting the upper two quartiles. As a result, 20,545 genes were
included in the analysis. On the other hand, to reduce the multiple testing burden, we only
tested SNPs with MAF >10% and within a smaller window around the gene (100kb on either
side of the gene body).
Bulk RNA-seq data to assess replication
Finally, we compared the resulting single cell eQTL maps with results obtained using bulk
RNA-seq both limited to the same set of samples (n=88, ‘matched bulk’, or ‘m-bulk’), and
using all samples that were available at the time (n=810 HipSci lines from 527 unique donors,
‘all bulk’, or ‘a-bulk’).
11This includes all genes annotated in the Ensembl reference [452], which include protein-coding genes, non-
coding genes (e.g. transfer RNAs, ribosomal RNAs, long intergenic non-coding RNAs, etc.) and pseudogenes.
12CV 2 = σ2/µ2.
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3.8.2 Aggregation strategies
In order to use traditional bulk eQTL mapping methods for single-cell eQTL mapping,
we first need to aggregate the multiple measurements from each donor to obtain bulk-like
measurements. Here, we explore different aggregation methods (Fig. 3.11, Table 3.1). In
particular, we consider the mean, the median, and the sum as aggregation strategies.
Initially, we performed aggregation at the donor (‘d’) level, i.e. taking all cells for a donor,
to maximise the numbers of cells per donor. We call the resulting methods ‘d-mean’, ‘d-
median’, and ‘d-sum’ (Table 3.1). Additionally, we consider aggregating not only at the
donor level but also for each individual sequencing run (i.e. all cells from a given donor in
a single sequencing run; designated ‘dr’, Table 3.1). While this approach better accounts
for variation across technical batches, it also introduces multiple measurements from the
same donor. We can account for these repeated measurements in our linear mixed model by
including replicate and population structure information as covariates (eq. (3.1), Fig. 3.6).
We call the corresponding methods ‘dr-mean’, ‘dr-median’, and ‘dr-sum’.
The ‘dr’ aggregation is very similar to the approach used in the first part of this chapter, i.e.
using the same principle of accounting for batches. The difference is that this is done at a
deeper level of batch, noting that cells from the same experimental pool were sometimes
sequenced in more than one run and thus some donors are present in multiple runs. Visually,
the various aggregation methods show a similar picture across donors/samples and genes,
with the median aggregations being most affected by the 0-inflated expression (Fig. B.4, B.5).
aggregation method normalisation aggregation level
dr-mean mean single cell level (scran) donor & run
dr-median median single cell level (scran) donor & run
dr-sum sum pseudo-bulk level (TMM) donor & run
d-mean mean single cell level (scran) donor
d-median median single cell level (scran) donor
d-sum sum pseudo-bulk level (TMM) donor
Table 3.1: Types of aggregation methods tested.
Summary of the six key aggregation-normalisation strategies used in this study. In particular, for each
approach we specify the aggregation method used, the type of normalisation adopted, and the level of
aggregation selected. TMM: trimmed mean of M-values; normalisation method proposed in [453].
In all cases (i.e. using any of the aggregation methods) aggregated expression values were
only calculated for samples (i.e. donors or donor-run combinations) with at least 5 cells.
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3.8.3 Normalisation strategies
Importantly, normalisation of the scRNA-seq data was performed in different ways depending
on the aggregation method used. For the mean and median aggregation (both at the donor
and the donor-run level), we performed single cell-level normalisation using scran [409]
implemented in scater [438], which is one of the standard methods used for single cell
normalisation. The mean and the median were then calculated on the resulting normalised
(logged) counts (Fig. 3.11, Table 3.1). As an alternative to scran, we also tested bayNorm
[454], another recent single-cell normalisation approach. We found that the normalised counts
are highly correlated (Pearson’s R2 mean: 0.88, median 0.93). On the other hand, summed
count values (both dr-sum and d-sum) were obtained directly from the raw count data (i.e.
non-normalised). Normalisation was then applied on the resulting pseudo-bulk counts, using
methods typically used for bulk RNA-seq data. In particular, we perform trimmed-mean of
M-values (TMM, [453]) normalisation on the aggregated counts, as implemented in edgeR
[455], one of the best-established methods for bulk RNA-seq normalisation (Fig. 3.11, Table
3.1), followed by log transformation.
3.8.4 Phenotype transformation
Linear (mixed) models assume normality of the phenotype vector y (Chapter 2). However,
when using gene expression, we are in the presence of count data. By log-transforming (log2)
and normalising (previous section) such counts, the model-fit is improved, yet this approach
still remains sub-optimal (see section 2.3.4).
In addition, two commonly-used phenotype transformations include standardising each
phenotype vector (as I have done before) or quantile-normalising it, i.e. ranking the values
and then making the data fit to a Gaussian distribution, forcibly. Here, we chose the latter
strategy, which is more conservative, as it ensures a better fit to the (Gaussian) model. While
common in the field (e.g. [151, 456]), this approach comes at the cost of some information
loss on the real distribution of the expression vector, which can result in reduced power
to identify eQTL. However, it is more robust to outliers, and thus better suited for this
comparison. I note that it is important to be aware of the limitations and implications for the
downstream analyses. For example, the additive genetic effect modelled in our LMMs (eq.
(3.1)) is only strictly additive with respect to the sample analysed and the transformation
that is performed on the phenotype vector. Consequently, it is important to confirm potential
interesting effects using non-transformed expression values, as the raw data would be needed
to estimate biologically meaningful effect sizes.
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Fig. 3.11: sc-eQTL workflow.
Different approaches tested to perform eQTL mapping using scRNA-seq profiles. Starting from one
gene × cell count matrix, counts were aggregated per sample (i.e. donor, or donor-run combination),
either by summing the data first at sample-level and then normalising using methods designed for
bulk RNA-seq (i.e. TMM implemented in edgeR [453, 455]) or by first normalising the single cell
counts (using scran/scater [409, 438] or baynorm [454]) and then calculating the mean or the median
at the sample-level.
3.8.5 Comparing sc-eQTL results across aggregation approaches
Next, the (normalised and ‘gaussianised’) aggregated expression values resulting from each
of the methods described were used to map eQTL. For this comparison, the first 20 principal
components were calculated from each of the aggregated matrices and included in the model
as covariates (as before, from eq. (3.1), P = 20).
Table 3.2 summarises the results across the aggregation methods tested, when restricting the
results to the set of 12,720 genes that were tested in all six eQTL maps. The comparison is
first of all in terms of yield, i.e. number of eGenes identified using each of the methods (at
FDR<5%; discovery). Next, we assess the degree of replication of the discoveries in the set
of results obtained using bulk RNA-seq, both using matched samples only (m-bulk), and
using all samples (a-bulk). Replication was assessed by considering significance (FDR<10%)
and consistent direction of the effect of each sc-eQTL in the bulk results (Table 3.2).
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discovery m-bulk replication a-bulk replication
# eGenes % tested # replicated % replicated # replicated % replicated
dr-mean 1,835 14.43% 889 48.45% 1,367 74.50%
dr-median 1,337 10.51% 650 48.62% 952 71.20%
dr-sum 1,463 11.50% 819 55.98% 1,153 78.81%
d-mean 1,305 10.26% 768 55.85% 1,046 80.15%
d-median 776 6.10% 470 60.57% 625 80.54%
d-sum 1,174 9.23% 709 60.39% 951 81.01%
m-bulk 2,590 20.36% - - 2,448 94.52%
a-bulk 9,729 76.49% - - - -
Table 3.2: Aggregation method comparison.
Number of eGenes and replication of eQTL for the different aggregation & normalisation strategies in
Smart-Seq2 iPSC cells. The same set of 12,720 genes were considered in all of the strategies. FDR
was controlled at 5% for the discovery; replication was defined as FDR<10% and consistent direction
of effect in the two bulk studies, i.e. matched donor bulk (N=88, m-bulk) and all bulk set (N=527,
a-bulk). Discoveries using bulk were also added, for reference (last two rows).
We identified between 776 and 1,835 genes with at least one eQTL (i.e. eGenes, at FDR<5%)
using the different aggregation methods (out of 12,720 genes tested). To put these numbers
in context, the equivalent eQTL map using matched samples with bulk RNA-seq (m-bulk)
identified 2,590 eGenes (Table 3.2). These results show two main trends. First, aggregation
at the donor-run level outperforms aggregation at the donor level only (e.g. dr-mean vs
d-mean). Next, our results indicate that mean aggregation (after single cell-specific normali-
sation; 1,835 eGenes) outperforms sum aggregation (followed by bulk-like normalisation;
1,463 eGenes), and median aggregation performs worst in all cases (1,337 eGenes, Table 3.2).
Next, we used two selected sets of bulk iPSC RNA-seq data as described above, i.e. m-bulk
(n=87) and a-bulk (n=526), to assess the replication of the iPSC sc-eQTL mapping results in
bulk data (assumed to be the gold standard). We assess replication of the top eQTL effects in a
single-cell method in bulk (i.e. direct eQTL replication), and define replication as FDR<10%
(in the replication set) and a consistent effect direction. Replication rates from the two sets of
samples show a very similar picture: on average we find slightly lower replication rates for
the single cell normalisation methods, but a substantially higher total number of replicated
discoveries at the eQTL level. In particular, the highest number of replicated eQTL is found
for dr-mean (1,450 considering a-bulk) and highest fraction of replication is found for d-sum
(82%, a-bulk). Moreover, we observe broadly consistent effect sizes between single cell
and bulk, across the different methods, with the median once again performing worse than
mean and sum aggregations (Fig. B.6). Finally, we see higher replication rates considering
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a-bulk as compared to m-bulk, indicating that some of the effects found in the single-cell
data can only be picked up from bulk datasets with more samples. When specifically looking
at the effects that get replicated, we observe that they are highly overlapping (86%) across
aggregation strategies. This result indicates that the same effects that get replicated in d-sum,
are also replicated in dr-mean, but since there are more effects found in dr-mean, the overall
fraction is lower.
We speculate that whilst the sum would perhaps be the most obvious approach to reproduce
bulk-like measurements, the mean might perform better because of the normalisation used.
Indeed, the normalisation at the cell-level may better balance the differences in read counts
across cells prior to the aggregation at individual-level. Next, we also tested an alternative
single cell normalisation approach, bayNorm [454], and mapped eQTL using the dr-mean
aggregation method, finding that the results were virtually indistinguishable (1,835 eGenes
vs 1,860, and Pearson’s correlation between both p values and effect sizes: R=0.99, p value <
2.2×10−16, total difference in effect sizes = 10−6; Fig. B.7).
Overall, reassuringly, we broadly recapitulate the key results found in the first part of this
chapter, confirming that eQTL maps using bulk RNA-seq are better powered that those
using single cells, at identical sample size. Additionally, ‘dr’ approaches (i.e. aggregating at
donor and batch) outperformed d approaches (i.e. aggregating only at donor level Table 3.2),
re-iterating the importance of considering replicated experimental designs for eQTL studies.
3.8.6 Comparing results using different expression covariates
As a second comparison, we varied the type and number of expression covariates included
in the model to account for global expression variation (see section 2.2.4). Since dr-mean
outperformed other aggregation methods, we only perform this comparison using the dr-
mean-aggregated values.
In particular, we compared multiple different methods to capture global expression covariates:
probabilistic estimation of expression residuals (PEER [325, 326]), principal component
analysis (PCA), linearly decoded variational autoencoder (LDVAE or linear scVI [330]), and
multi-omic factor analysis (MOFA [331]), for which we considered two different flavours:
with and without sparsity constraints). For each approach we tested the effect of including
5-25 factors as covariates in the model (eq. (3.1)), in steps of five. In a first instance, we
compared results when running these maps for chromosome 2 genes only (1,421 genes).
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To evaluate performance, as before, we first considered the number of eGenes (Table 3.3):
0 5 10 15 20 25
PCA 83 160 165 184 175 167
PEER 83 148 139 146 126 183
MOFA 83 129 168 164 165 154
MOFA-ns 83 155 152 149 154 112
LDVAE 83 113 118 135 158 144
Table 3.3: Number of eGenes for various types and numbers of covariates.
Rows are methods to calculate expression covariates, columns number of covariates considered for
the eQTL test. The numbers of eGenes are to be considered out of 1,421 (chromosome 2) genes tested.
The dr-mean is used as aggregation method, normalised using scran. MOFA-ns is MOFA non-sparse,
i.e. run without the default sparsity constraints.
Next, we considered the number of eQTL that were replicated using a-bulk (using all samples,
FDR<10% and same direction of effect, Table 3.4; for the equivalent results using ‘m-bulk’
see Table A.1):
0 5 10 15 20 25
PCA 64 116 124 132 133 123
PEER 64 106 102 109 95 136
MOFA 64 91 119 123 122 114
MOFA-ns 64 118 114 109 114 94
LDVAE 64 82 86 99 113 101
Table 3.4: Number of bulk-replicated eQTL for various types and numbers of covariates.
Similar to Table 3.3 (dr-mean as aggregation method, 1,421 chromosome 2 genes tested only), but
considering replication in the set of results using a-bulk (all samples, FDR<10% and same direction
of effect). MOFA-ns is MOFA non-sparse, i.e. run without the default sparsity constraints.
As previously described [326], we observed a big increase in the number of eGenes discov-
ered when considering covariates as compared to not considering covariates: the minimum
increase is 75%. However, when comparing the method-specific optimal number of covari-
ates (e.g. 15 for PCA, 25 for PEER), which is commonly done when optimising a eQTL
mapping protocol, we observe broadly similar results across methods (Table 3.3). LDVAE,
the only method included that works directly on the single-cell data, produces the smallest
increase in eGene discovery. Furthermore, the replication of the effects in a-bulk, fixed at 20
PCs as previously used, is similar between the different methods (Table 3.4). Our results also
show that more computationally expensive methods such as LDVAE, PEER or MOFA do not
perform measurably better than the historical default in bulk eQTL studies of correcting for
unwanted variation using principal components.
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In summary, our recommendation for optimising yield of eQTL mapping using single cell
expression profiles is to normalise counts at the cell-level, using single cell specific methods
such as scran [436] (or baynorm [454], which performed similarly well), then aggregate such
counts by considering the mean expression across cells. Depending on the experimental
design, if data from a given donor is present across multiple technical batches, we recommend
considering those batches as separate replicates for the donor, and calculating the mean for
the two separately. Next, principal components can be calculated from such aggregated
expression matrix, and the first 15-20 PCs should be included as covariates in the model. We
also acknowledge that the number of PCs to include will depend on the sample size of the
study. For example, in the case of several hundreds of individuals, 25 or 50 PCs may be more
appropriate.
Future work towards establishing a best-practice pipeline for single cell eQTL studies
includes confirming such recommendations using droplet-based data, for example using
data I will introduce in Chapter 5, which have been sequenced using the 10X Genomics
Chromium technology [389]. Moreover, future avenues involve the use of experimental-
data informed simulation experiments to assess the impact of additional variables including
varying numbers of cells per donor, varying sample size, batch effects and genetic effects
of varying strength, on our ability (and statistical power) to detect eQTL using single cell
expression data.
3.9 Discussion
Since being highlighted as ‘Method of the Year’ in 2013 [457], sequencing of the genetic ma-
terial of single cells has become common-practice to investigate cell-to-cell heterogeneity in
biological systems [458]. In particular, scRNA-seq enables the quantification of gene expres-
sion transcriptome-wide, and at single-cell resolution, allowing for cell type sub-populations
to be distinguished [459–464], and the identification of cells transitioning between states
[395, 465, 429, 430, 466].
Now an established method, scRNA-seq can be extended to profile single cell expression
across several individuals, enabling the study of the effect of different genetic backgrounds on
gene expression, at single cell resolution. Single cell eQTL (or as they called them scQTLs)
were first introduced in a paper by Wills et al., in 2013 [159]. In their paper, the authors
study lymphoblastoid cell lines from only 15 donors, but could already observe some cell
type-specific effect, which could not have been identified using bulk profiling. In 2018, Van
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der Wijst et al. [160] published the second sc-eQTL map, this time across blood cell types
from 45 individuals. They showed consistent direction of effects compared to bulk eQTL
on similar cell types, but could only replicate a very small percentage of the bulk-identified
eQTL (∼10%).
The work I present in this chapter (and in the next, and published in [447]) was the third
effort to map eQTL using scRNA-seq profiles, and the best powered at the time, with data
from over one hundred individuals. Additionally, the use of bulk and scRNA-seq data from
matched samples makes this the first step towards a systematic assessment of the differences
between bulk and single-cell transcriptomics, as applied to eQTL mapping. As I have shown,
compared to the results from [160], we could replicate approximately 50% of the eQTL
found using bulk, and almost all of the strongest signals (Fig. 3.7).
Our preliminary results on a best-practice workflow for sc-eQTL studies suggest that mean
is the preferable aggregation method, probably due to data normalisation considerations.
Additionally, PCA slightly outperforms other linear matrix decomposition approaches for
correcting for global expression covariates. This study begins to demonstrate that optimising
the sc-eQTL mapping workflow can increase the number of eGenes discovered substantially.
However, our conclusions come with some caveats; 1) simply discovering more eGenes
does not necessarily mean that an approach is better, as false positives could arise due to
data processing decisions; 2) bulk eQTL are a powerful, but not perfect, gold standard for
assessing truth, as biases in bulk-eQTL mapping may be replicated in sc-eQTL mapping
analyses. Future work includes validating these results when mapping eQTL using 10X data,
where we expect normalisation to have an even larger impact, due to the increased sparsity
of the data. Moreover, the use of real data-informed simulations will allow a more extensive
power analysis, as their use will enable us to scale up the numbers of donors and cells and
introduce group structure to comprehensively investigate the role of those parameters as
well13.
Yet, altogether, the results from this chapter illustrate a difference between bulk and single-
cell eQTL mapping: there is a trade-off between statistical power and cellular resolution.
Indeed, in this analysis of iPS cells, bulk RNA-seq data provided higher statistical power
for discovery of eQTL (about 30% more discoveries using bulk). However, iPSCs are a
rather homogeneous cell type, displaying relatively consistent expression profiles across
13Some of these analyses have now been done and strengthen our conclusions here, showing that our
guidelines can be generalised to a 10X data set and to simulated data [467].
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cells14. In more heterogeneous populations of cells, such as cells in the brain, the single cell
transcriptomes may become critical for defining pure populations, thus increasing discovery
power to detect eQTL.
A further advantage of the application of single-cell RNA-seq data in this study, was to
enable the pooled experimental design. Indeed, this setup allows us to assay cells from many
individuals in a single, neatly contained, experiment. As single-cell approaches are extended
to more disease-relevant tissues and cell types, this may provide important clues on the causal
role of genetic variants in disease.
These future studies are likely to be using droplet-based technologies, which allow the
assessment of a much larger number of cells. Although our main results are on (plate-based)
SmartSeq2 data, we could validate our approach with a subset of samples assayed with the
droplet-based 10X Genomics technology (Fig. 3.8), which is a strong indication that single
cell eQTL mapping can be performed using droplet-based scRNA-seq data. We observe
that 10X data recapitulates bulk eQTL slightly less well than SmartSeq2 (Fig. 3.8). This
can largely be explained by the lower number of reads obtained per individual using this
technology, despite the higher number of cells (Fig. B.2). However, the differences are
rather small (Fig. 3.8), which is reassuring, since droplet-based technologies are likely the
only feasible option as we move to larger data sets in terms of both budget and throughput
considerations.
Finally, in this chapter we have focused on reproducing standard ‘mean’ expression level
eQTL mapping using scRNA-seq, where the phenotype of interest is expression abundance
within a homogeneous population of cells. We can call such efforts ‘pseudo-bulk’ approaches,
where we are essentially replicating bulk-like expression values and performing the eQTL
test adapting approaches used for traditional eQTL mapping using bulk RNA-seq. In the
applications we and others have described [160, 447], the value of using scRNA-seq lies in
the fact that we are able, within a single experiment, to unbiasedly define and map eQTL in
multiple different cell types, whilst retaining a single cell resolution.
Now that we have established that such ‘mean-level’ eQTL maps are feasible, new eQTL
analyses, that specifically exploit the single cell resolution, can be performed (Fig. 3.3). One
such analyses is variance eQTL (varQTL, vQTL [468]) mapping, where one can assess the
14That is not to say that there is no sub-structure at all, see for example our results from section 5.4. However,
iPSCs are generally similar across protocols, and similar to ESCs [129].
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effect of common genetic variants on cell-to-cell transcriptional variability, rather than on
expression abundance. Unfortunately, these analyses have proven especially challenging,
largely because the variance of gene expression is strongly dependent on its mean, making it
hard to disentangle the two effects [469]. Moreover, variance QTL effects may be smaller
than anticipated. As a result, studies at current sample sizes are underpowered to detect any
variance QTL, as shown for instance by [444].
On the other hand, a single-cell approach allows detailed annotation of changing eQTL
effects across heterogeneous cell types and cell states, with the ability to better interpret the
context-specific role of individual genetic variants. In particular, dynamic eQTL, where the
effect of a genetic variant on gene expression is modulated by differentiation time [470, 302]
can be extended to single cell-resolved data, and expanded to include not only differentiation
trajectories, but any cellular state. In the next chapter (Chapter 4), I will present examples
of dynamic eQTL and eQTL affected by other cellular contexts.
4
Identifying dynamic eQTL effects during
iPSC differentiation using scRNA-seq
As outlined in section 1.2, human iPSCs and cells derived from them have proven to be an
excellent system to study cell fate decisions in early human development in vitro, which
cannot be studied in vivo. So far, experiments have been limited to a handful of individuals
or have focused on one single time point, thus the extent to which development varies from
individual to individual, and the role played by common genetic variants during the process,
remain largely unexplored. Here, we combine human iPS cell lines from over one hundred
donors, a pooled experimental design, and single-cell RNA-sequencing to study population
variation during differentiation to a definitive endoderm fate. We identify molecular markers
that can predict the differentiation efficiency of iPSC lines, and exploit natural variation in the
genetic background across individuals to map hundreds of eQTL that influence expression
dynamically during differentiation and across cellular contexts.
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As highlighted in section 1.2.2, the early stages of embryogenesis entail dramatic and dy-
namic changes in cellular states. As cells transition from a pluripotent state, where they still
have the potential to differentiate to all cell types, to committing to a specific cell fate, many
molecular programs and mechanisms are activated and tightly regulated. Our understand-
ing of such mechanisms in humans is still only partial, yet a lot has been learnt in model
organisms including fruit flies [471–473], zebrafish [474–476], and mice [477, 478, 463].
For obvious (ethical) reasons, such mechanisms cannot be studied in vivo for humans. There
exist a few studies that use human embryonic stem cells (hESCs) but the data is hard to
access, often limited to a narrow time frame within development and cannot be easily derived
from a variety of genetic backgrounds (section 1.2).
Additionally, the extent to which an embryo’s genetic background influences early develop-
ment has only been explored in a small number of special cases linked to rare large-effect
variants that cause developmental disorders. This missing information is critical and it can
provide a better understanding of how genetic heterogeneity is tolerated in normal develop-
ment, when controlling the expression of key genes is vital.
Human iPSCs and iPSC-derived cells offer great potential to interrogate cell types and states
that are challenging if not impossible to access in human, in vivo [294]. The generation of
population-scale collections of human iPSCs [294, 296] has already allowed for assessing
regulatory genetic variants in pluripotent [294, 296] as well as in differentiated cells [301,
300, 297]. Combined with a time-course experiment, iPSC-derived differentiation protocols
can be used to mimic human early development in vitro in a highly controlled setup. This, in
turn, provides a unique opportunity to study the dynamic effect of common genetic variants
on gene expression regulation during early development across several genetically distinct
individuals. However, iPSC differentiation protocols are challenging to apply in practice:
most protocols generate much more cell type diversity than intended [479]. Additionally,
extensive batch-to-batch as well as line-to-line heterogeneity has been observed [301, 296].
Finally, the protocols are lengthy and hard to scale, leading to limited throughput. In this
study, we employed different strategies to combat some of these issues.
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4.2 Single-cell RNA-seq profiling of differentiating hiPSCs
To assess the effect of common genetic variants on early human cell differentiation, human
iPSC lines from 125 unrelated donors were differentiated towards a definitive endoderm fate
[480]. In order to assess differences in expression and genetic regulation along development,
data were collected at four time points: at iPSC stage (day0) and then after 24, 48 and 72
hours post initiation (day1, day2, day3). To get a comprehensive picture of the process, single
cells’ transcriptomes were assayed using full-length RNA sequencing (using the SmartSeq2
technology [383]). Additionally, the expression of two selected cell surface markers was
recorded using fluorescence-activated cell sorting (FACS), a pluripotency marker (Tra-1-60)
and a definitive endoderm marker (CXCR4). In order to increase throughput and control for
technical batch effects, a pooled experimental design was adopted, where each differentiation
experiment (hereon simply ‘experiment’) consisted of iPS cells from 4 to 6 distinct cell lines
from the HipSci collection, which were grown and differentiated in the same plate. In total,
data were retained from 28 experiments. Imputed genotypes (see section 1.1.7) were also
available for all lines from the HipSci resource (Fig. 4.1).
Fig. 4.1: Experimental Design.
Human iPSC lines from 125 unrelated donors were differentiated to definitive endoderm (Fig. B.8)
using a pooled design, where cells from 4 to 6 lines were grown and differentiated together. Cells
were collected prior to differentiation (at day0) and every 24 hours along differentiation to definitive
endoderm (at day1, day2 and day3). Cells at day0 are expected to be pluripotent; cells at day1 are
considered to be bipotent for either mesoderm or endoderm (mesendoderm); by day3, cells should
have reached a definitive endoderm state. At each time point, cells were FAC-sorted and sequenced
using the SmartSeq2 technology. Imputed genotypes were also available for all lines.
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4.2.1 Data processing and QC
Demultiplexing donors from pooled experiments
In the considered pooled experimental design, cells from multiple donors are differentiated
together in the same experiment. To be able to link the genetic background of an individual
with their transcriptional profile we need to map the cells back to their donor of origin,
without the use of any barcode. Indeed, we find that for the large majority of cells the RNA-
seq reads map to a sufficient number of common genetic variants for us to reliably assign each
cell to its original donor. In particular, assignment of cells to donors was performed using
Cardelino [403]. In short, Cardelino estimates the posterior probability of a cell originating
from a specific donor using common genetic variants in scRNA-seq reads, while employing
a Bayesian beta binomial-based approach to account for technical factors such as differences
in read depth, allelic drop-out, and sequencing accuracy. To perform donor assignment, we
considered a larger set of HipSci lines with genotype information (n=490), including the
126 lines used in this study. A cell’s assignment to a donor was considered successful if the
model identified the match i) with posterior probability > 0.9, and ii) using a minimum of
10 informative variants. Cells for which the donor identification was not successful were
discarded and not considered for further analyses. Across the entire dataset, 99% of cells
that passed RNA QC steps (see below) were successfully assigned to a donor. In some cases,
unexpected donor assignment (where several cells from one experiment were found to be
assigned to none of the 4-6 donors used in that experiment) allowed me to identify (and
correct) plate swaps that happened in the lab, without losing any data (Fig. 4.2).
Flow cytometry
The success of the differentiation protocol was validated using expression of two protein
surface markers, a pluripotency marker, Tra-1-60, and a marker of definitive endoderm,
CXCR4. We note that while cells were gated using the two markers, we did not discard
any cells based on their expression. In contrast, the first cell QC step performed using
FACS consisted in identifying dead cells based on 7AAD2 using FACS staining. These
were discarded and were not plated. FACS data were analysed using the openCyto package,
implemented in R [481]. The FACS gating strategy we used is illustrated in Fig. 4.3.
2Staining with 7AAD is used a cell viability assay. 7AAD cannot readily pass through intact cell membranes,
thus only cells with compromised membranes will stain.
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Fig. 4.2: Demultiplexing donors.
Example of how donor assignment of cells helped identifying a plate swap. To explore the results
of the donor assignment algorithm [403], I plotted cells along two axes: on the x axis, the posterior
probability of being assigned to a certain donor, on the y the number of common variants found on
scRNA-seq reads used to perform the assignment. Because we know for each experiment which lines
are supposed to have been differentiated, we can colour cells based on whether the donor they have
been assigned to was used in the specific experiment or not. On the left, an example of a correct
donor assignment: most cells are assigned to one of the correct donors1and the few that are not had
very few usable genetic variants. On the right, the donor assignment is apparently incorrect. Most
cells were assigned to donors that were not differentiated in the experiment, in many cases with a
high level of confidence and using many variants, which would generally indicate high quality cells.
Indeed, investigating further we realised that all cells were assigned to donors that all belonged to the
same experiment, but that it was a different experiment. The wrong label was assigned in the lab: run
225216 actually contained cells from experiment 43 and not 39. By resolving this computationally, we
avoided mistakes and retained all of the cells from this sequencing run, which would have otherwise
been discarded.
scRNA-seq feature quantification and quality control
Single cell profiles were obtained using the SmartSeq2 technology [383]. This is a plate-
based technology that involves single cells being sorted into 384 independent wells on a
plate. Adaptors of raw scRNA-seq reads were trimmed using Trim Galore! [482–484], using
default settings. Trimmed reads were mapped to the human genome (build 37) using STAR
[485]. Gene-level expression quantification was performed using Salmon [451]. Briefly,
Salmon quantifies transcript- (rather than gene-) level expression levels, similar to Kallisto
[486]. Then, such values are summarised at a gene level (counts per million (reads) (CPM)).
2A cell technically could still have been assigned to a wrong donor within the correct experiment, but given
a threshold both on the variants used (> 10) and on the posterior probability (> 0.9) I deemed this unlikely.
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Fig. 4.3: FACS gating strategy.
Figure by Mariya Chhatriwala. FACS gating strategy: first, single cells were stained with 7AAD
to exclude dead cells. Unstained live cells were then used to gate for expression of Tra-1-60 and
CXCR4.
We performed quality control (QC) of scRNA-seq profiles following a widely used pipeline
(see section 3.1.2) using Bioconductor packages scater and scran, implemented in R
[436, 438, 439]. In particular, cells were retained for downstream analysis if they had
at least 50,000 counts from endogenous genes, at least 5,000 genes with non-zero expression,
if less than 90% of counts came from the top 100 most highly-expressed genes, less than
15% of reads mapped to mitochondrial (MT) genes, they had a Salmon mapping rate of at
least 60%, based on distribution observation and thresholding (Fig. 4.4) [399]. Addition-
ally, cells were only retained if they could be successfully assigned to a donor (QC1, Fig. 4.5).
I then performed an additional QC step, where I excluded all cells from plates and experiments
that had overall low quality. In the case of plates sequenced twice, I retained the one with
most cells. Finally, I retained plates that had enough cells for the majority of the donors
considered (QC2, Fig. 4.5).
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Fig. 4.4: Distributions of QC metrics.
Distributions of three exemplar QC metrics for six differentiation experiments (40-45). Shown
are the cell distributions along the metrics (number of genes detected, percentage of counts from
mitochondrial genes, Salmon [451] mapping rate), as well as the thresholds we used as dotted lines,
stratified by day and experiment. One can immediately spot how poor quality plates3perform similarly
badly across all metrics (i.e. < 5,000 genes detected, <60% reads mapped by Salmon).
scRNA-seq processing
SmartSeq2 data do not include UMIs, which can be used to accurately detect PCR duplicates
and quantify transcript abundance [487, 488, 392]. In the absence of UMIs, we can borrow
information from cells with similar total number of reads and correct for overall library size.
Such size factor normalisation of counts was performed using scater [438]. Expressed
genes with an HGNC symbol were retained for analysis, where expressed genes in each
batch of samples were defined based on (i) raw count >100 in at least one cell prior to cell
QC (i.e. Fig. 4.5) and (ii) average log2(CPM+1) >1 after cell QC. Normalised CPM data
were log transformed (log2(CPM+1)) for all downstream analyses. As a last QC step, we
considered possible differences between cell lines derived from healthy and diseased donors.
Specifically, a subset of 11 cell lines in our dataset were derived from monogenic neonatal
diabetes patients, and differentiated together with cell lines from healthy donors across 7
differentiation experiments (out of 28). There was no significant difference in differentiation
efficiency (see section 4.7) between healthy and neonatal diabetes lines in these experiments
(p value > 0.05), and cells from both sets of donors overlapped in principal component space
(Fig. B.9). Thus, we included cells from all donors in our analyses, irrespective of disease
state.
3e.g. cells from day0, experiment 42.
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Fig. 4.5: QC workflow.
Two stages of cell QC. First, at the level of single cells, all QC metrics and thresholds are indicated.
61% of cells passed QC1. Second, at the experiment/plate level. If plates had many cells not passing
QC1 they were considered poor quality batches and removed altogether. This stage removed far fewer
cells, with 96% of cells considered passing QC2.
4.3 Data overview
Following quality control (QC), 36,044 cells were retained for downstream analysis, across
which 11,231 genes were expressed. At each time point, cells from between 104 and 112
donors were captured, with each donor being represented by an average of 286 cells (after
QC, Fig. 4.6). The success of the differentiation protocol was validated using canonical
cell-surface marker expression: consistent with previous studies [489], an average of 72% of
cells were TRA-1-60(+) in the undifferentiated state (day0) and an average of 49% of cells
were CXCR4(+) three days post differentiation (day3, Fig. 4.6).
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Fig. 4.6: Overview of experimental metrics.
Statistics for number of cells, donors, experiments, days, and combinations. Cell counts are shown
after quality control. Additionally, shown are the percentages of cells that are positive for TRA-1-60,
a pluripotency marker, positive for CXCR4, a definitive endoderm marker, and positive for CXCR4
and negative for TRA-1-60, across all cell lines and all experiments.
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4.3.1 Sources of variation
To identify the main sources of variation in our dataset we performed variance component
analysis for each of the genes, using a linear mixed model. Variance component analysis
revealed the time point of collection as the main source of variation, followed by the cell line
of origin and the experimental batch (Fig. 4.7).
Fig. 4.7: Variance Component Analysis.
Summary of variance component analysis results for each of 4,546 highly variable genes, using
a linear mixed model fit to individual genes to decompose expression variation into time point of
collection, cell line and experimental batch. The number of genes for which each factor explains 10%,
20%, 30% and 40% of the variance respectively is indicated.
Next, we performed PCA on our dataset. To do so, we first identified the top 500 highly
variable genes (HVGs) defined as the most variable genes given a mean-variance trend
calculated across all genes, using the function trendVar as implemented in the R package
scran. Consistent with the results from the variance component analysis (Fig. 4.7), the first
principal component (PC1) was aligned with differentiation time, motivating its use to order
cells by their differentiation status (hereafter ‘pseudotime’, Fig. 4.8).
Pseudotime inference is a common step in the analysis of scRNA-seq data along differentia-
tion and development: while single cells are single snapshots along time, with enough points
and considering that cells differentiate at different rates, they can be used to reconstruct a
trajectory. In this case, the nature of the short and linear differentiation process of our data (i.e.
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Fig. 4.8: Overview of dataset.
Principal component analysis of gene expression profiles for 36,044 QC-passing cells, coloured by the
time point of collection. PC1 effectively captures differentiation time and is defined as pseudotime.
iPSC → mesendoderm → definitive endoderm) meant that PC1 captured the differentiation
trajectory. For comparison, we did apply alternative pseudotime inference methods, which
yielded similar orderings (Fig. 4.9). Further validation of our inferred pseudotime was
provided by the temporal expression dynamics of known marker genes that characterise
endoderm differentiation, which was captured by our ordering of cells as expected (Fig.
4.10).
4.3.2 Defining discrete developmental stages
While the continuous measure of pseudotime nicely highlights the dynamics of gene expres-
sion over time, in order to map eQTL, and to be able to exploit methods similar to those
described in the previous chapter (Chapter 3), it was also important to define homogeneous
populations of cells that represent specific developmental stages. To do so, we assign our
cells to one of three non-overlapping stages, corresponding to the three canonical stages
of endoderm differentiation: iPSC, mesendoderm (mesendo) and definitive endoderm (de-
fendo). In particular, we utilise i) the ordering of cells along our inferred pseudotime ii) the
expression of the previously described markers of differentiation progress and iii) the cell’s
day of collection to determine the cell assignment to each stage (Fig. 4.10). Specifically, we
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Fig. 4.9: Evaluation of pseudotime definition by comparison with alternative approaches.
(a) Comparison of the pseudotime defined based on principal component analysis with diffusion
pseudotime (DPT) [428]. The diffusion map was generated using 15 nearest neighbours and the first
20 PCs across the top 500 most highly variable genes. (b) Comparison of our defined pseudotime
with an alternative measure of pseudotime based on projection of each cell on to a principal curve
(using princurve as implemented in R [490]) calculated using the first two principal components from
the top 500 most highly variable genes. (c) Comparison of our pseudotime to the average expression
of 124 co-expressed genes associated with cell differentiation. (d) Scatter plot-derived loess curves of
FACS markers as a function of the our PCA-based pseudotime, showing expected trends.
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assign all day0 cells to the iPSC cluster given their very high homogeneity. Next, cells were
assigned to the mesendoderm stage if they were collected at either day1 or day2, and had
pseudotime values corresponding to the peak expression of Brachyury (T) along pseudotime
(pseudotime between 0.15 and 0.5, Fig. 4.10). Similarly, cells were assigned to definitive
endoderm if they were collected at day2 or day3 and had pseudotime values higher than
0.7, corresponding to a pseudotime window with maximal expression of GATA6 (Fig. 4.10).
In total, we assigned 28,971 cells (about ∼80% of all cells) to one of the three stages. A
smaller fraction of cells with intermediate pseudotime (between 0.5 and 0.7, n=7,073) could
not be confidently assigned to a canonical stage of differentiation; these cells were largely
collected at day2, at which stage rapid changes in expression profiles are expected, reflecting
a transitional population of cells. I note that these cells were excluded for the purposes of the
initial stage eQTL mapping (results in section 4.4), but are included in all other analyses.
Fig. 4.10: Marker gene expression in pseudotime-based developmental states.
Expression of exemplar canonical markers for iPSC (NANOG), mesendoderm (T) and definitive
endoderm (GATA6) along pseudotime. Developmental stages were defined taking into consideration i)
the day of collection, ii) the expression of canonical markers, and iii) the position along pseudotime.
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4.4 Mapping eQTL in iPSCs, mesendo and defendo
By combining single cell expression profiling and common genetic variation of over one
hundred individuals we can begin to assess the impact of genetic variability on expression
in a continuous manner across early human development. We have imputed genotypes
for all of our 125 samples [294], so this study allows discovery of single cell eQTL along
differentiation. Using the developmental stages just described and methods similar to those
described in the previous chapter, we mapped eQTL in each of the iPSC, mesendo and
defendo populations, yielding 1,833, 1,702 and 1,342 eGenes, respectively. Briefly, we quan-
tified each gene’s average expression level for each donor, experiment, and differentiation
stage4, before using a linear mixed model to test for cis eQTL, adapting approaches used for
bulk RNA-seq profiles (+ and - 250 kb, MAF >5% [294]).
For comparison, we also performed eQTL mapping in cells collected on day1 and day3,
i.e. the experimental time points commonly used to identify cells at mesendo and defendo
stages [480]. Interestingly, this approach identified markedly fewer eGenes: 1,181 eGenes at
day1, and 631 eGenes at day3. These results demonstrate the power of using the single-cell
RNA-seq profiles to define relatively homogeneous differentiation stages in a data-driven
manner (Fig. 4.11). Notably, this observation was not merely a consequence of differences
in the number of cells or donors considered in each cell population (Fig. 4.11).
Profiling multiple stages of endoderm differentiation allowed us to assess at which stage
along this process individual eQTL can be detected as well as the level of sharing of genetic
signal across time. We observed substantial regulatory and transcriptional remodelling upon
endoderm differentiation of iPSCs, with over 30% of eQTL being specific to a single stage.
To define pairwise replication (and conversely specificity) between two sets of test results we
considered nominal significance (p value < 0.05) and consistent direction of the effect size.
Importantly, we observed that stage-specificity of eQTL was not significantly explained by
stage-specific gene expression (Fig. 4.12). Our differentiation time course covers develop-
mental stages that have never before been accessible to genetic analyses of molecular traits
and thus this study provides the first eQTL maps at mesendoderm and definitive endoderm.
We next explored whether any of the eQTL identified in these two studies were novel, and
found that 349 of them have not been reported in either a recent iPSC eQTL study based on
bulk RNA-seq [449], or in a compendium of eQTL identified from 49 tissues as part of the
4This approach is the same as what is described in the first part of Chapter 3, and similar to the ‘dr-mean’
described in section 3.8, except that the aggregation is done at the experiment level rather than the sequencing
run level.
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Fig. 4.11: Mapping single cell eQTL at different developmental stages.
(a) Illustration of the single cell eQTL mapping strategy at various stages of differentiation. Shown is
an example of a defendo-specific eQTL. Box plots of gene expression stratified by the allelic state
of rs9648854 at each stage, showing an association between rs9648854 and CNTNAP2 expression
at the defendo stage, but not at earlier stages. (b) Comparison of eQTL mapping using different
strata of all cells. The use of pseudotime-based stages increases the number of detectable eQTL,
compared to using the corresponding time point of collection. Bar plots represent number of eGenes
(genes with at least one eQTL, at FDR < 10%). (c) Similar to b, the number of donors for which
gene expression data were assayed at day0, day1, and day3, compared to the number of donors
in the pseudotime-inferred mesendo and defendo stages. (d) As for (c), with the number of cells.
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GTEx project [150]. An eQTL was defined as novel when it was not reported as lead variant
(FDR < 10%) in any of the tissues considered nor was it in LD (see section 1.1.7) with any
reported lead variant, LD assessed using r2 < 0.2.
Finally, we investigated the presence of lead switching events. These correspond to two
distinct genetic variants that are identified as lead eQTL for the same gene at different stages
of differentiation (at LD: r2 < 0.2), We found lead switching events for 155 eGenes (an
example in iPSC and defendo is illustrated in Fig. 4.12). To explore the potential regulatory
role of these variants, we investigated whether the corresponding genetic loci also featured
changes in histone modifications during differentiation. To do so, we used ChIP-Sequencing
to profile five histone modifications that are associated with promoter and enhancer usage
(H3K27ac, H3K4me1, H3K4me3, H3K27me3, and H3K36me3) in human embryonic stem
cells (hESCs) that were differentiated towards endoderm (using the same protocol employed
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above) and measured at equivalent time points (i.e. day0, day1, day2, day3, see section C.1.3
for detailed experimental methods). Interestingly, we observed corresponding changes in
the epigenetic landscape for 20 of the lead switching events (i.e. stage-specific lead variants
overlapped with stage-specific changes in histone modification status), suggesting a direct
mechanism (Fig. 4.12).
Fig. 4.12: Stage-specific eQTL.
(a) Proportion of eQTL that are specific to a single stage, shared across two stages, or observed
across all stages (sharing defined as a lead eQTL variant at one stage with nominal p value < 0.05
and consistent direction at another stage). (b) Proportion of stage-specific eGenes (genes with a
stage-specific eQTL) that are expressed only at a single stage, expressed at two stages, or expressed at
all stages. Expressed is defined as normalised log2(CPM+1) > 2. CPM: counts per million. (c) A lead
switching event consistent with epigenetic remodelling. The overlap of H3K4me1 with the eQTL
SNPs across differentiation time points is shown by the coloured bars.
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4.5 Dynamic eQTL across iPSC differentiation
The availability of large numbers of cells per donor across a continuous differentiation
trajectory from pluripotent stage to definitive endoderm enabled the analysis of dynamic
changes of eQTL strength at fine-grained resolution. To formally test for eQTL effects
that change dynamically across differentiation (dynamic eQTL), we tested for associations
between pseudotime (both linear and quadratic) and the genetic effect size using allele-
specific expression (ASE) and a linear model (see Box 3):
ASE = α1pseudotime+α2pseudotime2 +ψ , (4.1)
where the genetic effect is defined based on ASE at the level of single cells, i.e. quantified as
fractional read counts overlapping each allele for a given gene-SNP pair (see details in Box
3). We assessed significance using a likelihood ratio test with two degrees of freedoom (i.e.
H0 : α1 = α2 = 0). For this analysis, we focused on the joint set of 4,422 eQTL lead variants
(4,470 SNP-gene pairs) discovered at the iPSC, mesendo, and defendo stages and explored
how they were modulated by developmental time (using our inferred pseudotime). In this
way, we uncovered a total of 899 time dynamic eQTL at FDR < 10%, including a substantial
fraction of eQTL that were not identified as stage-specific by the discrete approach previously
used (page 113). This analysis is somewhat complementary to the eQTL map perfomed on
discrete differentiation stages (Fig. 4.11), which identified substantial stage-specific effects
(Fig. 4.12). Namely, we observe that in general stage-specific effects are weaker and unique
to certain cell types. In contrast, the dynamic eQTL identified are detected to a certain extent
across all cell types, but the strength of the effect is modulated by differentiation time.
One obvious explanation for these subtle dynamic changes could be that they are simply
reflecting changes in overall expression. To visualise this, we used a sliding-window approach.
Because we need a rather large amount of cells to reliably estimate expression abundance for
each individual, we slide a window containing 25% of the cells along pseudotime by a step of
2.5% cells. In each window, we considered average expression quantifications and estimate
genetic effects using eQTL mapping, essentially performing the same analysis we performed
in developmental stages in section 4.4, now in each window. In parallel, we reassessed each
eQTL in each window taking advantage of the full length transcript sequencing to measure
ASE. Here, in each window, we quantified the deviation from 0.5 of the expression of the
minor allele at the eQTL (ratio of reads phased to eQTL variants, Fig. 4.13). Notably, ASE
can be quantified in each cell and is independent of expression level, thus mitigating technical
correlations between differentiation stage and genetic effect estimates (Box 3).
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Box3: Quantifying genetic effects using ASE
When full-transcript (phased) data is available, ASE can be used to quantify the genetic effect of a
variant on expression as a single ratio, by quantifying the relative expression of one allele over the
other. For a given eQTL - and the corresponding eQTL variant and eGene - we i) select individuals
that are heterozygous at the eQTL SNP of interest, ii) consider all exonic heterozygous variants on
the corresponding eGene, iii) map reads to these SNPs, iv) aggregate all reads coming from the
same chromosome and v) compute the ratio. Conventionally, we look at ratios < 0.5 i.e. in the
numerator goes the allele with fewer reads mapped to it:
If one of these alleles is more responsive to a particular environmental factor (e.g. because of
preferential transcription factor binding), then ASE is expected to vary consistently with that
factor. This observation has previously been used to identify GxE interactions in gene expression
across individuals [491]. Critically, these ASE tests are internally matched, because potentially
confounding batch effects and technical variation should affect both alleles in each cell similarly.
Additionally, this test increases power by reducing the number of parameters to estimate, i.e.









g⊙ ekγk +ψ ,
where for each of K environments ek two terms must be added (to account for E and GxE), resulting
in (2*K + 2) parameters needing to be estimated (including one effect size β and the variance






where we can test directly the effect of the K environments on ASE and therefore only K+1
parameters need estimation (the K αk’s and σ2n ).
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Fig. 4.13: Schematic of the sliding window approach.
Cells are binned based on pseudotime ordering, to (a) quantify average expression, (b) perform eQTL
mapping, and (c) quantify average ASE. Each bin includes 25% of cells, binned at incremental steps
of 2.5%.
Both methods result in a measure of genetic effect dynamics, i.e. changing strength of
genetic effects along differentiation. Reassuringly, the two approaches were highly consistent
across pseudotime (Fig. 4.14). To explore this hypothesis, we clustered the top dynamic
eQTL (FDR <1%) jointly based on both the relative gene expression dynamics (global
expression changes along pseudotime, quantified in sliding windows as above), and on
the genetic effect dynamics (using ASE). This identified four basic dynamic patterns (Fig.
4.14): decreasing early (cluster A), decreasing late (cluster B), transiently increasing (cluster
C), and increasing (cluster D). As expected, stage-specific eQTL were grouped together in
particular clusters (e.g. defendo specific eQTL in cluster D, Fig. 4.15). Notably, the dynamic
profiles of gene expression and those of eQTL effects tended to be distinct, demonstrating
that expression level is not the primary mechanism controlling variation in genetic effects. In
particular, genetic effects were not most pronounced when gene expression was high (Fig.
4.14). Distinct combinations of expression and eQTL dynamics result in different patterns
of allelic expression over time. This is illustrated by the mesendoderm-specific eQTL for
VAT1L. Overall expression of VAT1L decreases during differentiation, but expression of the
alternative allele is repressed more quickly than that of the reference allele (Fig. 4.14). This
illustrates how cis regulatory sequence variation can modulates the timing of expression
changes in response to differentiation, similar to observations previously made in C. elegans
using recombinant inbred lines [470]. In other cases, the genetic effect coincides with high
or low expression, for example in the cases of THUMPD1 and PHC2 (Fig. 4.14). These
examples illustrate how common genetic variation is closely linked to the dynamics of gene
regulation.
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Fig. 4.14: Dynamic eQTL.
Clustered heatmap of global expression levels, eQTL effect sizes, and ASE across pseudotime for the
top 311 genes with the strongest dynamic eQTL effects (FDR < 1%; out of 785 at FDR < 10%). For
each gene, the dynamic profiles of gene expression and ASE were jointly grouped using clustering
analysis, with 4 clusters. The membership of a genes’s expression and ASE dynamics to one of
these clusters is shown by colours in the right-hand panel. All values in the heatmaps are z-scores,
normalised by gene (row). In particular, for ASE, average ASE values are plotted such that red
indicates highest deviation from 0.5. The diagram in the top right summarises the four identified
cluster dynamics, displaying the average dynamic profile of each cluster, computed as the average
across z-score normalised gene expression/ASE profiles. Selected examples of the dynamics of allele
expression for different cluster-combinations are shown in the bottom right panel. Shaded regions
indicate standard error (+/- 1 SEM). This figure is based on one by Daniel Seaton.
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We next asked whether dynamic eQTL were located in specific regulatory regions. To do
this, we evaluated the overlap of our identified dynamic eQTL with epigenetic marks defined
using the hESC differentiation time series5 (Fig. 4.15). This revealed an enrichment of
dynamic eQTL in enhancer (i.e. H3K27ac and H3K4me1), and promoter (H3K4me3) marks
as compared to non-dynamic eQTL (i.e. eQTL we identified which did not display dynamic
changes along pseudotime, Fig. 4.15), consistent with these SNPs being located in active
regulatory elements.
Fig. 4.15: Characterisation of dynamic eQTL.
(a) Summary of the identified cluster dynamics6and assignment of stage-specific eQTLs to dynamic
eQTL clusters. The numbers of each of the 3 classes of stage-specific eQTL (i.e. iPSC-, mesendo- ,
and defendo-specific eQTLs) that are assigned to each of the 4 dynamic eQTL clusters. (b) Number
of genes categorised by the combination of expression and ASE cluster from (a). Average dynamics
of expression clusters (rows) and ASE clusters (columns) are shown. (c) Overlap of dynamic eQTL
variants from a with histone marks. The odds ratio compared to the background of all other eQTL
variants is shown (*p value < 0.01; **p value < 1x10−4; Fisher’s exact test).
5using bulk, at equivalent time points along endoderm differentiation, see section C.1.3 for methods.
6displaying the average dynamic profile of each cluster, computed as the average values across z-score
normalised gene expression/ASE profiles.
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4.6 Cellular environment modulates eQTL effects
Whilst differentiation was the main source of variation in the dataset, single cell RNA-seq
profiles can be used to characterise cell-to-cell variation across a much wider range of cell
state dimensions [465, 327, 492]. Next, we identified sets of genes that varied in a co-
regulated manner (co-expressed genes) using clustering. In particular, grouping of genes by
single-cell co-expression was performed using affinity propagation7 [493], as implemented
by the Python scikit-learn library [494], using the top 8,000 highest expressed genes. This
resulted in a set of 60 clusters of co-expressed genes. Exemplar co-expression clusters
were selected to represent 4 dimensions of cellular state: cell cycle G1/S transition (clus-
ter 10), cell cycle G2/M transition (cluster 30), cellular respiration (cluster 0), and sterol
biosynthesis (cluster 28). This selection was done according to two criteria: (i) strongest
enrichment of relevant GO terms8, and (ii) a priori expectation of sources of cell-to-cell
variation. Indeed, variation in cell cycle stage is a common feature of single-cell datasets
[465], while variation in metabolic state during iPSC differentiation is well known [496].
These functional annotations were further supported by enrichment of relevant transcription
factor binding (e.g. enrichment of SMAD3 and E2F7 targets in the differentiation and cell
cycle modules, respectively). Additionally, expression of the cell differentiation module
(cluster 6) was correlated with pseudotime, as expected (Pearson’s R=0.62; Fig. 4.9, panel d).
Using the same ASE-based interaction test as applied to identify dynamic eQTL, reflecting
ASE variation across pseudotime, we assessed how the genetic regulation of gene expression
responded to these cellular contexts. Briefly, we tested for genotype by environment (GxE)
interactions using a subset of four co-expression modules as markers of cellular state, while
accounting for effects that can be explained by interactions with pseudotime:
ASE = α1pseudotime+α2pseudotime2 +β factor+ψ , (4.2)
where the test performed is: H1 : β ̸= 0 (using a likelihood ratio test), and factor represented
one of the four co-expression modules, and was quantified as the normalised mean expression
levels in each cell across all genes in the cluster. This approach extends previous work using
ASE to discover GxE interactions [491, 497], taking advantage of the resolution provided by
single-cell data.
7The Pearson correlation across all cells was used as the similarity/‘affinity’ metric.
8GO enrichment of each cluster was performed by Fisher’s exact test in Python using GOATOOLS [495].
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Fig. 4.16: Allele-specific expression reveals interactions with fundamental cellular processes.
(a) Results summary: numbers of eQTL identified as displaying GxE interactions with pseudotime
(purple), displaying GxE interactions with other cellular contexts but not with pseudotime, (after
appropriately accounting for pseudotime, red), displaying GxE interactions with both pseudotime
and at least one other cellular context (yellow), and displaying no GxE interactions at all (grey).
Significance is assessed at FDR < 10%. (b) ASE variation for two example eQTL SNPs that show
GxE interactions (FDR < 10%) and tag cancer-associated GWAS variants. The eQTL for RNASET2
(rs2247315) tags a risk variant for basal cell carcinoma, and its effect size is modulated by cellular
respiration, while the eQTL for SNRPC (rs9380455) tags a risk variant for prostate cancer and is
responsive to the G2/M transition of the cell cycle. For each cell, cellular contexts were inferred using
GO annotations of co-expression modules. Shaded regions indicate standard error (+/- 1 SEM).
We identified 668 eQTL that had an interaction effect with at least one factor (at FDR <
10%), with many of these eQTL having no evidence for an interaction with differentiation.
Indeed, 369 genes had no association with pseudotime, but responded to at least one other
factor. Conversely, of the 872 dynamic eQTL, 299 were also associated with GxE effects
with other factors, whereas 573 were exclusively associated with pseudotime.
These interactions encompass regulatory effects on genes and SNPs with important functional
roles. Specifically, 95 interaction eQTL variants overlap with variants previously identified
in genome-wide association studies (GWAS, LD r2 > 0.8). For example, the effect size of a
RNASET2 eQTL is sensitive to cellular respiratory metabolic state. This eQTL SNP is in LD
(r2 = 0.86) with a GWAS risk variant for basal cell carcinoma [498]. Furthermore, an eQTL
for SNRPC showed sensitivity to the G2/M state, and is in LD (r2 = 0.92) with a GWAS
risk variant for prostate cancer [499] (Fig. 4.16). These cellular factors vary not only across
cells in the experiments considered here, but also across cells in vivo, across individuals, and
across environments. Thus, these examples illustrate the versatility of our single cell dataset
and how it can provide regulatory information about variants in contexts beyond early human
development.
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Finally, we explored whether we could detect higher order interaction effects, where the
genetic effect varies with a cellular state in different ways along differentiation, effectively
testing for genotype x environment x environment (GxExE) interactions. To this end, we
fitted a linear model with fixed effects for differentiation and each of the factors, plus a
combined term (factor x pseudotime):
ASE = α1pseudotime+α2pseudotime2 +α3factor+β (pseudotime∗ factor)+ψ , (4.3)
where we test: H1 : β ̸= 0.
This approach identified 176 genes with significant higher order (GxExE) interactions
between a genetic variant, pseudotime, and at least one other factor. For example, an eQTL
for EIF5A, was responsive to G2/M state, especially early in differentiation, as measured
using ASE (Fig. 4.17).
Fig. 4.17: Second order GxE interactions with fundamental cellular processes.
Figure by Daniel Seaton. Higher order interaction example: an eQTL variant for EIF5A (rs7503161)
is affected by a GxExE higher order interaction with both pseudotime and the G2/M transition. Left
panel: effects of G2/M transition on ASE for cells with low and high pseudotime. Regression lines
are indicated with 95% confidence intervals for the 30% of cells with lowest and highest pseudotime
values. Right panel: heatmap of averaged ASE for cells falling within the specified windows of
pseudotime and G2/M transition. Only values for windows containing more than 30 cells are shown
(n=6,423 cells in total).
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4.7 Early markers are predictive of differentiation efficiency
The final piece of analysis we performed on this dataset was based on the observation that
iPSC lines have been shown to vary in their capacity to differentiate, as demonstrated by
previous studies [479]. This motivated us to look at whether we could detect clear differences
in the ability to differentiate among our 126 lines. We used the average pseudotime value
at the latest time point considered (day3) as a measure of differentiation efficiency in our
analysis. This was motivated by the observation that there was significant variation across
cell lines, which remained consistent across replicate differentiation experiments of the same
cell line (Fig. 4.18, n=33). Exploiting the scale of our study and the pooled experimental
design, we set out to look for potential markers of differentiation efficiency that are accessible
prior to differentiation.
Fig. 4.18: Line-to-line variation in differentiation efficiency.
Variation in differentiation efficiency across cell lines. Left: average pseudotime values for each line,
showing trajectories over time for 98 cell lines, coloured by differentiation efficiency. Shown are 98
cell lines (out of 126) for which we had sufficient data at all time points (> 10 cells at each time point).
Differentiation efficiency of a cell line was defined as its average pseudotime value across all cells on
day 3. Right: differentiation efficiency across cell lines (points), and consistency of individual cell
lines differentiated in multiple experiments (vertical bars, n=33).
First, we looked for genetic markers. Given our small sample size and consequent low
statistical power, we limited our pool to the set of 4,422 eQTL lead variants at any of the
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three developmental stages9. We tested each variant for association with differentiation
efficiency using a linear mixed model, similar to eq. (2.31):
Differentiation efficiency = β ∗Marker+Experiment+Donor+ψ , (4.4)
where Experiment is a random effect grouping sets of samples from the same experiment,
and Donor is a random effect grouping samples from the same donor (and cell line). Here,
a Marker is a genetic variant (i.e., eQTL SNP), and it is modelled as a fixed effect, with
corresponding weight β . The models were fitted using the lme4 package in R [500], and
significance was determined using a likelihood ratio test (H1 : β ̸= 0). This identified only
one significant association, with the eQTL variant for DPH3, at FDR < 10%. In an attempt
to validate this finding, we performed an additional set of differentiations in HipSci iPSC
lines derived from individuals that were not part of the variant discovery, selected based on
genotype at this variant (n=20). In these experiments, differentiation efficiency was measured
by the percentage of CXCR4+ cells on day3:
%CXCR4+= β ∗Marker+ψ . (4.5)
While the direction of effect was consistent, the association was not statistically significant
(p value = 0.24, Student’s t-test), probably reflecting low power at this sample size. We
conclude that larger sample sizes will be required to conclusively identify genetic predictors
of in vitro differentiation efficiency.
Secondly, we asked whether levels of gene expression at the iPSC stage (prior to differen-
tiation) could represent molecular markers of differentiation efficiency. We used the same
model as in eq. (4.4), with Marker in this case indicating the expression of genes at iPSC
stage. This revealed 38 associations at FDR < 10%, out of 11,231 genes tested (Fig. 4.19).
A subset of those genes (9/38) were also observed when using independent bulk RNA-seq
data from the same cell lines to look for an association between gene expression and dif-
ferentiation efficiency (nominal p value < 0.05). We note that expression of these marker
genes is largely orthogonal to pseudotime itself, i.e. these are not genes that vary across
pseudotime, and only as a consequence of that are associated with differentiation efficiency
(which is defined as average pseudotime at day3, Fig. 4.19). We noted that 17 of the 38
differentiation-associated genes were located on the X chromosome, reflecting a significant
enrichment of X chromosome genes (24.5-fold enrichment, p value = 8x10−16, Fisher’s exact
test). For all of the X chromosome genes, higher expression was associated with reduced
9rather than testing all variants genome-wide. Note that this would be essentially a GWAS, and normally a
GWAS is considered to be well powered at around 1,000 individuals.
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Fig. 4.19: Associations between iPSC gene expression levels and differentiation efficiency.
(a) Genome-wide analysis to identify markers of differentiation efficiency (defined as average pseudo-
time at day3), considering iPSC gene expression levels. Displayed are negative log (nominal) p values
signed by the direction of the effect. The horizontal blue lines denote the significance threshold (FDR
= 10%, Benjamini-Hochberg adjusted). Significant associations are shown in blue for autosomal
genes and in red for X chromosome genes. (b) Scatter plot comparing, for all genes, the statistical
significance of associations with differentiation efficiency for their expression on day0 and day3.
The y axis shows the association between the expression of the gene on day0 (i.e. in iPSC) and
differentiation efficiency of cell lines. The x axis shows the association between the expression of the
gene on day3 and differentiation efficiency. The correlation between these associations is R = 0.06,
demonstrating that the genes identified as predictive markers of differentiation efficiency (i.e. those
with high values on the y axis) are not the genes that define differentiation capacity (i.e. those with
high values on the x axis). Significance measured as -log10(p value). Significant genes are coloured
as in (a): autosomal genes in blue, X chromosome genes in red.
differentiation efficiency (Fig. 4.19). The majority of these associations (14/17) persisted
when performing the same analysis for only female lines (p value < 0.05), indicating variation
beyond differences between sexes.
These results are consistent with observations made by other groups, showing that X chromo-
some reactivation is a marker of poor differentiation capacity for iPSCs in general (see page
38) [501, 502]. We did not identify any other striking patterns in the genes identified other
than the reported over-representation of chromosome X genes, partly due to a small sample
size.
4.8 Discussion
Here, we generated a map of early endoderm differentiation across human iPSC lines from
125 unrelated individuals (Fig. 4.1, 4.8). This offers a unique and powerful tool which allows
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the interrogation of the role of genetic heterogeneity in early human development.
First, we characterise the effects of common genetic variants on gene expression at three
distinct developmental stages, adapting methods traditionally used for bulk RNA-sequencing
to single cell expression data (Fig 4.11 and see Chapter 3 for ample discussion on single
cell eQTL mapping). This was one of the first single cell eQTL mapping studies (after [159]
and [160]), and the first with over 100 individuals (previous largest sample size was 45).
Additionally, we mapped eQTL in mesendoderm and definitive endoderm cells, providing
the first eQTL maps (single cell or otherwise) at these key developmental stages. In this
application, the benefit of using single cell expression profiles resides mainly in the ability to
define homogeneous cell populations in an unbiased manner, resulting in a higher number of
detected eQTL (Fig. 4.11). We can also use this tool to start assessing the amount of sharing
of eQTL signal between closely related developmental stages. In particular, we found that
about one third of the identified eQTL at any given stage was specific to that stage (Fig. 4.12).
While relevant from a developmental biology perspective, the discretisation into three devel-
opmental stages (iPSC, mesendoderm, definitive endoderm) is somewhat arbitrary, as the
differentiation trajectory clearly appears as a continuum (Fig. 4.8, 4.10). To reflect this, we
exploited this resource to identify hundreds of dynamic eQTL, i.e. eQTL whose strength
is modulated by differentiation time in a continuous manner (Fig. 4.14). Reassuringly, we
found that eQTL dynamics were largely independent of total gene expression dynamics (Fig.
4.15). These findings nicely complement results from a similar study [302], where they iden-
tify eQTL in cells from iPSC lines that are differentiated toward cardiomyocytes across more
time points (16) but for fewer individuals (19). I note that we cannot completely rule out that
differentiation itself may be genetically regulated, although the results presented in section
4.7, where we found no common genetic variant associated with differentiation efficiency
indicates that those effects, if present, are probably negligible for our dynamic eQTL analysis.
Additionally, we extend the concept of context-specific eQTL [143, 161, 491] to single cell
resolution, identifying eQTL which are modulated by specific cellular states including cell
cycle phases and preferential metabolic pathways, thus fully utilising the power of single-cell
transcriptomics. These results highlight the power of using a single cell approach for eQTL
mapping, which allows detailed annotation of changing eQTL effects across heterogeneous
cell types and cell states, with the ability to better interpret the context-specific role of
individual genetic variants (Figures 4.16, 4.17).
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A further advantage of the application of single-cell transcriptomics in this study was to
enable the pooling strategy. While the feasibility of pooling samples has already been demon-
strated for PBMCs [402], in this study we have extended this to cell lines differentiated
together in culture. This strategy provided higher throughput, and enabled the characterisa-
tion of line-to-line variability in terms of differentiation efficiency in a controlled setting.
While the differentiation protocol considered here (to definitive endoderm) is short and
efficient, other protocols (e.g. to generate neurons [503]) are much more challenging, making
a pooling strategy useful for scaling up these protocols to population-scale (this aspect is
further discussed in the next chapter, Chapter 5). There are some possible drawbacks of a
pooled design. For example, paracrine signalling [504] could affect differentiation dynamics
of cell lines grown together and obscure genetic effects. Additionally, although we have
considered replicates of the same line across different experimental pools, our study is based
on a single iPSC line per donor. In the future, experimental designs may consider multiple
lines per donor, which, however, would require a different barcoding scheme as these cannot
be discriminated using genetic barcodes. As a result of this experimental design, we cannot
definitively distinguish between donor and cell line effects.
In summary, our results demonstrate the power of combining iPSC line pooling and scRNA-
seq to investigate development and genetics in vitro. Sorting of cells along different cellular
states allows eQTL context-specificity to be probed in detail across many axes of cellular
variation. The scRNA-seq readouts also provide a rich description of the progress of differen-
tiation over time across different cell lines.
This work acts as a proof of principle study, where we establish the feasibility of combining a
pooled experimental design, differentiation of human iPSCs and scRNA-seq readouts across
several individuals. In the next chapter (Chapter 5), we apply a similar set up to a larger scale
and much more complex differentiation protocol, with cells differentiating to dopaminergic
neurons, which are preferentially lost in Parkinson’s disease. This other protocol generates
more mature cell types, which are directly disease-relevant, and thus allows us to characterise
the genetic component of differentiation across a larger spectrum of human development
and disease. Additionally, we will have more power to explore differences in differentiation
capacity across more lines and after a much longer differentiation period.
5
Population-scale differentiation of iPSCs to
a neuronal fate
The work described in Chapter 4 acted as a proof of principle study, where we demonstrated
the feasibility of pooling cells from several lines prior to differentiating them towards an
endodermal fate. This means that in a single experiment we can obtain data from many
independent donors, which in turn allows us to increase throughput of these studies thus
enabling population-scale genetics to be performed. Additionally, the single cell readouts
make it possible to trace back the donor of origin of each cell, without the need for any
barcoding. We and others have shown that single cell RNA-seq can be used to map eQTL
and, despite the pooling, we retain enough cells per individual to do so successfully. Finally,
by profiling differentiations of several lines we can start to disentangle differences in differ-
entiation efficiency across lines and experimental batches.
In this second study, we considered a larger-scale experiment in terms of both the number of
donors (from 125 to 215) and cells (from around 40,000 to over 1 million) and apply similar
principles to a more challenging differentiation protocol, considering iPSCs differentiating
towards a midbrain neuronal fate. First, the use of a droplet-based scRNA-seq technology
allows us to assay a much larger number of cells, providing an overview of the cell types
generated by this protocol. Second, the larger number of cell lines included, and the
longer protocol, allows us to dive deeper into the differences across lines in terms of their
efficiency to differentiate, and allows us to start exploring possible causes. Lastly, the closer
resemblance of the differentiated cells to primary tissues enables the exploration of the
effects of disease-associated variants on relevant cell types both at a specific stage and across
development.
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As discussed in previous chapters, genetic variation can significantly alter cell function, for
example by leading to changes in gene expression. Human iPSCs are a promising cellular
model for assessing the cellular consequences of human genetic variation across different
lineages, developmental states and cell types. In particular, human iPSCs enable the study
of developmental stages and stimulation conditions that would be challenging to access in
vivo. The creation of cell banks containing hundreds of iPSC lines [294] provides an exciting
opportunity to carry out population-scale studies in vitro [447, 302, 301, 300]. However, dif-
ferentiating iPSCs is costly and labour-intensive, and differentiation experiments are difficult
to compare due to substantial batch-to-batch variation (section 1.2.5). Thus, experiments
with more than a handful of cell lines remain a significant challenge. Moreover, most iPSC
differentiation protocols generate a heterogenous cell population, of which the target cell type
represents only a subset [505, 298, 506, 507]. This variability in differentiation outcomes
hampers efforts to assess the genetic contributions to cellular phenotypes.
Single cell profiling has enabled ‘multiplexed’ experimental designs, where cells from mul-
tiple individuals are pooled together [447, 507]. Pooling improves throughput and allows
experimental variability between differentiation batches to be rigorously controlled, by en-
abling cell type heterogeneity to be accounted for in downstream analysis. As we have seen in
the previous chapter (Chapter 4), multiplexed experimental designs have only been applied
to one short differentiation protocol [447], which generated cells corresponding to very early
stages of development, and thus have not captured differentiation progression toward a mature
cell fate. Population-scale pooling during long-term differentiation offers the opportunity
to examine the effect of common genetic variants on gene expression in each cell popula-
tion produced over neural development, providing a foundation for future mechanistic studies.
Here, we develop and apply a multiplexing strategy to profile the differentiation and mat-
uration of more than two hundred iPSC lines derived from the HipSci towards a midbrain
neural fate, including dopaminergic neurons (DA). DA are involved in motor function and
other cognitive processes and play key roles in neurological disorders, including Parkinson’s
Disease (PD)1 [509, 510]. Additionally, we expose some cells to an oxidative stress, which
is thought to play a role in PD [511].
1Parkinson’s disease (PD) is a progressive neurodegenerative disorder, characterised by the loss of midbrain
DA neurons. These neurons control motor behavior, and, as they degenerate, they result in several motor
features of the disease, such as bradykinesia, rigidity, resting tremor, gait disturbances and postural instability
[508].
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5.2 Single cell map of iPSCs neuronal differentiation
5.2.1 Experimental strategy and data generation
215 feeder-free iPSC lines were selected from 215 unique, healthy, unrelated donors from
the HipSci consortium [294]. Cells from multiple iPSC lines were pooled together in 17
pools, each containing cells from 7 to 24 lines. 24h after plating, neuronal differentiation of
the pooled lines to a midbrain lineage was performed, as described by Kriks et al. [284]. To
capture transcriptional changes during neurogenesis and neuronal maturation, scRNA-seq
was performed from cells captured at day 11 (midbrain floorplate progenitors), day 30 (young
post-mitotic midbrain neurons) and day 52 (more mature midbrain neurons). The three
time points were selected based on the data available in the original paper, where molecular
profiling, biochemical and electro-physiological data defined developmental progression of
midbrain DA neurons [284]. The timeline was aligned to theirs: in their paper they described
days 11, 25, 50 as, respectively, midbrain DA progenitors, time of cell cycle exit, and long
term neurons. Day 30 was selected instead of day 25 to enrich for young post-mitotic neurons.
Additionally, half of the cells on day 51 were exposed to a sub-lethal dose of rotenone, a
chemical stressor that preferentially leads to DA death in models of PD [511]. Droplet-based
scRNA-seq was performed using the 10X Genomics™ technology [389]. After QC, a total
of 1,027,401 cells was retained across 17 cell pools and four conditions - day 11, day 30, day
52 untreated and day 52 rotenone-treated (Fig. 5.1).
Fig. 5.1: Experimental Design.
Figure created by Julie Jerber. Experimental design for pooled differentiations of iPSCs to midbrain
dopaminergic neurons. The three time points (day 11, day 30, day 52) at which cells were collected
for scRNA-seq profiling are shown. On day 51, 50% of the cells were stimulated with rotenone (ROT)
for 24h, to induce an oxidative stress. Single cell RNA-seq data from 215 iPSC lines (for 215 donors)
across 17 pools were collected for a total of over a million cells.
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5.2.2 Demultiplexing donors from pooled experiments
For each of the 17 pooled experiments, donors (i.e. cell lines) were demultiplexed using
demuxlet [402], considering genotypes of common exonic variants (MAF > 1%) available
from the HipSci bank, and a doublet prior of 0.05. Only single cells for which donor
identification was successful were considered further. This QC step filtered out two kinds
of droplet: droplets that contained two or more cells from different donors, and droplets
containing no cells, but enough free-floating RNA to pass the CellRanger UMI filter.
5.2.3 Normalisation, dimensionality reduction, and clustering
Independent analysis of each time point allowed efficient batch effect correction, as all
samples were from the same time point, containing similar mixtures of cell types. Moreover,
by reducing the number of cells analysed together, computational tasks were made more
tractable. In particular, the following steps were performed (at each time point): counts
were normalised to the total number of counts per cell. Next, only genes with non-zero
counts in at least 0.5% of cells were retained and the top 3,000 highly variable genes were
selected, after correcting for the mean-variance relationship in expression data. The first 50
principal components (PCs) were then calculated, and batch correction was applied on the
level of PCs using Harmony [512], with each 10X sample treated as a distinct batch. UMAP
and clustering was performed using the resulting transformed PCs. In particular, clustering
was performed using Louvain clustering [513] with 10 nearest neighbours. Data processing
steps besides batch correction were performed using the Scanpy package [440]. This identi-
fied a total of 26 clusters (6, 7 and 13 clusters at day 11, day 30, day 52, respectively Fig. 5.2).
Next, clusters were assigned to cell types using a set of literature-curated marker genes for
major brain cell types (n=48 marker genes, see Fig. B.11). When two clusters showed the
same gene set enrichment, they were assigned the same cell type identity (see next section).
5.2.4 Cell type annotation
Cell type annotation was carried out independently at each time point (day 11, day 30 and
day 52). For midbrain dopaminergic neurons, which is the target cell type of this protocol,
I also performed additional analyses to verify the cell type identity. In the next section, I
describe the mapping from clusters (identified unbiasedly using the entire transcriptome) to
cell types (using literature-curated gene markers).
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Fig. 5.2: Clustering and cell type assignment.
At each individual time point (day 11, day 30, day 52), cells were clustered using Louvain clustering
[513], after normalisation and batch correction using Harmony [512]. Subsequently, clusters were
annotated as cell types using known marker genes. When two clusters showed the same gene
set enrichment they were computationally assigned to the same cell type identity. (a) UMAPs of
cells sampled at each time point and coloured by cell clusters. (b) Same UMAPs as in (a), this
time coloured by assigned cell types. Astro: Astrocyte-like, DA: Midbrain dopaminergic neurons,
Epen1,2: Ependymal-like, FPP: Floor plate progenitors, NB: Neuroblasts, P_FPP: Proliferating floor
plate progenitors, P_Sert: Proliferating serotonergic-like neurons, Sert: Serotonergic-like neurons,
U_Neur1,2,3: Unknown neurons.
Day 11
Three cell type populations were identified at day 11. The two most prevalent ones, which
constituted circa 96% of all cells at this time point, were classified as proliferating and
non-proliferating midbrain floorplate progenitors (both expressing LMX1A and FOXA2 and
expressing MIK67, TOP2A when proliferating [514], Fig. B.11). The third cell population
(making up the remaining 4% of day 11 cells) was labelled a neuroblast (NB) population,
based on the expression of pro-neuronal genes NEUROD1, NEUROG2 and NHLH1 [515,
516], Fig. 5.2, B.11).
Day 30
At day 30, cells with floorplate progenitor (23%) and proliferating progenitor (7%) identity
could still be detected, whereas the neuroblast population was not seen any longer.
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Additionally, five new cell types were identified. Four of these additional cell types appeared
neuronal and one was non-neuronal, as characterised by the expression (or lack thereof) of
the pan-neuronal markers SNAP25 and SYT1 [517]. Of the four neuronal populations, two
could be assigned to a midbrain neuronal identity. The first expressed canonical DA markers
NR4A2, PBX1, and TMCC3 [514, 518, 519] and was labelled as a population of midbrain
dopaminergic neurons (DA, 27%). The second cell population expressed some serotonergic
neuronal markers (TPH2, GATA2 [520]) and was categorised as serotonergic-like (Sert,
21%) neurons. One additional large neuronal population (expressing SNAP25 and SYT1),
expressed both midbrain DA markers and cortical markers, and thus could not be assigned to
a specific neuronal identity (Unknown neurons 1, around 8%). Finally, one smaller neuronal
population (less than 2%) could also not be assigned to a specific identity (Unknown neurons
2). The only non-neuronal cell type identified at day 30 expressed all the classical markers of
ependymal cells (Ependymal 1 [521], 11%, Fig. 5.2, B.11).
Day 52
At day 52, the cell types identified at day 30 were largely recapitulated (Fig. 5.2). Floor-
plate progenitors were present in smaller proportions (13 and 5%). In addition to DA, Sert,
the mixed neuronal population 1 and the ependymal-like cell population 1, a population
of astrocyte-like cells could be identified, which were unique to day 52 (Astrocyte-like
[522, 523]). Finally, three additional rare cell types (present in less than 2% of cells sampled
at any time point) were detected, namely a second ependymal-like population (Ependymal
2), a population of proliferating neuronal serotonergic-like cells (Prolif. serotonergic-like
neurons), and one additional neuronal population which could not be annotated unambigu-
ously (Unknown neurons 3, Fig. 5.2, B.11).
We note that in general, we are careful to clarify that these are in vitro-generated cell types,
which will not be exactly the same as their in vivo counterpart, especially for cell types that
were not the target of the protocol used - thus the nomenclature xx-like, e.g. astrocyte-like,
and serotonergic-like. In the next section I discuss this further for the two cell populations
which we assigned to a midbrain neuronal identity.
Serotonergic-like neuronal population
First, the population we call serotonergic-like was an especially hard one to define. Seroton-
ergic neurons are located in the same brain region as dopaminergic neurons (the midbrain),
and share some common functions and gene markers. However, whilst dopaminergic neurons
have been very well characterised, partly because of their involvement in PD, serotonergic
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neurons have not been studied as much, and there are no well defined markers (at least not
in human, whereas there are a few mouse studies [520]). Additionally, there is no in vivo
single cell reference dataset. The only study containing a human serotonergic neuronal cell
population to the best of my knowledge is La Manno et al. [514], which contained only 14
cells. In the same study they also derive midbrain neurons from human iPSCs, but do not
obtain any serotonergic neurons. Since our population expressed some, but not all, canonical
serotonergic markers, we could not unambiguously say that these were serotonergic neurons,
hence the name serotonergic-like.
Dopaminergic neuronal population
In contrast, human midbrain dopaminergic neurons are much better annotated, and in par-
ticular there exist published in vivo datasets we can compare to. Specifically, to confirm
the dopaminergic identity of our DA cell population, I compared our cells to three datasets:
human iPSC-derived dopaminergic neurons and human fetal cells from La Manno et al.
[514] and substantia nigra samples from post-mortem donors from Welch et al. [416].
To perform the mapping, I performed joint PCA (using the multiBatchPCA from the batchelor
package, implemented in R) and batch correction (using MNN [412]) of log-normalised
counts (using scater [438]) from our data and each of the three reference datasets. The set of
genes used was the union of 2,000 highly variable genes (HVGs, using the trendVar function
from scran) from our data and 2,000 HVGs from the reference dataset. Next, I asked which
reference cell each of our cells was most similar to (i.e. ‘mapped to’, using queryKNN as
implemented in BiocNeighbors, with k=1 nearest neighbour).
I mapped our DA cells to the set of all neurons from each of three datasets. First, I compared
to the La Manno et al. iPSC data, and found that 99% of our DA cells mapped to the ‘iDAb’
population. Second, to the La Manno et al. embryonic data. 85% of our DA cells mapped to
one of the dopaminergic populations in the reference, i.e. 39% to ‘hDA1’, 36% to ‘hDA2’,
and 10% to ‘hDA0’. Finally, we mapped our DA cells to the Welch et al post-mortem data,
and found that for 91% cells mapped to ‘NEUROdop’, with the remaining 8% mapping
to a population of inhibitory neurons, ‘NEUROinh1’. These combined analyses provide
confidence in the identity of DA neurons from our iPSC differentiation model.
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5.2.5 Data overview
For visualisation purposes, we also performed a combined analysis of a random subsample
of 20% of all cells (after QC) from the three time points. In this case, the Harmony batch
correction was performed across pools (rather than across individual 10X samples, as before).
A joint UMAP projection of cells collected across all time points, stimuli and lines revealed
broad co-clustering of cell types (using the labels described previously, see Fig 5.2), but with
noticeable differences between time points and stimuli (Fig. 5.3).
Substantial variation in the cell type proportions could be observed, across time points and
stimuli (Fig. 5.3). For example, the proportion of DA cells was significantly reduced upon
rotenone stimulation (30% reduction, Fisher’s exact test, p value = 2.2×10−16), which was
consistent with previous observations that dopaminergic neurons are most affected by apopto-
sis due to oxidative stress [524–526]. Collectively, our population-scale scRNA-seq analysis
revealed a diverse repertoire of cell types, enabling both the study of cell line differentiation
propensity (sections 5.3, 5.4) and the identification of genetic variants that affect expression
in a cell type-specific manner (sections 5.5, 5.6).
Fig. 5.3: Overview of study.
Top: UMAP plots of a subset of 205,416 cells assayed (20% of the total), coloured by cell type
identity. Cells that were not collected at a given (time point, stimulus) condition are shown in light
grey. ROT: rotenone; Prolif: Proliferating. Bottom: Bar plots showing, for each condition, the fraction
of cells assigned to each cell type.
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5.3 Line-to-line variation in neural differentiation efficiency
The great diversity of cell types generated by this protocol raised the question of whether it
may be driven by variation in differentiation outcome between different iPSC lines, which,
as we have seen, is prevalent in iPSC differentiation studies (see section 4.7 as well as other
studies, e.g. [527, 506]). Yet, as we discussed, the biological basis for this high variability in
differentiation outcomes between lines remains largely obscure, which complicates efforts
to rationally select cell lines for different applications. Here, we found substantial variation
in the proportions of different cell types produced by different iPSC cell lines at each time
point. For example, the proportion of day 52 untreated cells assigned to DA neurons ranged
from 1% to 100% from line to line. (Fig. 5.4).
Fig. 5.4: Cell type fractions across lines. Box plots showing, for each cell type, the proportions
of that cell type across cell lines at day 11, day 30, untreated day 52, rotenone (ROT) treated day
52. Each point indicates a different cell line. Astro: Astrocyte-like, DA: Dopaminergic neurons,
Epen1,Epen2: Ependymal-like, FPP: Floor Plate Progenitors, NB: Neuroblasts, P_FPP: Proliferating
FPP, Sert: Serotonergic-like neurons, P_Sert: Proliferating Sert, U_Neur: Unknown Neurons.
Looking at the cell type fractions per cell line and pool across time points, we observed a
bimodality in the data, with roughly 2/3 of the iPSC lines mostly making DA and Sert at day
30 and day 52, and the other 1/3 making very few midbrain neurons but many glial cells
(Ependymal-like and Astrocyte-like) instead (Fig. 5.5). When we performed PCA of such
cell type fractions matrix, we identified the proportion of midbrain neurons (DA and Sert)
on day 52 as the largest axis of variation (PC1, 47% variance, Fig. 5.5). Since DA and Sert
cells are derived from similar progenitor populations in vivo, it is not surprising that both
populations are observed in our differentiation experiment [528, 529]. This motivated us to
estimate a ‘neuronal differentiation efficiency’ for each iPSC line, defined as the sum of the
fractions of DA and Sert cells produced on day 52 (Fig. 5.5).
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Fig. 5.5: Distribution of cell proportions at day 52 and definition of neuronal differentiation
efficiency. Cell proportions were generated for each cell type and time point for all combinations of
cell lines and pools with at least 10 cells at all time points (10 pools). (a) Heatmap of the resulting
cell proportion matrix. Pools are shown in the first bar and the colours indicate in which of the
10 pools each line was differentiated. Rows (i.e. cell line, pool combinations) were hierarchically
clustered according to Euclidean distance. (b) Comparison of the first principal component (PC1) to
the sum of fractions of dopaminergic and serotonergic-like neurons present on day 52. (c) UMAP of
cells included in (a), coloured by PC1. Astro: Astrocyte-like, DA: Dopaminergic neurons, Epen1:
Ependymal-like, FPP: Floor Plate Progenitors, NB: Neuroblasts, P_FPP: Proliferating FPP, Sert:
Serotonergic-like neurons, U_Neur: Unknown Neurons.
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We assessed the reproducibility of this measure of neuronal differentiation efficiency using
data from 32 lines that were differentiated twice, in two different pools. Importantly, we
found that iPSC line neuronal differentiation efficiency defined in this way was highly
reproducible between different pools (Pearson’s R = 0.75; p value = 2×10−6, Fig. 5.6).
Fig. 5.6: Reproducible variation in differentiation trajectories.
(left) Hierarchical clustering of (cell line, pool) combinations (same as Fig. 5.5) by neuronal differenti-
ation efficiency. Colours in the first bar indicate in which of 10 pools (for which we had data at all time
points, used to define neuronal differentiation efficiency) each line was differentiated. Differentiation
replicates for lines present in two pools, are indicated in the second bar (red for replicate 1 blue for
replicate 2). (middle) UMAPs, highlighting the distributions of cells on day 52 for two selected cell
lines with low and high differentiation efficiencies respectively (HPSI0514i-fiaj_1, in seagreen and
HPSI1213i-hehd_1, in dark blue). (right) Scatter plot showing estimated neuronal differentiation
efficiency between differentiation replicates (i.e. cell lines differentiated in two different pools, out of
the 10 pools considered here, n=21). Highlighted are the same two cell lines.
5.3.1 Organoids
Given the robustness of our measure of neuronal differentiation efficiency, we next wondered
if it was generalisable to other differentiation approaches. We therefore differentiated a
pool of 18 lines (pool 4) into cerebral organoids for 113 days (as previously described in
Lancaster et al. [530]) and profiled the resulting cell populations using scRNA-seq (11,445
cells). The same steps of dimensionality reduction, batch correction and clustering applied to
the midbrain dataset were applied to the cerebral organoid data. These steps identified eight
clusters that were labelled as different cell types (i.e. neuronal cells, intermediate progenitor
cells, radial glial progenitor cells, satellite cells, mesenchymal cells, myotube and Wnt and
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PAX7 positive cells) using 24 marker genes (Fig. 5.7). We found that the proportion of brain
cell types (all neuronal, glial, and neural progenitor cells) produced by each line in the cerebral
organoids was strongly correlated with neuronal differentiation efficiency as estimated from
the dopaminergic differentiation (R = 0.94; p value = 2× 10−5; n=12). Taken together,
these results strongly suggest that variation in iPSC neuronal differentiation efficiencies arise
primarily due to cell-intrinsic factors. Furthermore, the consistency of neuronal differentiation
efficiency suggests that these properties extend to neuronal differentiation more generally.
Fig. 5.7: Differentiation efficiency in cerebral organoids.
(a) Experimental workflow for single cell profiling of iPSC-derived cerebral organoids using one
pool containing 18 cell lines, profiled using scRNA-seq after 113 days of differentiation. UMAPs
for both our dopaminergic neuron study and the cerebral organoid study (1: floor plate progenitors
(FPP), 2: proliferating FPP, 3: neuroblasts, 4: dopaminergic neurons (DA), 5: serotonergic-like
neurons (Sert), 6: proliferating Sert, 7: astrocyte-like, 8: ependymal-like (Epen) 1, 9: Epen2, 10:
unknown neurons (UN) 1, 11: UN2, 12: UN3. a: neurons, b: intermediate progenitors, c: radial glial
progenitors, d: satellite cells, e: mesenchymal cells, f: myotube, g: paired box (PAX)7+ cells, h:
Wnt+ cells.) (b) UMAPs of two representative cell lines making non-brain and brain cell types in
the organoid study. (c) Scatter plot of neuronal differentiation efficiency as measured using midbrain
dopaminergic neuronal differentiation (x axis) versus neural differentiation efficiency as measured in
organoid differentiation (y axis) for a subset of 12 iPS cell lines in common. Highlighted are the same
two cell lines as in (b).
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5.4 iPSC expression can predict neuronal differentiation efficiency
Motivated by the reproducibility of differentiation outcomes across multiple independent
pools, we set out to explore possible predictors (similar to the analysis described in section
4.7). The idea was that, if we could find characteristics that could be measured in iPSCs and
that would predict a bad differentiation outcome, they could become a useful tool to select
the most suitable lines prior to differentiation.
We began by testing for associations between neuronal differentiation efficiency and other
experimental and biological factors. Those included cell line passage number (p value = 0.77),
donor sex (p value = 0.008), chromosome X activation status (p value = 0.01), and PluriTest
scores [280] (p value = 0.01). Although some of these were nominally significant, they
explained little variation as compared to line-specific effects, when we performed variance
component analysis, by modelling:
neuronal differentiation efficiency = Donor/Line+Pool+Sex+Age+ψ , (5.1)
where Line (which cannot be distinguished from Donor), Pool, Sex and Age are all modeled
as random effects (n=230 line-pool combinations). To assess specifically the effect of X
chromosome inactivation status, we fitted an alternative model which was limited to the
female donors (n=115 line-pool combinations):
neuronal differentiation efficiency = Donor/Line+Pool+XCI+Age+ψ . (5.2)
Fig. 5.8: Variance component analysis of neuronal differentiation efficiency.
Results from variance component models in eq. (5.1) and (5.2), respectively. The variance explained
by each component was re-scaled to sum up to 100. XCI is categorised into 0.1-wide bins: [0-
0.1]..[0.4-0.5].
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We note that there is some effect of the technical batch iPSC lines were differentiated in,
as it has been observed before [294, 301], yet line-specific effects are prevalent (Fig. 5.8).
This is confirmed when we consider data from 6 lines (from pools 1, 2 and 3) that were
differentiated individually, as well as in pools. When we compared our measure of neuronal
differentiation efficiency for each of the lines when differentiated alone or in a pool, we
found rather concordant results (R = 0.83, p value = 0.034, n = 6).
Next, we assessed whether neuronal differentiation efficiency was associated with particular
patterns of gene expression in undifferentiated iPSCs. Using data from independent bulk
RNA-seq data available for a subset of 184 iPSC lines included in this study [294, 129] we
identified significant associations with neuronal differentiation efficiency for 2,045 genes
(983 positive and 1,062 negative associations; F-test, FDR < 5%, Fig. 5.9).
Fig. 5.9: An iPSC expression signature is associated with neuronal differentiation efficiency.
(middle) Histogram of Pearson correlation coefficients between iPSC gene expression of individual
genes (measured using bulk RNA-seq [129]) and neuronal differentiation efficiency. Two exemplar
genes (UTF1, TAC3) are highlighted (left and right, respectively). UTF1 is an example of a gene
whose expression level in iPSC (based on bulk RNA-seq) is negatively correlated with neuronal
differentiation efficiency (R = -0.5, p value = 3.5×10−13 ), whereas TAC3 is positively correlated (R
= 0.38, p value = 9.8×10−8).
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5.4.1 A predictor of (poor) differentiation using iPSC gene expression
The examples shown in Fig. 5.9 suggest that differentiation potential and especially poor
differentiation (< 0.2) may be associated with clear expression signatures. Motivated by this
observation, we used the genome-wide gene expression signature in undifferentiated iPSCs to
build a model to predict poor differentiation outcomes, where we defined poor differentiation
as a binary outcome (neuronal differentiation efficiency < 0.2). We used a logistic regression
and obtained 100% precision at 35% recall as assessed by cross-validation. This result was
robust to alternative thresholds for defining poor differentiation outcomes (Fig. 5.10).
Fig. 5.10: Predicting differentiation failure from iPSC gene expression.
(a) Histogram of neuronal differentiation efficiencies across cell lines. The threshold chosen to
define differentiation success or failure (i.e. neuronal differentiation efficiency = 0.2) is shown by the
dashed line, separating the two modes of the distribution. (b) Precision-recall curves for a logistic
regression model predicting differentiation failure from iPSC gene expression data [129] using a
range of thresholds between 0.1 and 0.35 to define differentiation failure. Results are presented from
leave-one-out cross validation.
We then used this model to generate predicted scores for all 812 HipSci lines for which
bulk RNA-seq data was available. This analysis indicated that a substantial fraction of lines
in the HipSci resource (26%) were predicted to produce < 20% neuronal cells under the
differentiation conditions we tested. Furthermore, we tested whether the same experimental
and biological factors previously associated with neuronal differentiation efficiency replicated
in this larger sample and found consistent results. Finally, we did not observe strong
concordance between the predicted differentiation outcomes of different cell lines from the
same donor, suggesting that donor genetic background is unlikely to play an important role
in driving differentiation biases (Fig. B.12).
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5.4.2 A subpopulation of iPSCs is associated with poor differentiation
Next, we hypothesised that the predictive gene expression signature identified in bulk RNA-
seq at iPSC state may reflect variation in the proportion of subpopulations in iPSCs. To
test this hypothesis, we re-analysed scRNA-seq data from 112 iPSC lines that were assayed
previously under iPSC culture conditions similar to those used here [447], 45 of which
were also included in this study2. After processing the data using the same pipeline as used
above (i.e. Harmony batch correction, Louvain clustering), we identified 5 clusters, which
expressed similarly high levels of core pluripotency markers (NANOG, SOX2, POU5F1, Fig.
5.11, B.13).
We found that genes whose expression predicted poor differentiation (e.g. UTF1) were highly
enriched in one of those clusters (cluster 2), while genes whose expression were predictive
of successful differentiation (e.g. TAC3), were downregulated in cluster 2 relative to the
remaining iPSC clusters (Fig. 5.11). As a validation of this hypothesis, we also tested for
and confirmed a significant association between the fraction of cells in cluster 2 and neuronal
differentiation efficiency for each cell line (Pearson R = -0.76, p value = 2.05×10−9, Fig.
5.11). We used additional data from [447] to assess the consistency of the portion of cluster
2 cells across replication experiments, finding good concordance (Pearson R = 0.9; n=23,
Fig. 5.11). Using the known relationship between iPSC bulk RNA-seq and the proportion of
cluster 2 cells, we predicted this proportion for 182 cell lines included in our differentiation
experiments, and confirmed the negative correlation with neuronal differentiation efficiency
(Pearson R = -0.49; p value = 3×10−12, Fig. B.13).
Finally, we also analysed an additional scRNA-seq dataset from iPSCs derived from Lym-
phoblastoid Cell Lines (LCLs) [444]. Using our single cell analysis pipeline, we identified
a cluster of cells with a concordant (R2=0.4) expression profile to cluster 2 (Fig. B.14).
Combined, these results provide further evidence that an iPSC sub-population with poor
differentiation capability can be consistently detected across iPSCs from different banks, and
that this bias can be predicted robustly using gene expression at iPSC stage.
Importantly, despite the variability in neuronal differentiation efficiencies, we still retained
significant numbers of cells across many cell lines and disease-relevant cell types and stimuli,
which enabled us to explore the impact of common genetic variants on gene expression,
across such cell populations (next section, section 5.5).
2This is the day 0 population from the data presented in Chapter 4, and the same iPSC single cell population
used in Chapter 3.
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Fig. 5.11: A subpopulation of iPSCs is associated with poor differentiation.
(a) UMAPs of single-cell RNA-seq profiles in iPSCs from 112 donors from [447]. Colours denote the
expression level of the two example genes from Fig. 5.9: UTF1 and TAC3. Cluster 2 is shown by
the dashed lines. (b) Comparison of marker gene association results with expression markers of the
cluster 2. For each gene, the Pearson correlation coefficient of association between the gene’s iPSC
expression and neuronal differentiation efficiency (x axis; iPSC gene expression assessed using bulk
RNA-seq, as in Fig. 5.9) is compared to its log fold change between cluster 2 and all other clusters (y
axis, scRNA-seq). UTF1, and TAC3 are highlighted. (c) Scatter plot between the proportion of cells
assigned to cluster 2 (y axis) and neuronal differentiation efficiency (x axis) across 45 cell lines which
were included in both sets of experiments. Where measurements across multiple pools were available
for a cell line, these were averaged.
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5.5 Mapping eQTL in neuronal cell types
Next, in order to understand how individual-to-individual genetic variation influenced gene
expression in this system, we mapped eQTL across our identified cell types during differ-
entiation, and in response to stimulation. Specifically, we mapped cis eQTL in each of
the well represented3 ‘cell type’-‘condition’ contexts defined above i.e. the 14 distinct cell
populations shown in Table 5.1.
FPP P_FPP DA Sert Epen1 Astro
Day 11
Day 30
Day 52 - untreated
Day 52 - ROT treated
Table 5.1: Overview of the 14 cell populations we mapped eQTL for (rows: conditions, columns:
cell types). FPP: floor plate progenitors; P_FPP: proliferating FPP; DA: dopaminergic neurons; Sert:
serotonergic-like neurons; Epen1: ependymal-like cell population 1; Astro: astrocyte-like.
Cis eQTL were mapped by calculating average expression levels for each donor4, considering
common gene-proximal variants (MAF > 0.05, +/- 250 kb around genes). For each context
(cell type, condition), all genes detected in at least 1% of the cells of that context were tested,
and expression quantification was only included for a donor if it represented the mean of
at least 10 cells. The observed variability in neuronal differentiation efficiency between
lines5 (Fig. 5.5) resulted in substantial differences in the number of cells collected for each
donor, affecting accuracy of the estimates of aggregated expression. To account for this
source of noise, we adapted commonly used eQTL mapping strategies [447] based on LMMs





αiPCi +gβ + ũ+ψ , (5.3)
where ũ ∼N (0,diag( 1ni )), where ni is the number of cells for each individual i. Note that
since our LMM implementation only allows one random effect component to be considered
(see page 64), in this model we are not accounting for population structure. Consequently,
we have to rely on samples being unrelated (Fig. B.15), and cannot consider multiple
3top 4 cell types per condition with at least 20% cells.
4Similar to the d-mean aggregation method described in Chapter 3, section 3.8.
5i.e. as we have seen, some lines made mostly neuronal cell types and barely any non-neuronal, thus
expression estimates for those lines in non-neuronal cell types will be less accurate because they are estimated
using very few cells, and vice versa for lines that mostly made non-neurons, and very few neurons.
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observations for the same lines (e.g. across pools). Therefore, expression was aggregated at
the cell line/donor level, averaged across pools for the lines assessed in more than one pool.
Using this approach, we found a total of 4,828 genes with at least one eQTL in any of the
contexts (hereafter ‘eGenes’, FDR < 5%, Storey procedure, Table 5.2).
FPP P_FPP DA Sert Epen1 Astro
Day 11 2,560 2,457 - - - -
Day 30 881 - 872 776 1,011 -
Day 52 - untreated - - 1,024 1,436 1,391 257
Day 52 - ROT treated - - 458 1,043 1,122 205
Table 5.2: Number of eGenes at FDR < 5% for each assessed eQTL map. FPP: floor plate progenitors;
P_FPP: proliferating FPP; DA: dopaminergic neurons; Sert: serotonergic-like neurons; Epen1:
ependymal-like cell population 1; Astro: astrocyte-like.
This approach greatly increased the number of detected eQTL, as compared to the base-model





αiPCi +gβ +ψ , (5.4)
confirming the importance of taking into account the large effect that the number of cells for
each individual has on the uncertainty of the mean expression estimation (Fig. 5.12).
Fig. 5.12: Increase in
number of discovered
eQTL. Number of eGenes
for each cell type, time point
and stimulation discovered
using either a traditional
linear model (coral, from
eq. (5.4)) or our enhanced
model accounting for noise
due to variation in the
number of cells collected
for each donor (seagreen,






cell population 1; Astro:
astrocyte-like.
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The main insight from this specific analysis is that variation in cell count across donors for a
given cell type/condition (Fig. 5.4,5.5) is a substantial source of variation in single-cell based
designs. Accounting for this effect in the noise model substantially improves the ability to
detect eQTL (Fig. 5.12). This is especially pronounced in this dataset, and motivated us
to prioritise accounting for this source of variability over considering data across multiple
batches (i.e. dr-mean, which had emerged as the best approach in Chapter 3, section 3.8).
5.5.1 Comparison with alternative eQTL methods
In order to more generally compare alternative approaches to map eQTL, for one selected
cell population (untreated dopaminergic neurons at day 52), we compared our results (which
yelded 1,024 eGenes, Table 5.2) to those obtained from alternative eQTL methods. Specifi-
cally, these methods differ in the approach taken to account for variability in cell count (or
not), and in how we deal with replicate lines in the analysis. In particular, by aggregating at
the donor level, we may not be accounting properly for batch differences. As an alternative,
we could aggregate at the line and experiment level (similar to the dr-mean approach de-
scribed in Chapter 3, which is also adopted in the eQTL analysis from Chapter 4), and use
a standard kinship matrix-approach to account for the repeatedness (rather than the number





αiPCi +gβ +u+ψ , (5.5)
where u ∼N (0,σ2g K); In this model, we do not account for the variability in cell count; this
resulted in 471 eGenes at FDR < 5%. Another possibility would be to include the batch (and





αipooli + γ sex+gβ +u+ψ , (5.6)
where u ∼N (0,σ2g K). This resulted in markedly fewer eGenes - 320. Finally, in order to
account for batch effects whilst still including the number-of-cell noise term, it is possible to





αipooli + γ sex+gβ + ũ+ψ , (5.7)
where ũ ∼N (0,diag( 1ni )), and ni is the number of cells for each individual i, as above. This
approach, too, resulted in fewer eGenes (608) compared to our chosen approach.
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Fig. 5.13: eQTL methods comparison.
Scatter plots of eQTL effect sizes (left) and p values (right) obtained when testing association of
untreated day 52 dopaminergic neuron eQTL discovered using our approach (from eq. (5.3), x axis)
and each of the three alternative methods described in equations (5.5), (5.6) and (5.7), respectively (y
axis). Pearson’s correlations (R) are indicated.
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Compared to these alternative methods, our approach resulted in the most discoveries (with
1,024 eGenes, see Table 5.2), yet the results were highly consistent between methods (Fig.
5.13), excluding the possibility that our model may be generating mostly false positives. This
demonstrates that our results are robust to these specific choices, with the strategy we chose
yielding more total eQTL discoveries. As an additional quality control metric, frequently
used by other studies (e.g. [127]), we assess and confirm an enrichment of eQTL variants at
gene promoters (Fig. 5.14).
Fig. 5.14: Distribution of eQTL genomic locations.
Genomic location of eQTL lead variants relative to normalised gene coordinates, considering 1,024
eQTL identified in day 52 untreated dopaminergic neurons (using eq. (5.3)).
Moreover, the incorporation of PCs is an efficient approach for capturing global trends and
hence can often replace the use of a potentially large number of technical covariates (e.g. we
have 16 pools in our data alone). Additionally, accounting for pool is not straightforward in
our study, as some lines (n=35) were included in two pools. Finally, we have also tested the
extent to which the 15 PCs we have included in our model capture the key known covariates,
which we do not model directly. When fitting a linear model to explain different covariates
as a function of the 15 PCs:
cov = PC1 + ..+PC15 + ε , (5.8)
We observed that the 15 PCs explained 57% of the variance across pools (where only one
pool replicate was considered for lines differentiated in multiple pools), 67% of the variance
of the donor sex covariate (male=0, female=1), 78% of the X chromosome status, and 9% of
average age.
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5.5.2 Comparison of eQTL across cell types and conditions
Next, we set out to compare eQTL maps across cell types and conditions. First, we observed
that the largest number of eQTL were detected in progenitor cell populations, likely reflecting
increased detection power due to the larger number of well-represented donors (> 100 cells
per donor). Next, we noted that the cumulative number of eGenes (genes with an eQTL)
in each cell type increased considerably when taking into account cells further progressed
along the differentiation axis, as well as upon stimulation (Fig. 5.15).
Fig. 5.15: Mapping cis eQTL in distinct cell contexts across midbrain differentiation.
Cumulative number of eGenes for each cell type and condition (D11 = day 11; D30 = day 30; D52 =
day 52 (untreated); ROT = rotenone-treated day 52).
For example, in DA cells, eQTL mapping in matured (untreated) cells (day 52) identified
an additional set of 441 eGenes (at FDR < 5%) compared to day 30 cells. An example
of a timepoint-specific eGene is HSPB1, for which SNP rs6465098 is an eQTL in day 52
cells, but not day 30 (Fig. 5.16). HSPB1 encodes a heat shock protein that plays a key
role in neuronal differentiation [531] and for which changes in gene expression have been
observed in neurons after ischemia [532] and associated with toxic protein accumulation in
Alzheimer’s disease [533, 534].
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Similarly, we detected 248 additional eGenes with a rotenone-specific effect in DA and Sert
neurons. As an example, the SNP variant rs12597281 is an eQTL for ACSF3 in rotenone-
stimulated serotonergic-like neurons at day 52, but not in unstimulated cells (Fig. 5.16).
ACSF3 encodes an acyl-CoA synthetase localised in the mitochondria and for which in-
herited mutations have been associated with a metabolic disorder, combined malonic and
methylmalonic aciduria (CMAMMA), where patients exhibits a wide range of neurological
symptoms including memory problems, psychiatric problems and/or cognitive decline [535].
These examples highlight how changes in the expression of genes known to be associated
with human disease can be transient and specific to a cell type and state. More importantly,
this data shows how our experimental design brings an extra level of resolution to understand
disease mechanisms that were previously inaccessible from primary tissues, and opens up
new experimental avenues.
Fig. 5.16: Context-specific eQTL examples.
Left: day 52-specific eQTL for HSPB1 in DA (rs6465098; FDR < 5%). In figure are Manhattan
plots for DA cells at day 30 (top) and day 52 (bottom). Right: a rotenone stimulus-specific eQTL
for ACSF3 in serotonergic-like neuronal cells (rs12597281, right). Manhattan plots are shown for
rotenone-stimulated (top) and unstimulated (bottom) Sert day 52 cells.
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5.5.3 Comparison of eQTL from our study with in vivo maps
In order to put our eGene discovery in relation to previous studies, we compared the number
of eGenes identified here with bulk eQTL maps from in vivo tissues from the GTEx consor-
tium [150]. For a first coarse-grain comparison between bulk and single-cell eQTL maps, we
aggregated6 eQTL across cell types and found that the number of discovered eGenes was
similar to that expected in a primary tissue of the same sample size (Fig. 5.17).
However, when focusing on individual cell populations, we observed fewer ‘cell type’-
‘condition’ eGenes than detected in GTEx tissues of similar sample size (Fig. 5.17), likely
due to the uneven representation of donors across cells, which in turn results in noisier
expression estimates compared to the GTEx results using bulk measurements. This result is
consistent with what we observed in work presented in Chapter 3, where we found increased
number of discoveries when mapping eQTL using bulk compared to single cell RNA-seq,
even when considering the same cell type and matched individuals.
Fig. 5.17: Sample size vs number of discoveries.
Comparison of the number of genes with at least one eQTL (number of eGenes; FDR < 5%; y
axis) as a function of effective sample size (number of unique donors; x axis) across studies and
cell types. Left: results from overlapping eQTL results in this study with in vivo eQTL maps from
GTEx, divided into brain tissues and non-brain tissues. The result from our study when aggregating
across cell types and conditions is coloured in red. The right panel shows a magnified view of results
from our study coloured by cell type and shaped by condition. Astro: Astrocyte-like, DA: Midbrain
dopaminergic neurons, Epen1: Ependymal-like, FPP: Floor Plate Progenitors, P_FPP: Proliferating
FPP, Sert: Serotonergic-like neurons. ROT: rotenone-treated.
6Considered the union of eQTL identified in any of our 14 cell populations.
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A key question of eQTL maps from in vitro iPSC-based models is how closely these re-
semble eQTL maps from the equivalent primary tissues, which typically differ in cell type
composition. To explore this, we tested the extent to which regulatory variants were shared
between our eQTL maps and 48 in vivo maps from the GTEx consortium, as measured by
genome-wide consistency of eQTL effect sizes (using MASHR [536]). First, reassuringly,
we observed that the sharing of genetic signal7 between our eQTL maps and GTEx tissues is
considerably higher when we consider brain tissues compared to all other tissues (using the
subset of 6,205 genes that were assessed in each of our cell types and in all GTEx tissues;
Fig. 5.18, panel a).
Next, we performed a second MASHR analysis, this time including only the 13 GTEx brain
tissues (as well as our 14 maps, and one iPSC map from [129]). The main motivation to do so
is that in order to quantify the amount of sharing between eQTL results obtained from several
tissues or conditions, MASHR only considers gene-SNP pairs that have been assessed in every
one of the conditions considered, which naturally will depend on the number of genes ex-
pressed in the various conditions and that can be quantified by the different technologies used.
As a consequence, the number of genes considered decreases as the number of conditions
included increases, which in turn results in the inflation of the amount of sharing. Here,
in particular, excluding non-brain eQTL maps from GTEx rescued several brain-specific
genes, and allowed us to assess sharing for 8,706 genes (∼2,500 more). This second analysis
enabled us to assess the similarity of our maps to the brain tissues in particular. We found
that the extent of eQTL sharing between our eQTL maps and GTEx brain tissues increased
as iPSCs were differentiated to increasingly mature neuronal cell types (Fig. 5.18, panel b).
This result provides confidence that eQTL discovered in iPSC-derived neuronal cell types
mimic eQTL maps from in vivo tissues. Consistent with the trend of increased sharing of
eQTL signal, we also observed that the fraction of eQTL that are not represented in GTEx
brain tissues decreases as the cells become increasingly mature. In particular, we identified
2,366 eQTL that could not be detected in GTEx brain tissues (q value > 0.05 in any of the 13
tissues), demonstrating the utility of iPSC and scRNA-seq analysis to assess previously un-
explored cell populations and therein discover regulatory changes in disease associated genes.
7Following recommendations by the MASHR authors [537], for each pair of conditions, we considered
eQTL that were significant (local false sign rate < 0.05) in at least one of the two conditions, and then assessed
sharing as the fraction of those for which posterior estimates of effect size were of similar magnitude (0.5 <
ratio < 2) and of concordant direction of effect.
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Fig. 5.18: Brain sharing is higher than non-brain sharing, and it increases over time.
(a) Box plots indicating the amount of sharing as quantified by MASHR [536] of our 14 eQTL maps
considered together, with each of the GTEx brain tissues (yellow, n=13) and with each of other (non-
brain) GTEx tissues (black, n=35). (b) Sharing of eQTL signals discovered in iPSCs and in our study
(for each of our 14 cell types and conditions), with in vivo brain eQTL maps (from GTEx). Violin
plots show the extent of eQTL sharing with each of 13 GTEx brain eQTL maps. Astro: Astrocyte-like,
DA: Midbrain dopaminergic neurons, Epen1: Ependymal-like, FPP: Floor Plate Progenitors, iPSC:
induced pluripotent stem cells, P_FPP: Proliferating FPP, Sert: Serotonergic-like neurons.
Finally, we note that quantifying the amount of sharing of eQTL signal is a notoriously
difficult problem. As mentioned, MASHR considers only genes assessed in all conditions
analysed. As a result, the degree of sharing may be inflated, because only relatively few
highly expressed genes are included in the analysis, and those are more likely to be common
eQTL. In particular using scRNA-seq we can assay fewer genes (as compared to bulk), thus
the number of genes that we can assess in our single cell maps becomes the limiting factor
in terms of genes included in the analysis (i.e. 8,706/8,738 genes assessed in all of our
maps are also assessed in all GTEx brain maps). On the other hand, as a complementary
strategy to quantify eQTL sharing, we have also considered conventional definitions of eQTL
replication, based on nominal significance of lead eQTL variants discovered in each of the
13 GTEx brain tissue eQTL maps, in each of our 14 eQTL maps (Fig. 5.19). Notably, this
comparison allows for teasing apart lack of replication versus lack of assessment of an eGene
because of difference in expression. We found that of the eGenes identified at FDR<5% in
each of the GTEx maps, approximately 50% were tested in our different maps (Fig. 5.19,
panel a). For the shared fraction of genes assessed, 20-40% eQTL were nominally significant
(p value < 0.05) across our 14 maps. Cumulatively, this means that 10-20% of the eQTL
from a GTEx brain map could be re-discovered in our single cell maps (Fig. 5.19, panel b).
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Fig. 5.19: Rediscovery of GTEx brain eQTL maps.
(a)Fraction of GTEx brain eGenes that could be assessed in each of the considered contexts (cell
type-conditions). (b) Fraction of GTEx brain eQTL that were replicated in this study (nominal p value
< 0.05; fraction relative to the set of assessed genes from a). Astro: Astrocyte-like, DA: Midbrain
dopaminergic neurons, Epen1: Ependymal-like, FPP: Floor Plate Progenitors, P_FPP: Proliferating
FPP, Sert: Serotonergic-like neurons.
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5.6 Colocalisation of eQTL with disease risk variants
The identified cell-type specific eQTL maps across different differentiation contexts provide
an exciting opportunity to improve our understanding of human disease traits and their
genetic risk factors identified by GWA studies. To systematically test for colocalisation
events (page 21), we applied COLOC [175] to the summary statistics from 25 neurological
traits8, eQTL discovered in our study, as well as eQTL obtained from GTEx (v7) [150].
In total, we identified 1,284 eQTL in our study with evidence of colocalisation (PP4>0.5)
with at least one disease trait, 597 of which were found only in our dataset. This corresponds
to an additional >10% of colocalisation events of GWAS variants compared to eQTL across
all GTEx tissues (5,028 across 48 tissues, Fig. 5.20). Notably, 401 (67%) of the colocalisa-
tions in our data were associated with eQTL detected in later differentiation stages (day 52)
or upon stimulation (day 52 ROT).
Fig. 5.20: Coloc overview.
Figure by Natsuhiko Kumasaka. Overview of colocalisation analysis between our eQTL maps and
25 neuro-related GWAS traits. (left) Venn diagram showing the numbers of colocalisation events
overlapping between our study, GTEx brain and GTEx non brain tissues. (right) Heatmap showing
the posterior probability of colocalisation (PP4 from COLOC [175]) for our eQTL that colocalised
with one or more GWAS traits. N: Neuronal differentiation (this study), B: GTEx Brain tissues, O:
Other GTEx tissues.
8including Parkinson’s disease, Alzheimer’s disease, schizophrenia, bipolar disorder, neuroticism, depres-
sion, and other behaviour and intelligence-related traits, see Table A.4.
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Among the most interesting colocalisation events was an eQTL for SFXN5, a mitochondrial
amino-acid transporter, which was specific to the rotenone-stimulated serotonergic neurons
at day 52, and which colocalised with a Schizophrenia hit (PP4 = 0.78, Fig. 5.21). Exposure
to rotenone is known to induce oxidative stress by inhibiting the mitochondrial respiratory
chain complex I [538, 539]. We therefore speculate that the specific genetic signal observed
for the mitochondrial gene SFXN5 in serotonergic neurons is a possible factor modulating
environmental stress response.
Fig. 5.21: A colocalisation event between a rotenone-specific eQTL and schizophrenia.
Figure by Natsuhiko Kumasaka. Locus zoom plots around the SFXN5 gene. The Schizophrenia GWAS
association (left) is colocalised with the eQTL in rotenone-stimulated serotonergic-like neurons at day
52 (second panel from the left). No colocalisation signal was found in unstimulated serotonergic-like
neurons at day 52 (third panel from the left) or any other brain GTEx tissues as illustrated here with
GTEx Brain Amygdala (rightmost panel). The lead variant is indicated with a purple diamond and
other points were coloured according to the LD index (r2 value) with the lead variant.
Another example that colocalised with a Schizophrenia GWAS variant was an eQTL for
FGFR1, detected both in proliferating and non proliferating floor plate progenitors at day
11 (PP4 = 0.93 and 0.88 respectively, Fig 5.22) . Previous studies have shown that nuclear
FGFR1 plays a key role in regulating neural stem cell proliferation and central nervous
system development, in part, by binding to the promoters of genes that control the transi-
tion from proliferation to cell differentiation [540]. Additionally, it was shown that altered
FGFR1 signaling was linked to the progression of the cortical malformation observed in
schizophrenia [541].
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Fig. 5.22: A schizophrenia colocalisation event with a developmental eQTL.
Figure by Natsuhiko Kumasaka. A midbrain progenitor-specific eQTL for FGFR1 associated with
schizophrenia. We identified a colocalisation event with this eQTL in both proliferating (second panel
from the left) and non-proliferating floor plate progenitors (third panel from the left) at day 11. No
colocalisation was found in any other cell type from our study (not shown) nor in any brain GTEx
tissues (shown with GTEx Brain Hypothalamus, rightmost panel).
These examples suggest that a combination of genetic and environmental factors during
early development might contribute to schizophrenia pathology and illustrate how these data
represent a valuable resource to understand the molecular basis of complex neurological
diseases.
5.7 Discussion
The characterisation of the function of human trait-associated genetic variation requires
large-scale studies, performed in disease-relevant cell types and states. Here, we demonstrate
how human iPSCs can be efficiently profiled at scale throughout a 52 day-long differentiation
to a midbrain neuronal cell fate.
First, we demonstrate high heterogeneity of cell types generated by this protocol (Fig. 5.3),
and uncover a highly reproducible (Fig. 5.6, 5.7), cell line-intrinsic neuronal differentiation
bias (Fig. 5.5). Next, we show how this bias can be robustly predicted using gene expression
profiling at iPSC state (Fig. 5.9). This is an important step towards the optimised design
of future large-scale iPSC experiments, where cell lines can be rationally selected a priori
without the need for laborious testing of differentiation capacity.
Indeed, the ‘quality’ of human iPS cells has been carefully examined by several studies
using both genetic and functional genomic data [280, 542, 543, 479], see also section 1.2.5.
Despite these efforts, variation in differentiation potential between cell lines has been widely
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acknowledged, yet poorly understood. To the best of our knowledge, the work we presented
here is the first effort to systematically survey differentiation biases at the scale of an entire
iPSC bank. To address this question, we leveraged the detailed phenotyping of cell lines in the
HipSci bank. We excluded the cell type of origin hypothesis [544] in this instance since all
HipSci lines were derived from fibroblasts. Moreover, we observed rather weak associations
between neuronal differentiation efficiency and other biological factors, including sex and X
chromosome activation status, which has been described as relevant for other differentiation
lineages (i.e. endoderm lineage, see Chapter 4 and [447]). In this work, we focused on the
cell-line effects, that were especially prevalent (Fig. 5.8), but further investigation into the
effects of sex and X chromosome inactivation (as well donor ethnicity, although that could
not have been assessed in this study) is left for future work.
Our analysis indicates that the reduced production of neurons was best correlated with
increased abundance of a specific subpopulation (cluster 2) of iPS cells that express the
transcription factor UTF1 and other genes at elevated levels (Fig. 5.11). Counter-intuitively,
the proportion of cells in this subpopulation was positively correlated with the proportion of
neuroblast cells on day 11, but lower fractions of dopaminergic and serotonergic-like neurons
at later stages of differentiation. One possible explanation is that cell lines that commit earlier
to a neuronal fate disproportionately lose neurons upon passaging at day 20 (Fig. 5.1, cells
are passaged at day 20 as from original protocol [284]; this would explain the lack of clear
differences between lines at day 11, with instead divergence appearing at the day 30 time
point and then becoming even more evident by day 52).
In alternative, cluster 2 may preferentially differentiate to radial glial cells which are more
prone to switch to an astroglial and ependymal differentiation programme [545]. In support
of this hypothesis, we identified several genes that were upregulated in cluster 2, including
SIX3, MT1F and PITX2, that are thought to play a role in astrocyte and ependymal cell
biogenesis [546–548].
A second implication of our study is that, despite growth competition between cell lines,
pooled experiments retain sufficient cells per donor to carry out genetic analysis, even follow-
ing extended periods in culture. Although cells from different lines were pooled in similar
numbers, we observed extensive variation throughout our differentiation experiments in the
numbers of cells produced by different lines. For example, 50% of the cells we sequenced
were produced by only 12% of lines. As we have demonstrated, this was an important effect
to take into account in our eQTL analysis (Fig. 5.12). Future technical improvements, for
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instance more precise matching of growth rates of cell lines within pools, or line selection
based on predicted differentiation efficiency using markers in the iPSC state may further
increase the utility of multiplexed iPSC differentiation experiments.
Finally, we could map eQTL across several neuronal cell types and in response to oxidative
stress (Fig. 5.15). As we have seen, in order to understand the functional role of trait-
associated variants it is crucial to perform genetic analyses in relevant cell types. Indeed, as
a community, we have largely been unable to identify genetic variants that drive expression
changes in narrowly-defined cell populations. This is due to our reliance on tissue-level data
(e.g. GTEx), our incomplete knowledge of cell populations present in a tissue, or because
rare cell populations do not provide enough substrate for common genomics assays.
Our analysis attempts to be a step towards investigating cell type-specific genetic effect,
which are often masked in tissue-level assays. Indeed, despite a modest sample size, our study
reveals a disproportionately large number of novel colocalisations between neurological traits
and diseases and eQTL (Fig. 5.20) compared with GTEx tissues of equivalent sample size.
For example, the number of novel trait/disease-eQTL colocalisations added by GTEx liver
or cerebellar hemisphere (n=208, 215 respectively) are 80 and 107, respectively, compared
to 597 in this study. A simple explanation for this result is that our experiment profiled
expression states that are hard to capture using post-mortem tissue, including time points
during neuronal differentiation and rotenone exposure.
Additionally, the single-cell resolution of our study enabled the detection of many eQTL that
were specific to individual cell types, or could only be detected upon stimulation (Fig. 5.16).
These signals, while present, are challenging to detect in bulk tissue because the relevant cell
types are often rare. Combined, these results suggest that many ‘missing’, disease-relevant




The genomes of any two unrelated people are 99.9% identical. Yet, the 0.1% that differs
is critical: it explains why individuals look different, and also why some are more predis-
posed than others to certain diseases. Thus, identifying DNA variants that are associated
with complex disorders, and understanding the molecular mechanisms that mediate such
associations, can lead in the future to better disease diagnosis, treatment and prevention.
While GWAS (section 1.1.7) have identified thousands of associations between genetic
variants and traits and diseases, the mechanisms involved have proven hard to disentangle.
Associations between genetic variants and gene expression levels (i.e. eQTL, section 1.1.8)
can help uncover such mechanisms, as gene expression often acts as an intermediate between
DNA sequence and organismal phenotypes. Importantly, since these regulatory effects often
arise in specific tissues or under specific stimuli [300], eQTL mapping studies need to be
conducted in disease-relevant cell types. These are often hard to access, historically limiting
studies to easily accessible tissues such as skin and blood [161, 114], or to cell lines [549].
More recently, the GTEx consortium released eQTL maps across over 50 human post-mortem
tissues [151]. Whilst this represents a great resource, these tissues have been probed using
bulk RNA-seq, making it difficult to isolate specific disease-relevant cell types, especially
since these are often rare. Moreover, very little is known about the genetic regulation of gene
expression at early stages of human development, most of which are impossible to access in
vivo. Human iPSCs have proven to be a versatile in vitro model to study early development
in a neatly controlled setup (section 1.2.5). Human iPSCs can be derived in a donor-specific
manner, and, critically, they can be differentiated towards virtually any cell type of interest.
Recently, large cohorts of human iPSCs across hundreds of individuals have enabled eQTL
analyses in both iPSCs and a number of iPSC-derived cell types [294, 301].
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In this thesis, I have shown that human iPSC technology combined with single cell expression
readouts (which allow the isolation of cell types of interest), and pooling strategies (which
increase throughput by enabling the differentiation of cells from several individuals in the
same experiment), represent an excellent system to study the effect of common genetic
variants on gene expression during cellular differentiation.
In particular, I have analysed two population-scale scRNA-seq datasets of differentiating
human iPSCs along two different lineages, one toward definitive endoderm and the other to
a midbrain neuronal fate. These represent important resources in their own right, as most
current human scRNA-seq datasets only contain samples for a handful of genetically unique
individuals.
Indeed, while the main objective of these studies was to identify eQTL across cell types and
states during differentiation, one interesting side product of this work was the evaluation
of differences in terms of differentiation outcome across several iPSC lines. In particular,
full transcriptome information across hundreds of iPSC lines allowed us to assay these
differences at a much larger scale than any previous study, to the best of my knowledge. In
one case, we identified a set of genes whose expression at pluripotent stage can be used to
predict neuronal differentiation efficiency, and which we could use to predict differentiation
scores for the entire HipSci bank. This represents important progress toward understanding
predictors of differentiation outcome and a useful resource for future studies using these lines.
Nevertheless, the main contributions of this thesis are in the context of eQTL mapping,
specifically when using single cell RNA-seq profiles to measure gene expression. In particu-
lar, we systematically evaluated differences between mapping eQTL using bulk and single
cell RNA-seq for a homogeneous cell population (human iPSCs). Additionally, we provide
preliminary best-practice guidelines for single cell eQTL studies, in terms of normalisation
strategies, aggregation approaches and covariate adjustment.
Furthermore, we mapped eQTL at different stages and cell types along human early devel-
opment toward endoderm (mesendoderm and definitive endoderm) and along the midbrain
neural lineage (floor plate progenitors, dopaminergic and serotonergic neurons, ependymal
cells and astrocytes). To the best of our knowledge, these are the first eQTL maps at these
stages of differentiation and thus represent an important resource for the genetics community.
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Finally, work in this thesis provides insight into the importance of performing genetic analyses
of gene expression in a context-specific manner, both by performing eQTL in discrete cell
types and stimulation states, and by considering continuous axes of variation which modulate
the genetic response.
6.1 Conclusions and discussion
The analyses we conducted have several important implications, in two main areas, which
I discuss in the following sections. First, I use section 6.1.1 to summarise and discuss
our results assessing variability in the differentiation outcome of human iPSC lines and
possible molecular predictors. Second, in section 6.1.2 I discuss technical considerations
and biological implications of mapping eQTL using single cell expression profiles.
6.1.1 Human iPSCs to model development and disease
In work presented in this thesis, we attempted to quantify the differentiation efficiency of
different iPSC lines in two distinct protocols. In the first case, (described in Chapter 4)
the protocol used was very short (three days) and very well understood, describing early
stages of endoderm differentiation. Even so, we observed noticeable differences between
lines in their ability to differentiate towards definitive endoderm. We identified a few tens of
genes whose expression at iPSC stage was predictive of endoderm differentiation efficiency
(section 4.7). These were mostly on chromosome X, confirming previous reports that the
X chromosome reactivation in human iPSC lines may hamper their quality, especially with
regards to their differentiation potential.
In the second study I describe in this thesis (in Chapter 5) the differentiation protocol used
was much longer (52 days), and we differentiated significantly more lines (215). Here, we
observed even more extreme differences across lines in their ability to generate neurons,
with roughly one third of the lines preferentially producing non-neuronal cell types, namely
ependymal- and astrocyte-like cells. Similar to previous reports [301], some batch effects
were observed, but were significantly weaker than cell line effects. On the other hand,
we identified an iPSC gene signature that was predictive of poor neuronal differentiation
efficiency, finding around two thousand genes whose expression at pluripotent stage was sig-
nificantly correlated (either positively or negatively) with a line’s ability to generate neurons.
We further hypothesised that this may be linked to a sub-population of iPSCs that exhibited
differential expression of these genes. We speculate on possible mechanisms (section 5.7),
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but argue that further validation would be needed to state anything conclusively. Lastly, we
observe no correlation between the differentiation efficiencies defined in the two protocols,
suggesting that a line’s differentiation potential toward one lineage is independent, or perhaps
even inversely correlated with that toward another.
Future work is required to gain a better understanding of the mechanisms and causes behind
an iPSC line’s differentiation potential. In particular, we note that since in both studies we
only chose to differentiate one cell line per individual, we could not distinguish between cell
line effects and donor effects. In future efforts, it will be important to include multiple lines
per individual, to be able to effectively separate the two sources of variation. Moreover, all
lines used here are skin-derived, thus the differences observed could not be driven by the
somatic cell type of origin. A future area of study would involve investigating differences
in the differentiation outcome of iPSC lines derived from different cell types, as well as
across donor characteristics including sex, age and ethnicity. As highlighted on page 40,
several human iPSC cohorts derived from different cell types, and for donors of different
ethnicities and varying degrees of relatedness, are already available for research purposes,
and could be used to address some of these aspects. Finally, in work presented here we
did not have the appropriate sample size to detect genetic variants affecting differentiation
efficiency. In the future, as protocols become more efficient and pooling strategies combined
with single cell readouts become common-practice, it will be possible to perform in vitro
differentiation experiments at increasingly large sample sizes. These studies will finally
enable the exploration of the potential role of genetic variation on differentiation outcomes.
As more and more in vitro differentiation studies are conducted, across different lineages and
iPSC cohorts, a systematic comparison of the outcomes can be performed, which will greatly
improve our understanding of the processes involved. Indeed, such comparative studies
will shed light on several unanswered questions. For example, is an iPSC line’s inability to
differentiate toward mature cell types simply an indication of its poor quality? And if so,
is it simply not possible to use these lines for differentiation studies? Or, alternatively, are
some lines more prone toward one cell fate and as a consequence less so to another? And to
what extent is this dependent on the cell type of origin of those iPSCs? Importantly, is poor
differentiation ability a characteristic of the cell line, or of the donor (genetic or otherwise)?
This would have critical consequences, for example on the importance on deriving several
iPSC lines from the same donor to maximise yield of ‘good differentiating lines’. And if not,
will it be harder to derive functional iPSC lines from some individuals compared to others?
These and other questions remain to be investigated.
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6.1.2 Bridging the genotype-phenotype gap
A large gap remains in our understanding of the functional mechanisms that link genotypes
to phenotypes. eQTL studies can be used to fill some of this gap by identifying the putative
regulatory role of common variants on gene expression. Indeed, when performed across
tissues and contexts, eQTL maps can provide insights not only into which genes are regulated,
but also in which cell types and under which conditions they are active.
The profiling of molecular traits, especially gene expression, at single cell resolution has
represented a true revolution in the last ten years (section 3.1.2). In particular, experimental
methods, and computational approaches to examine the resulting data, have become estab-
lished in recent years, leading to the explosion of scRNA-seq data, with > 1,000 datasets
published since 2009. Single cell expression profiling can now be deployed at population-
scale and, combined with pooling strategies, permits the efficient quantification of cell-level
expression across several individuals. Additionally, single cell transcriptomics can be used to
estimate cell states and contexts at increased resolution [327]. For example, rare cell types
and cells in different cell cycle phases can be identified unbiasedly within one experiment.
Lastly, the use of single cell expression profiles allows the ordering of single cells along a
continuous trajectory, without the need to discretise cells into distinct populations. Adding
such cell-level context information to eQTL mapping provides one more layer to our under-
standing of the molecular consequences of common genetic variation, potentially making the
genotype-phenotype gap one bit smaller.
In this thesis, I provide examples of how the single cell resolution of expression profiles can
be leveraged to better understand the molecular machinery of gene regulation. First, single
cell expression profiles can be used to unbiasedly identify pure cell populations, quantify
expression within those, and then test for eQTL in such populations. Second, single cell
profiles can be used to order cells along a differentiation trajectory, and used to identify
dynamic eQTL, i.e. eQTL whose strength varies over time. Third, single cell transcriptomic
data can be used to define other axes of variation, and thus context-specific eQTL can be
identified across a plethora of cell states. From a technical standpoint, linear and linear
mixed models (Chapter 2) are flexible frameworks that allow the user to efficiently test
for associations whilst correcting for confounders and other sources of variation. Finally,
colocalisation analysis between the identified eQTL and relevant GWAS trait connects the
final dots to link the identified regulatory mechanisms to complex traits and diseases.
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Historically, eQTL have been mapped using bulk RNA-seq profiles as a measure of expression
level. The first implication of work described here is the feasibility of large-scale genetics
using single cell RNA-seq data instead. Whilst this has to an extent been demonstrated before
[160, 402], the small sample size of those studies only allowed the identification of tens or
at most a few hundred eQTL. Moreover, these studies failed to recapitulate eQTL results
obtained using bulk RNA-seq from equivalent tissues. Here, on the other hand, we identify
thousands of eQTL across a range of cell types (Tables A.2, 5.2), and could re-discover
a larger portion of bulk-discovered eQTL (Fig. 3.7, 5.19). Moreover, we demonstrated
feasibility of single cell eQTL mapping using both plate-based (SmartSeq2, Chapters 3, 4)
and droplet-based (10X Genomics, Chapter 5) scRNA-seq data.
To systematically compare the performance of using scRNA-seq as opposed to bulk RNA-seq
to map eQTL, in Chapter 3 we selected human iPSCs as a homogeneous cell type, and
compared results when mapping iPSC eQTL using a common set of samples (Fig. 3.7). This
analysis revealed an increased number of discovered eQTL when using bulk RNA-seq pro-
files in this well defined, pure cell population, probably due to decreased noise in expression
estimates. On the other hand, we appreciated the power of the single cell transcriptomics to
isolate several cell types within more heterogeneous populations, quantify expression and
map eQTL within them, without the need for any gating or other experimental techniques to
separate cell populations (Fig. 4.11, 5.16).
In addition, we provide here the first hints towards the establishment of a best-practice
workflow to maximise yield of single cell eQTL studies (section 3.8), identifying the mean
(after single cell-specific normalisation) as the optimal aggregation method, and principal
component analysis as the preferable approach to capture global expression trends which
should be included in the model as covariates. From a methodological perspective, linear
mixed models were confirmed as the appropriate tool to identify genetic associations, given
their ability to deal with confounding effects (section 2.2.4). In particular, LMMs can control
for effects due to population structure, including replicate measurements across donors (for
example across multiple differentiation experiments, Chapters 3 and 4). In addition, LMMs
enabled the introduction of a variance term to account for number of cells across individuals,
which varied widely thus rendering the expression estimates less precise (Chapter 5); this
expedient resulted in a great boost in the number of eQTL discoveries. In future work, models
which enable the incorporation of multiple random effect terms, to effectively correct for
several confounders simultaneously, should be developed.
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The availability of eQTL maps across cell types and stages provided the opportunity to assess
the amount of eQTL signal sharing both within our studies and in comparison with existing
maps. This is a notoriously complicated task, because different eQTL studies may differ in
the technology used to measure expression, in the number of genes expressed and in sample
size, which is in general fairly low. Here, we used two separate approaches to tackle this issue.
On the one hand, we used p value thresholding to identify cell type-specific eQTL (eQTL
that could only be detected in one of the cell populations considered within our study, Fig.
4.12, 5.16), and assess the number of eQTL identified in our study that were not discovered
in eQTL maps of primary tissues (i.e. from GTEx) and viceversa (Fig. 5.19). On the other
hand, we used a recently proposed method (MASHR [536]) to quantify genome-wide sharing
across eQTL maps (Fig. 5.18). These approaches are complementary, representing the two
ends of the spectrum: the first approach may miss signals that only just do not reach the
(arbitrary) significance threshold used, whilst the second may overestimate sharing by only
considering gene-SNP pairs assessed across all conditions included. To partially overcome
these issues, methods exist that consider multiple eQTL datasets jointly [550, 551]. However,
such methods are currently computationally too demanding for large-scale scRNA-seq data.
Next, in Chapter 4, we added the temporal axis, by identifying dynamic eQTL, i.e. eQTL
whose strength is modulated by developmental time. This extends similar work from
[470, 302], to single cell-resolved data. Indeed, in this study cells were collected at very
close time points, which combined with varying differentiation rates across both cells and
lines resulted in a continuous differentiation trajectory. Importantly, we observed that changes
in genetic effects over time did not merely reflect changes in overall expression (Fig. 4.14).
Moreover, we found that dynamic eQTL were enriched for epigenetic marks consistent with
promoter and enhancer regions. We next used the same approach, building on allele-specific
expression (similar to [491] for GxE), to test for eQTL effects that are modulated by alterna-
tive cell states, including cell cycle phase and metabolic state (Fig. 4.16, 4.3). This type of
analysis is similar to previous work to identify ‘interaction eQTL’ [157, 160].
Finally, in Chapter 5, we assessed disease-relevance of our identified associations, by
performing colocalisation analysis between eQTL maps from our neuronal cell populations
and GWAS for neurological traits. Here, we uncover several colocalisation events that
had not been previously identified (Fig. 5.20), highlighting once again the importance of
studying the molecular consequences of genetic variation in relevant cell types, especially
when investigating the genetic basis of disease. Indeed, some of these examples provide
insight into the genetic underpinning of neurological diseases, including schizophrenia.
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Overall, the work in this thesis demonstrates the feasibility of eQTL mapping using single
cell expression profiles and the importance of modelling context-specific eQTL effects across
cellular types and states. The methods used build on the linear mixed model framework
and are extremely flexible, as demonstrated by their application across technologies and
designs. Whilst extremely useful and efficient, these models assume normality of the residual
phenotypes, an assumption that is often violated, as discussed (section 2.3.4). In particular,
scRNA-seq data has has been described to follow a Poisson or a negative binomial [552–554]
distribution. Future work should include the evaluation of the feasibility of integrating
non-Gaussian likelihoods in the models to map eQTL using scRNA-seq data.
Moreover, in this thesis I have focused on the study of context-specific eQTL by either first
discretising cells into populations and mapping eQTL in each, or by considering interactions
with one single continuous cell state (or at most two, Fig. 4.17). In the future, it will be
important to develop methods to jointly test for context-specificity of eQTL across several
(continuous and discrete) cell states simultaneously. For example, a recently proposed
method, Struct-LMM [555] allows the assessment of GxE interactions using larger numbers
of conditions. While originally proposed in the context of population studies, the same
principles could be adopted here, where one could map sc-eQTL that vary jointly across up
to hundreds different cell states and types. These advanced models will enable us to leverage
the rich information from single cell-resolved, transcriptome-wide population-scale datasets,
to further improve our understanding of the genetic architecture of traits.
6.2 Outlook and future directions
6.2.1 More complex and realistic in vitro models
Work presented in this thesis demonstrated how iPSC differentiation combined with mul-
tiplexed experimental designs and single cell RNA-seq profiling unlocks population-level
studies in increasingly complex, dynamic and biologically realistic cellular models. We
anticipate that, in the future, uses of this model system will focus on experimental settings
that are challenging or impossible with primary cells. For example, these may include single
cell resolution sampling along longer differentiation times to more complex differentiation
trajectories, such as cell organoids, or involve large panels of disease relevant-stimuli and
drug exposures. These future efforts will greatly contribute to our understanding of the
common genetic basis of complex disorders, and facilitate the development of iPSC-based
approaches for modelling, and even eventually treating, these diseases.
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6.2.2 More population-scale scRNA-seq datasets
The work presented in this thesis has focused on applications in iPSCs and iPSC-derived
cells, however we note that the same technologies and methodologies can be applied across
a variety of biological systems. For instance, scRNA-seq PBMC data across multiple
conditions from a growing number of individuals (currently approximately 1,600), will be
available as part of the single-cell eQTLGen (sc-eQTLGen) consortium, whose manifesto
was recently published [446]. Similarly, through the UK Biobank [556], one of the largest
and most deeply phenotyped cohorts of individuals in the world, blood samples as well as
key biomarkers for circa 500,000 people are stored and available for the research community.
Performing scRNA-seq on blood cells from these many (and well characterised) samples
will provide an invaluable resource to study the effect of genetic variants across cell types
and contexts. Last but not least, the human cell atlas (HCA) project [557], whose mission
is “to create comprehensive reference maps of all human cells”, will likely in the future
be collecting samples from several donors across all human tissues, to evaluate differences
across genetic backgrounds and disease states. It will be critical, when these data become
available, to have robust and efficient statistical models to make use of this wealth of data.
6.2.3 Alternative single cell technologies
Finally, here we have focused on single cell transcriptomic data, which is the most well-
established of the single cell sequencing technologies. Yet more recently, several alternative
molecular traits have been assayed at single cell resolution, including chromatin accessibility
[558, 559], DNA methylation [560–562], histone modifications [563] and chromatin 3D
organisation [564]. Novel technologies even allow multiple molecular layers to be probed
in parallel from the same individual cells [565–567]. The LMM-based models used here
can readily be adapted to map alternative single cell molecular QTL (e.g. sc-mQTL, sc-
caQTL, etc.), which could provide a much richer understanding of the molecular machinery
associated with genetic regulation. Using multi-omics data, similar models can further
be used to study the interplay between molecular layers (e.g. effects of methylation or
accessibility on expression). Finally, standard eQTL assess the effect of naturally occurring
genetic variation on gene expression. However, recent pioneering studies have used the
induction of CRISPR/Cas9 perturbations, followed by scRNA-seq to identify the effect of
such induced variation on gene expression [568]. Models describe here can naturally be
extended for the identification of cell type- and context-specific ‘crisprQTL’ as well.
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6.3 Genetic mapping at single cell resolution
The use of single cell omics, particularly gene expression, has revolutionised our under-
standing of cellular variability in several biological systems. These technologies can now
be deployed across hundreds of individuals, enabling the study of the effects of common
genetic variants on gene expression level (i.e. by mapping eQTL), which was once only
assessed using bulk RNA-seq. In particular, the single-cell resolution can help to uncover
eQTL that are only active in rare cell populations, or that change dynamically along cellular
states. Taken together, the work in this thesis demonstrates the utility of mapping eQTL
using single cell expression data, to reveal the function of genetic variation across cellular
types and states. The models described here, combined with the increasing availability of
population-scale single cell expression studies, and in the future extended to include multiple
molecular layers, have the potential to greatly advance our understanding of the complex
machinery that links genotype to phenotype.
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0 5 10 15 20 25
PCA 41 77 78 88 86 84
PEER 41 70 70 71 63 87
MOFA 41 64 76 75 77 73
MOFA-ns 41 74 78 73 74 72
LDVAE 41 58 54 71 74 73
Table A.1: Number of m-bulk-replicated eQTL across covariates.
Equivalent to Table 3.4 (i.e. mean as aggregation method, 1,421 chromosome 2 genes tested only,
FDR<10% and same direction of effect as replication), except considering replication using bulk with
matched samples only (m-bulk; n=88).
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eGenes genes tested cells unique donors unique samples*
iPSC (day0) 1,833 10,840 9,661 111 136
mesendo 1,702 10,924 9,809 123 224
defendo 1,342 10,901 10,924 116 238
transitioning 227 10,924 6,387 118 313
day1 1,181 10,787 9,443 111 138
day2 718 10,788 8,455 105 116
day3 631 10,765 8,485 108 127
Table A.2: Summary of the type and number of eQTL.
Including all eQTL discovered based on single cell RNA traits, both at the level of our computationally-
defined stages (iPSC, mesendo and defendo) and the time points of collection by design (day1, day2
and day3). We note that in the stage definition a number of cells (∼20%) were excluded and considered
to not belong to any well defined stage (see page 110), exclusively for the purposes of stage-level
eQTL mapping. We included here an eQTL map of such transitioning population, which as expected
was a very underpowered analysis. Additionally, we added results for day2 cells, for completeness.
Shown are the number of genes that were considered for eQTL mapping, as well as the number of
genes for which a eQTL was detected. *Samples are donor-experiment(-time point) combinations
which were effectively used for testing (see section 4.4).
Antibody raised against Catalog number Company
Histone H3 ab1791 Abcam
Histone H3 (tri methyl K4) ab8580 Abcam
Histone H3 (tri methyl K27) C15200181 (MAb-181-050) Diagenode
Histone H3 (mono methyl K4) ab8895 Abcam
Histone H3 (acetyl K27) ab4729 Abcam
Histone H3 (tri methyl K36) ab9050 Abcam
Table A.3: Antibodies used for the ChIP-seq experiments.
Experimental methods for this analysis are described in section C.1.3, and these data were used for
analysis shown in Fig. 4.12 and 4.15.
A.3 Additional information for Chapter 5 223
A.3 Additional information for Chapter 5
trait category study n n (replication)
Alzheimer’s Disease (late onset) neurodegenerative [569] 55,134 19,884
Parkinson’s Disease neurodegenerative [570] 442,271 -
Schizophrenia neurodevelopmental [571] 150,064 -
Bipolar disorder neurodevelopmental [572] 34,950 5,305
Neuroticism personality [573] 170,911 -
Neuroticism personality [574] 329,821 122,867
Neuroticism personality [575] 168,105 -
Depression (broad) behavioural [576] 322,580 -
Educational attainment intelligence [577] 111,114 -
Paternal history of Alzheimer’s disease neurodegenerative [578] 260,279 -
Family history of Alzheimer’s disease neurodegenerative [578] 314,278 -
Maternal history of Alzheimer’s disease neurodegenerative [578] 288,676 -
Depressed affect behavioural [579] 357,957 -
Cognitive performance intelligence [580] 257,841 -
Sleeplessness / insomnia personality [581] 360,738 -
Nervous feelings behavioural [581] 351,829 -
Worrier / anxious feelings behavioural [581] 351,833 -
Tense / ’highly strung’ behavioural [581] 350,159 -
Suffer from ’nerves’ behavioural [581] 348,082 -
Neuroticism score personality [581] 293,006 -
Intelligence questions1 intelligence [581] 117,131 -
Risk taking behavioural [581] 348,549 -
College or University degree intelligence [581] 357,549 -
A levels/AS levels or equivalent intelligence [581] 357,549 -
Other professional qualifications intelligence [581] 357,549 -
Table A.4: Neurological traits used for the colocalisation analysis.
Table compiled by Natsuhiko Kumasaka. Traits used for the colocalisation analysis in Chapter 5
(section 5.6). The corresponding publication and sample size (both for the initial study and, when
available for a replication study) are indicated. Additionally, traits are divided into broad categories.
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Fig. B.1: Distribution of total reads from a scRNA-seq dataset, when considering the same number of
cells for each donor. Same as the left panel from Fig. 3.4, but downsampling to the same number of
cells (n=10) from each donor.
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Fig. B.2: Distribution of total reads between scRNA-seq technologies, when considering the same 29
lines. Similar to Fig. 3.4, but considering SmartSeq2 and 10x data from the same 29 cell lines.
Fig. B.3: Population structure of donors included in the study.
Principal component (PC) decomposition of the kinship matrix (calculated using PLINK [355]) across
all cell lines included in our study. The four outlier cell lines were excluded from the analyses
described in section 3.8.
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Fig. B.4: Comparison of ‘dr’ aggregated measures.
(a) For a random selection of 4 donors (two of which present in two sequencing runs, resulting in
6 donor-run combinations, or samples), scatter plots between aggregation metrics, across the set of
common genes (n=12,720). First row is dr-mean vs dr-sum, second dr-mean vs dr-median, third
dr-median vs dr-sum. The last column represents, for each of the comparisons a histogram of the
distribution of correlations, across donors. (b) Histograms representing the distribution of correlations
across donors, for each genes, for the same three comparisons as in (a).
228 Supplementary Figures
Fig. B.5: Comparison of ‘d’ aggregated measures.
(a) Histograms of correlations between ‘dr’ and ‘d’ aggregation measures, for each of mean, sum,
median. (b,c) Similar to Fig. B.4, panels a and b, but across ‘d’ aggregation methods (instead of ‘dr’;
the same donors are considered).
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Fig. B.6: Comparison of results between single cell and bulk iPSC eQTL.
Scatter plots of eQTL effect sizes obtained when testing association of iPSC eQTL discovered using
single cell (SmartSeq2) and bulk RNA-seq. The bulk eQTL results considered are obtained using
all samples available (‘a-bulk’) The same set of n=12,720 genes that were assessed in all maps are
considered. First two columns, ‘dr’-aggregations (dr-mean, dr-sum, dr-median; aggregated at donor
and sequencing run). Left, top SNP per gene (such that there are exactly as many points as there
are genes) from the single cell data (‘discovery set’; x axis) in bulk results (‘replication set’; y axis).
Right, vice versa (i.e. top SNP per gene in bulk results (now ‘discovery set’ y axis), in single cell
results, now ‘replication set’, x axis). In blue, for each pair of sets of results are the ‘replicated’ eQTL,
i.e. eQTL at FDR<5% in the discovery set, replicated in the replication set (FDR<10% and same
direction of effect; consistently with the results presented in section 3.8). Third and fourth columns,
same as first two but for ‘d’ methods, i.e. d-mean, d-sum, d-median (aggregated at donor level).
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Fig. B.7: Correlation of results between scran and bayNorm normalisation.
Related to results from Table 3.2. Scatter plots of eQTL effect sizes (left) and p values (right) obtained
when testing association of iPSC single cell eQTL discovered using dr-mean as aggregation method
and after normalising counts using two alternative methods: scran/scater [438] (x axis) and bayNorm
[454] (y axis).
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Fig. B.8: Endoderm differentiation protocol.
Adapted from Touboul et al. [582]. Related to Chapter 4, section 4.2. Schematic representation
of the chemically defined protocol used to initiate differentiation towards definitive endoderm. Tra-
1-60 and CXCR4 are canonical cell surface markers of pluripotent and definitive endoderm stages,
respectively, which were used to sort live cells by differentiation stage.
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Fig. B.9: Comparison of expression patterns between healthy and diseased cell lines.
PCA plot (similar to Fig. 4.8) of cells from cell lines derived from monogenic diabetes donors (red),
cells from healthy donors from the same seven experiments (dark blue), against the background of all
cells (grey).
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Fig. B.10: Immunostaining of midbrain neural progenitors and DA neurons (Full legend on
next page).
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Fig. B.10: Immunostaining of midbrain neural progenitors and DA neurons (continued).
Figure by Julie Jerber. (a) Immunostaining for known midbrain progenitor markers LMX1A and
FOXA2 at day 11. Nuclei were counterstained with Hoechst. Scale bar: 25µm. (b) Immunostaining
of differentiated dopaminergic neurons for the neuronal marker MAPT2 (white) and the dopaminergic
neuronal markers TH and LMX1A. Scale bar: 25µm. Data is shown for two example individual cell
lines (HPSI0155i-hecn_6 and HPSI0514i-uenn_3) as well as three entire differentiation pools (Pools
1,2,3).
Fig. B.11: Neuronal cell type markers.
Heat map showing the average expression of the 48 literature-curated neuronal marker genes used to
annotate the identified clusters as cell types (columns) by the annotated cell types at different time
points (rows, as in Fig. 5.2).
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Fig. B.12: Predicted differentiation scores.
Results related to section 5.4.1. (a) Histogram of predicted differentiation scores across all HipSci cell
lines. The bimodal distribution is especially extreme in this case, and 0.5 was used as the threshold to
split bad from good differentiator lines. (b) Scatter plot of predicted differentiation scores for donor
for which we have data for two different cell lines. Replicate1 (rep1) is chosen as the line with lower
predicted score (n=270). Colours indicate three categories of donors, according to whether both lines
from the same donor are predicted to fail differentiation (blue), both are predicted to succeed (green),
the two lines are discordant (one is predicted to successfully differentiate, but not the other, yellow).
(c) Bulk RNA-seq expression of UTF1, TAC3 for the two replicate lines per donor stratified by the
categorization described in (b).
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Fig. B.13: Re-analysis of iPSC scRNA-seq data reveals a subpopulation characterised by ex-
pression of predictive marker genes associated with lower neuronal differentiation efficiency.
(a) UMAP overview of the dataset. iPSC scRNA-seq data from [447] were re-analysed following
the same batch correction and clustering steps applied to our neural differentiation data, identifying
5 clusters. (b) Violin plots of gene expression for genes related to pluripotency (NANOG, SOX2,
POU5F1) and two gene markers that are respectively upregulated and downregulated in cluster 2
(UTF1, TAC3, from Fig. 5.9). (c) Scatter plot showing the proportion of cells assigned to cluster 2
between replicates (n=23). (d) Scatter plot between the proportion of cells assigned to cluster 2 (y
axis) and differentiation efficiency (x axis) similar to Fig 5.11, panel c, but where we use imputed
proportions of cluster 2 cells from bulk RNA-seq available for most cell lines (n=182, out of 199 lines
for which we have day 52 data and thus a measure of neuronal differentiation efficiency).
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Fig. B.14: Analysis of a single cell iPSC dataset from Sarkar et al.
Similar to Fig. B.13. (a) UMAP overview of the dataset. iPSC scRNA-seq data from [444] were
re-analysed following the same data normalisation and clustering steps applied to our neural differenti-
ation data, identifying 4 clusters. (b) Violin plots of gene expression for genes related to pluripotency
(NANOG, SOX2, POU5F1) and a subset of markers of the cluster 2 population (UTF1, TAC3). (c)
Scatter plot showing the proportion of cells assigned to cluster 2 between replicates (n=59). (d)
Expression log fold change between cluster 2 and all other clusters from [447] compared to the same
between cluster 2 and the rest from [444]. Shown are all 5,397 DE genes between cluster 2 and all
other clusters from Sarkar et al. (FDR < 0.05).
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Fig. B.15: Absence of population structure.
Principal component (PC) decomposition of the kinship matrix (calculated using PLINK [355]) across
all cell lines included in the study described in Chapter 5, coloured by batch.
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C.1 Experimental methods for Chapter 4
Experimental methods compiled by Mariya Chhatriwala, as in [447].
C.1.1 Cell culture for maintenance and differentiation
Human iPSC lines were thawed for differentiation and maintained in Essential 8 (E8) media
(LifeTech) on vitronectin (StemCell Technologies, #07180) coated Corning plates according
to the manufacturer’s instructions. Cells were passaged at least twice after thawing and always
3 - 4 days before plating for differentiation to ensure all the cell lines in each experiment were
growing at a similar rate prior to differentiation. Gelatine/MEF coated plates were prepared
24 – 48 hours before plating for differentiation by incubating plates with 0.1% gelatine for
20 minutes at room temp. The gelatine was then aspirated and plates were incubated in MEF
medium overnight at 37°C. Immediately prior to plating cells, plates were washed once with
D-PBS to remove any residual MEF medium. To plate for endoderm differentiation, cells
were washed once with D-PBS and dissociated using StemPro Accutase (Life Technologies,
A1110501) at 37°C for 3 - 5 min. Colonies were fully dissociated through gentle pipetting.
Cells were resuspended in MEF medium, passed through a 40 µm cell strainer, and pelleted
gently by centrifuging at 300 x g for 5 min. Cells were re-suspended in E8 media and
plated at a density of 15,000 cells per cm2 on gelatin/MEF coated plates [480, 583] in
the presence of 10 µM Rock inhibitor – Y27632 (Sigma, #Y0503 - 5 mg). Media was
replaced with fresh E8 free of Rock inhibitor every 24 hours post plating. Differentiation
into definitive endoderm commenced 72 hours post plating. Cells were washed 1x gently
with D-PBS to remove residual E8. Cells were then incubated in CDM-PVA containing
100 ng/mL ActivinA (made in house), 80 ng/mL FGF2 (made in house), 10 ng/mL BMP4
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(R&D systems, #314-BP-050), 10 µm Ly294002 (Promega, #V1201), and 3 µM CHIR99201
(Selleckchem, #S1263) for 24 hours (day 1). After 24 hours, the day 1 media was replaced
with CDM-PVA containing 100 ng/mL ActivinA, 80 ng/mL FGF2, 10 ng/mL BMP4, and 10
µm Ly294002 for another 24 hours (day 2). Day 2 media was then replaced with RPMI/B27
containing 100 ng/mL ActivinA and 80 ng/mL FGF2 for another 24 hours (day 3) [480].
The overall efficiency of the differentiation protocol was validated using reference lines with
good and poor differentiation capacity, respectively. All media was filtered through 0.22 µm
filters prior to use.
C.1.2 Single cell preparation and sorting for scRNAseq
Cells were dissociated into single cells using Accutase and washed once with MEF medium
as described above when plating cells for differentiation. For all subsequent steps, cells
were kept on ice to avoid degradation. Approximately 1 x 106 cells were re-suspended in
PBS + 2% BSA + 2 mM EDTA (FACS buffer); BSA and PBS were nuclease-free. For
staining of cell surface markers, 1 x 106 cells were re-suspended in 100 µL of ice-cold
FACS buffer containing 20 µL anti-Tra-1-60 antibody (BD Pharmingen, BD560380) and
5 µL of anti-CXCR4 antibody (eBioscience 12-9999-42), and were placed on ice for 30
min. Cells were protected from light during staining and all subsequent steps. Cells were
washed with 5 mL of FACS buffer, passed through a 35 µm filter to remove clumps, and
re-suspended in 300 µL of FACS buffer for live cell sorting on the BD Influx Cell Sorter
(BD Biosciences). Live/dead marker 7AAD (eBioscience 00-6993) was added immediately
prior to analysis at a concentration of 2 µL/mL and only living cells were considered when
determining differentiation capacities. Living cells stained with 7AAD but not TRA-1-60
or CXCR4 were used as gating controls. Data for TRA-1-60 and CXCR4 staining were
available for 31,724 cells, of the total 36,044. Single-cell transcriptomes of sorted cells were
assayed as follows: reverse transcription and cDNA amplification was performed according
to the SmartSeq2 protocol [383], and library preparation was performed using an Illumina
Nextera kit. Samples were sequenced using paired-end 75bp reads on an Illumina HiSeq
2500 machine (one lane of sequencing per 384 well plate).
C.1.3 ChIP-seq experiments and data processing
ChIP-seq was performed using FUCCI-Human Embryonic Stem Cells (FUCCI-hESCs, H9
from WiCell) in a modified endoderm differentiation protocol to that used for the iPSC
differentiations (see details below). Cells were grown in defined culture conditions as
described previously [584]. Pluripotent cells were maintained in Chemically Defined Media
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with BSA (CDM-BSA) supplemented with 10ng/ml recombinant Activin A and 12ng/ml
recombinant FGF2 (both from Dr. Marko Hyvonen, Dept. of Biochemistry, University of
Cambridge) on 0.1% Gelatin and MEF media coated plates. Cells were passaged every 4-6
days with collagenase IV as clumps of 50-100 cells. The culture media was replaced 48
hours after the split and then every 24 hours.
The generation of FUCCI-hESC lines has been described in [585] and are based on the
FUCCI system described in [586]. hESCs were differentiated into endoderm as previously
described [587]. Following FACS sorting, Early G1 (EG1) cells were collected and
immediately placed into the endoderm differentiation media and time-points were collected
every 24h up to 72h. Endoderm specification was performed in CDM with Polyvynilic acid
(CDM-PVA) supplemented with 20ng/ml FGF2, 10µM Ly-294002 (Promega), 100ng/ml
Activin A, and 10ng/ml BMP4 (R&D).
We performed ChIP as described previously [588]. For ChIP-sequencing, ChIP for various
histone marks (H3K4me3, H3K27me3, H3K4me1, H3K27ac, H3K36me3) (see Table A.3
for antibodies) was performed on two biological replicates per condition. At the end of
the ChIP protocol, fragments between 100bp and 400bp were used to prepare barcoded
sequencing libraries. 10ng of input material for each condition were also used for library
preparation and later used as a control during peak calls. The libraries were generated by
performing 8 PCR cycles for all samples. Equimolar amounts of each library were pooled
and this multiplexed library was diluted to 8pM before sequencing using an Illumina HiSeq
2000 with 75bp paired-end reads.
Reads were mapped to GRCh38 reference assembly using BWA [589]. Only reads with
mapping quality score ≥ 10 and aligned to autosomal and sex chromosomes were kept for
further processing. Peak calling analysis [590] was performed using PeakRanger [591], and
only the peaks that were reproducible at an FDR of ≤ 0.05 in two biological replicates were
selected for further processing. Peak calling was done using appropriate controls with the
tool peakranger 1.18 in modes ranger (H3K4me3, H3K27ac; ‘-l 316 -b 200 -q 0.05’), ccat
(H3K27me3; ‘-l 316 –win_size 1000 –win_step 100 –min_count 70 –min_score 7 -q 0.05’)
and bcp (H3K4me1, H3K36me3; ‘-l 316’). Adjacent peak regions closer than 40 bp were
merged using the BEDTools suite [592], and those overlapping ENCODE blacklisted regions
were filtered out (ENCODE Excludable Mappability Regions [593]). Finally, peaks were
converted to GRCh37 coordinates using UCSC LiftOver.
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C.2 Experimental methods for Chapter 5
Experimental methods written by Julie Jerber, as in [445].
C.2.1 Human iPSC culture
Feeder-free human iPSCs were obtained from the HipSci project [294]. Lines were thawed
onto tissue culture-treated plates (Corning, 3516) coated with 10 µg/mL VitronectinXF
(StemCell Technologies, 07180) using complete Essential 8 (E8) medium (Thermo Fisher,
A1517001) and 10 µM Rock inhibitor (Sigma, Y0503). Cells were expanded in E8 medium
for 2 passages using 0.5 µM EDTA pH 8.0 (Thermo Fisher, 15575-020) for cell dissociation.
C.2.2 Pooling and differentiation of midbrain dopaminergic neurons
iPSC colonies were dissociated into a single-cell suspension using Accutase (Thermo Fisher,
A11105-01) and resuspended in E8 medium containing 10 µM Rock inhibitor. Cells were
counted using an automated cell counter (Chemometec NC-200) and a cell suspension
containing an equal amount of each iPSC line was prepared in E8 medium containing 10
µM Rock inhibitor and seeded at 2 x 105 cells per cm2 on 0.01% Geltrex- (Thermo Fisher,
A1413202) coated plates. Each pool of lines contained between 7 to 24 donors. 24h after
plating, neuronal differentiation of the pooled lines to a midbrain lineage was performed
as described by12 with minor modifications: 1. SHH C25II was replaced by 100nM SAG
(Tocris, 6390) in the neuronal induction phase. 2. On day 20, the cells were passaged with
Accutase containing 20 units/mL of papain (Worthington, LK00031765) and plated at 3.5 x
105 cells per cm2 on 0.01% Geltrex-coated plates for final maturation.
C.2.3 Rotenone stimulation
On day 51 of differentiation, the cells were exposed for 24h to freshly prepared 0.1 µM
rotenone (Sigma, R8875, purity HPLC ≥ 95%) diluted in neuronal maturation medium [284].
The final DMSO concentration was 0.01% in all exposure conditions. Unstimulated control
samples (i.e. DMSO only) were taken concurrently.
C.2.4 Generation of cerebral organoids
Cerebral organoids were generated according to the enCOR method as previously described
by [530]. Briefly, one pool of 18 iPSC lines was thawed and expanded for 1 passage before
seeding 18,000 cells onto PLGA microfilaments prepared from Vicryl sutures. STEMdiff
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Cerebral Organoid kit (Stem Cell Technologies, 08570) was used for organoid culture
with timing according to manufacturer’s suggestion and Matrigel embedding as previously
described57. From day 35 onward the medium was supplemented with 2% dissolved Matrigel
basement membrane (Corning, 354234), and processed for scRNA-seq after 113 days of
culture.
C.2.5 Generation of single cell suspensions for sequencing
On harvesting days, the cells were washed once with 1X DPBS (Thermo Fisher, 14190-144)
before adding either Accutase (day 11) or Accutase containing 20 units/mL of papain
(days 30 and 52). The cells were incubated at 37°C for up to 20 min (day 11) or up to 35
min (days 30 and 52) before adding DMEM:F12 (Thermo Fisher Scientific, 10565-018)
supplemented with 10 µM Rock inhibitor and 33 µg/mL DNase I (Worthington, LK003170,
only for days 30 and 52). The cells were dissociated using a P1000 and collected in a 15
mL tube capped with a 40 µm cell strainer. After centrifugation, the cells were resuspended
in 1X DPBS containing 0.04% BSA (Sigma, A0281) and washed 3 additional times in 1X
DPBS containing 0.04% BSA. Single-cell suspensions were counted using an automated cell
counter (Chemometec NC-200) and concentrations adjusted to 5 x 105 cells/mL.
Organoids were washed twice in 1X DPBS before adding EBSS (Worthington, LK003188)
dissociation buffer containing 19 U/mL of papain, 50 µg/mL of DNase I and 22.5X of
Accutase. Organoids were incubated in a shaking block (750 rpm) at 37°C for 30 min. Every
10 min, the organoids were triturated using a P1000 and BSA-coated pipette tips until large
clumps were dissociated. Dissociated organoids were transferred into a new tube capped
with a 40 µm cell strainer and pelleted for 4 min at 300g. After centrifugation, the cells were
resuspended in EBSS containing 50µg/mL of DNase I and 2 mg/mL ovomucoid (Worthington,
LK003150). 0.5 volume of EBSS, followed by 0.5 volume of 20 mg/mL ovomucoid were
added to the top of the cell suspension and the cells were mixed by flicking the tube. After
centrifugation, the cells were resuspended in 1X DPBS containing 0.04% BSA. Single-cell
suspensions were counted using an automated cell counter and concentrations adjusted to 5
x105 cells/mL.
C.2.6 Immunohistochemistry
Cells were fixed in 4% paraformaldehyde (Thermo Fisher Scientific, 28908) for 15 min,
rinsed 3 times with PBS1X (Sigma, D8662) and blocked with 5% normal donkey serum
(NDS; AbD Serotec, C06SBZ) in PBST (PBS1X + 0.1% Triton X-100, Sigma, 93420) for
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2h at room temperature. Primary antibodies were diluted in PBST containing 1% NDS and
incubated overnight at 4°C. Cells were washed 5 times with PBS1X and incubated with
secondary antibodies diluted in PBS1X for 45 min at room temperature. Cells were washed 3
more times with PBS1X and Hoechst (Thermo Fisher Scientific, H3569) was used to visualize
cell nuclei. Image acquisition was performed using Cellomics array scan VTI (Thermo Fisher
Scientific). The following antibodies were used: FOXA2 (Santa Cruz, sc101060 - 1/100)
LMX1A (Millipore, AB10533 - 1/500) TH (Santa Cruz, sc-25269 - 1/200) MAP2 (Abcam,
5392 - 1/2000) Donkey anti-chicken AF647 (Thermo Fisher Scientific, A21449) Donkey
anti-mouse AF488 (Thermo Fisher Scientific, A11008) Donkey anti-mouse AF555 (Thermo
Fisher Scientific, A31570) Donkey anti-rabbit AF488 (Thermo Fisher Scientific, A21206)
Donkey anti-rabbit AF555 (Thermo Fisher Scientific, A27039)
C.2.7 Chromium 10x Genomics library and sequencing
Single cell suspensions were processed by the Chromium Controller (10x Genomics) using
Chromium Single Cell 3’ Reagent Kit v2 (PN-120237). On average, 15,000 cells from each
10x reaction were directly loaded into one inlet of the 10x Genomics chip. All the steps were
performed according to the manufacturer’s specifications. Barcoded libraries were sequenced
using HiSeq4000 (Illumina, one lane per 10x chip position) with 50bp or 75bp paired end
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